WorldWideScience

Sample records for anti-infective drugs advisory

  1. 78 FR 48690 - Anti-Infective Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-08-09

    ... the public. Name of Committee: Anti-Infective Drugs Advisory Committee. General Function of the... (involving internal organs), mucosal (involving areas such as inside the mouth and nose), and cutaneous... limited. If the number of registrants requesting to speak is greater than can be reasonably...

  2. 76 FR 59405 - Anti-Infective Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-09-26

    ...-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia, and the draft document entitled ``Guidance for Industry: Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment,'' published November 2010 (see FDA Web site at...

  3. 78 FR 48174 - Anti-Infective Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-08-07

    ..., 2013, from 8 a.m. to 5 p.m. Location: FDA White Oak Campus, Building 31, the Great Room, White Oak... discuss susceptibility interpretive criteria for systemic antibacterial drugs and for dosing... susceptibility interpretive criteria. We will also discuss revising dosing recommendations in product...

  4. Emerging paradigms in anti-infective drug design.

    Science.gov (United States)

    Barrett, Michael P; Croft, Simon L

    2014-01-01

    The need for new drugs to treat microbial infections is pressing. The great progress made in the middle part of the twentieth Century was followed by a period of relative inactivity as the medical needs relating to infectious disease in the wealthier nations receded. Growing realisation that anti-infectives are needed in many parts of the world, to treat neglected diseases as well as to combat the burgeoning risk of resistance to existing drugs, has galvanised a new wave of research into anti-microbial drugs. The transfer of knowledge from the Pharmaceutical industry relating to the importance of understanding how to target drugs successfully within the body, and improved understanding of how pathogens interact with their hosts, is driving a series of new paradigms in anti-infective drug design. Here we provide an overview of those processes as an introduction to a series of articles from experts in this area that emerged from a meeting entitled "Emerging Paradigms in Anti-Infective Drug Design" held in London on the 17th and 18th September 2012. The symposium was organised jointly by British Society for Parasitology (BSP) and the Biological & Medicinal Chemistry sector of the Royal Society of Chemistry (RSC) and held at the London School of Hygiene & Tropical Medicine. The symposium set out to cover all aspects of the identification of new therapeutic modalities for the treatment of neglected and tropical diseases. We aimed to bring together leading scientists from all the disciplines working in this field and cover the pharmacology, medicinal chemistry and drug delivery of potential new medicines. Sessions were held on: "Target diseases and targets for drugs", "Target based medicinal chemistry", "Bioavailability and chemistry", "Targeting intracellular microbes", "Alternative approaches and models", and "New anti-infectives - how do we get there?" This symposium was organised by Simon Croft (LSHTM) and Mike Barrett (University of Glasgow) for the BSP, and David

  5. Causes and consequences of anti-infective drug stock-outs.

    Science.gov (United States)

    Luans, C; Cardiet, I; Rogé, P; Baslé, B; Le Corre, P; Revest, M; Michelet, C; Tattevin, P

    2014-10-01

    Anti-infective drugs stock-outs are increasingly frequent, and this is unlikely to change. There are numerous causes for this, mostly related to parameters difficult to control: i) 60 to 80% of raw material or components are produced outside of Europe (compared to 20% 30 years ago), with subsequent loss of independence for their procurement; ii) the economic crisis drives the pharmaceutical companies to stop producing drugs of limited profitability (even among important drugs); iii) the enforcement of regulatory requirements and quality control procedures result in an increasing number of drugs being blocked during production. The therapeutic class most affected by drug stock-outs is that of anti-infective drugs, especially injectable ones, and many therapeutic dead ends have recently occurred. We provide an update on this issue, and suggest 2 major actions for improvement: i) to implement a group dedicated to anticipating drug stock-outs within the anti-infective committee in each health care center, with the objectives of organizing and coordinating the response whenever a drug stock-out is deemed at risk (i.e., contingency plans, substitution, communication to prescribers); ii) a national reflection lead by scientific societies, in collaboration with government agencies, upstream of the most problematic drug stock-outs, to elaborate and disseminate consensus guidelines for the management of these stock-outs.

  6. Fabrication of drug-loaded anti-infective guided tissue regeneration membrane with adjustable biodegradation property.

    Science.gov (United States)

    Xue, Jiajia; Shi, Rui; Niu, Yuzhao; Gong, Min; Coates, Phil; Crawford, Aileen; Chen, Dafu; Tian, Wei; Zhang, Liqun

    2015-11-01

    For guided tissue regeneration (GTR) membrane, synchronization of the membrane biodegradation rate and tissue regeneration rate is important. Besides, the major reason for GTR membrane failure in clinical application is infection which can be prevented by loading anti-bacterial drug. To realize the consistency in membrane degradation rate and tissue regeneration rate of the anti-infective membrane, we developed metronidazole-loaded electrospun poly(ɛ-caprolactone)-gelatin nanofiber membranes with different poly(ɛ-caprolactone)/gelatin ratios (95:5, 90:10, 80:20, 70:30, 60:40, and 50:50). Homogeneous nanofibers were successfully fabricated. The mechanical strength of the membranes increased with the poly(ɛ-caprolactone) content, while the hydrophilicity decreased. The controlled and sustained release of metronidazole from all the membranes prevented the colonization of anaerobic bacteria. At all poly(ɛ-caprolactone)/gelatin ratios, all the membranes presented good biocompatibility while the increase of gelatin content resulted in enhanced cell adhesion and proliferation. Subcutaneous implantation in rabbits for 8 months demonstrated that all the membranes showed good biocompatibility without infection. Both in vitro and in vivo results showed that the biodegradation rate of the membranes was accelerated with the increase of gelatin content. The biodegradation rate and biocompatibility of the membranes can be adjusted by changing the PCL/gelatin ratio. The optimal membrane can be chosen based on the patient and tissue type to realize the synchronization of membrane degradation with tissue regeneration for the best treatment effect.

  7. Multifunctional Electrospun Nanofibers Incorporated with an Anti-infection Drug and Immobilized with Proteins

    Science.gov (United States)

    Zhou, Shufei

    Electrospinning has been used to fabricate ultrafine fibers with sizes ranging from nano to micrometers. Nanofibers electrospun from biocompatible and biodegradable polymers have been extensively investigated for their potential applications in wound healing and tissue regeneration. These nanofiber materials can be modified to incorporate bioactive molecules, such as antibacterial agents that provide infection control, or functional proteins which promote cell proliferation and tissue reconstruction. Despite the numerous studies on the development and design of nanofibers for biomedical applications, there has been little research on multifunctional nanofibers that are incorporated with both antibacterial drug(s) and bioactive proteins. The objective of the current study is, therefore, to develop nanofibers that are functionalized by several bioactive molecules. In this study, electrospinning was utilized to fabricate nanofibers from biodegradable polymers PLLA (Poly-L-lactide) and the copolymer PLLA-PEG (Polyethylene glycol)-NH2.A water soluble antibiotic drug, Tetracycline Hydrochloride (TCH), was incorporated into the electrospun nanofibers via emulsion electrospinning. The TCH-loaded nanofibers were surface modified to produce functional groups that can be further conjugated with a model protein, Bovine Serum Albumin (BSA).Drug releasing profiles of the medicated nanofibers were monitored and their antimicrobial properties were evaluated. Proteins (BSAs) immobilized on the fiber surface were verified by ATR-FTIR. The number of immobilized BSAs was determined using a UV-Vis spectrophotometer. The results of the study suggested that this multifunctional nanofibrous material could be a promising material for wound dressing or scaffolds for tissue engineering.

  8. Drug loaded homogeneous electrospun PCL/gelatin hybrid nanofiber structures for anti-infective tissue regeneration membranes.

    Science.gov (United States)

    Xue, Jiajia; He, Min; Liu, Hao; Niu, Yuzhao; Crawford, Aileen; Coates, Phil D; Chen, Dafu; Shi, Rui; Zhang, Liqun

    2014-11-01

    Infection is the major reason for guided tissue regeneration/guided bone regeneration (GTR/GBR) membrane failure in clinical application. In this work, we developed GTR/GBR membranes with localized drug delivery function to prevent infection by electrospinning of poly(ε-caprolactone) (PCL) and gelatin blended with metronidazole (MNA). Acetic acid (HAc) was introduced to improve the miscibility of PCL and gelatin to fabricate homogeneous hybrid nanofiber membranes. The effects of the addition of HAc and the MNA content (0, 1, 5, 10, 20, 30, and 40 wt.% of polymer) on the properties of the membranes were investigated. The membranes showed good mechanical properties, appropriate biodegradation rate and barrier function. The controlled and sustained release of MNA from the membranes significantly prevented the colonization of anaerobic bacteria. Cells could adhere to and proliferate on the membranes without cytotoxicity until the MNA content reached 30%. Subcutaneous implantation in rabbits for 8 months demonstrated that MNA-loaded membranes evoked a less severe inflammatory response depending on the dose of MNA than bare membranes. The biodegradation time of the membranes was appropriate for tissue regeneration. These results indicated the potential for using MNA-loaded PCL/gelatin electrospun membranes as anti-infective GTR/GBR membranes to optimize clinical application of GTR/GBR strategies.

  9. 77 FR 13612 - Anti-Infective Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-03-07

    .... to 3:30 p.m. Location: DoubleTree by Hilton Hotel Washington DC/Silver Spring, The Ballrooms, 8727 Colesville Rd., Silver Spring, MD. The hotel telephone number is: 301 589-5200. Contact Person: Minh Doan... of pneumonic plague (plague infection with extensive lung involvement) in African Green Monkeys...

  10. 77 FR 58400 - Anti-Infective Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-09-20

    ...: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae (penicillin susceptible strains). FDA intends to make background material available to the public no...

  11. 75 FR 81283 - Oncologic Drugs Advisory Committee; Cancellation

    Science.gov (United States)

    2010-12-27

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Cancellation AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The meeting of the Oncologic Drugs Advisory... of December 6, 2010 (75 FR 75680). On February 9, 2011, the Oncologic Drugs Advisory Committee...

  12. 75 FR 71450 - Oncologic Drugs Advisory Committee; Amendment of Notice

    Science.gov (United States)

    2010-11-23

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Amendment of Notice AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of a meeting of the Oncologic Drugs Advisory Committee....

  13. 77 FR 37911 - Oncologic Drugs Advisory Committee; Amendment of Notice

    Science.gov (United States)

    2012-06-25

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Amendment of Notice AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Oncologic Drugs Advisory Committee. This meeting...

  14. 77 FR 63839 - Oncologic Drugs Advisory Committee; Cancellation

    Science.gov (United States)

    2012-10-17

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Cancellation AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The meeting of the Oncologic Drugs Advisory... committee have been resolved. FOR FURTHER INFORMATION CONTACT: Caleb Briggs, Center for Drug Evaluation...

  15. 75 FR 16151 - Antiviral Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-03-31

    ... HUMAN SERVICES Food and Drug Administration Antiviral Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  16. 76 FR 82310 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-12-30

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  17. 76 FR 82309 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-12-30

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  18. 76 FR 11489 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-03-02

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  19. 76 FR 59404 - Gastrointestinal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-09-26

    ... HUMAN SERVICES Food and Drug Administration Gastrointestinal Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open...

  20. 75 FR 9419 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-03-02

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  1. 78 FR 37820 - Nonprescription Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-06-24

    ... HUMAN SERVICES Food and Drug Administration Nonprescription Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open...

  2. 75 FR 75680 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-12-06

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  3. 77 FR 7587 - Gastrointestinal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-02-13

    ... HUMAN SERVICES Food and Drug Administration Gastrointestinal Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of...

  4. 77 FR 5813 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-02-06

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  5. 78 FR 57166 - Antiviral Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-09-17

    ... HUMAN SERVICES Food and Drug Administration Antiviral Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  6. 76 FR 44595 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-07-26

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  7. 76 FR 62418 - Antiviral Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-10-07

    ... HUMAN SERVICES Food and Drug Administration Antiviral Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  8. 76 FR 65736 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-10-24

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  9. 78 FR 13348 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-02-27

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  10. 78 FR 48690 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-08-09

    ... HUMAN SERVICES Food and Drug Administration Oncologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to...

  11. Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs.

    Directory of Open Access Journals (Sweden)

    Katherine Kay

    Full Text Available Mechanism-based pharmacokinetic-pharmacodynamic (PK/PD modelling is the standard computational technique for simulating drug treatment of infectious diseases with the potential to enhance our understanding of drug treatment outcomes, drug deployment strategies, and dosing regimens. Standard methodologies assume only a single drug is used, it acts only in its unconverted form, and that oral drugs are instantaneously absorbed across the gut wall to their site of action. For drugs with short half-lives, this absorption period accounts for a significant period of their time in the body. Treatment of infectious diseases often uses combination therapies, so we refined and substantially extended the PK/PD methodologies to incorporate (i time lags and drug concentration profiles resulting from absorption across the gut wall and, if required, conversion to another active form; (ii multiple drugs within a treatment combination; (iii differing modes of action of drugs in the combination: additive, synergistic, antagonistic; (iv drugs converted to an active metabolite with a similar mode of action. This methodology was applied to a case study of two first-line malaria treatments based on artemisinin combination therapies (ACTs, artemether-lumefantrine and artesunate-mefloquine where the likelihood of increased artemisinin tolerance/resistance has led to speculation on their continued long-term effectiveness. We note previous estimates of artemisinin kill rate were underestimated by a factor of seven, both the unconverted and converted form of the artemisinins kill parasites and the extended PK/PD methodology produced results consistent with field observations. The simulations predict that a potentially rapid decline in ACT effectiveness is likely to occur as artemisinin resistance spreads, emphasising the importance of containing the spread of artemisinin resistance before it results in widespread drug failure. We found that PK/PD data is generally very

  12. 78 FR 13349 - Psychopharmacologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-02-27

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Psychopharmacologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the...

  13. 75 FR 47309 - Psychopharmacologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-08-05

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Psychopharmacologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the...

  14. 76 FR 65736 - Psychopharmacologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-10-24

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Psychopharmacologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the...

  15. Evaluation of new anti-infective drugs for the treatment of cholera. Infectious Diseases Society of America and the Food and Drug Administration.

    Science.gov (United States)

    Corrado, M L; DuPont, H L; Cooperstock, M; Fekety, R; Murray, D M

    1992-11-01

    Cholera is an acute gastrointestinal infection caused by Vibrio cholerae. It is characterized by watery diarrhea that may lead to massive fluid loss, which in turn may result in hypotension, shock, and death within hours. Key to the treatment of cholera is fluid replacement. Anti-infective therapy decreases the severity and duration of diarrhea and the duration of shedding of V. cholerae. Enrolled patients should have diarrhea that is moderate to severe and a culture that ultimately yields V. cholerae. A prospective, randomized, active-controlled clinical trial is preferred. Studies should be double-blinded or evaluator-blinded. The rapidity with which the organism is eliminated from stool may be assessed. Both clinical and microbiological outcome should be determined. Assessment of microbiological eradication is paramount, since fluid replacement may suffice for treatment of signs and symptoms.

  16. 76 FR 36930 - National Advisory Council on Alcohol Abuse and Alcoholism and National Advisory Council on Drug...

    Science.gov (United States)

    2011-06-23

    ... HUMAN SERVICES National Institutes of Health National Advisory Council on Alcohol Abuse and Alcoholism... the National Advisory Council on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse... Committee: National Advisory Council on Alcohol Abuse and Alcoholism and National Advisory Council on...

  17. Tendency analysis on medication cost proportion of the anti-infective drugs from 2007 to 2010%2007-2010年抗感染药物金额占比趋势分析

    Institute of Scientific and Technical Information of China (English)

    朱志峰; 黄小萍; 朱瑜

    2013-01-01

    目的 了解实施细则(试行)制定以后,该院抗感染药物金额占比的变化情况.方法 收集整理(卫生部医院管理合作项目)2007-2010年抗感染药物购药品种数据,并进行统计分析.结果 2007-2010年抗感染药物金额逐年上升,金额占比逐年下降.结论 及相关文件制定以后该院抗感染药物金额占比有所下降,其金额占比受宏观调控影响,同及相关文件有依从性.%Objective To investigate the tendency on medication cost proportion of the anti -infective drugs after the implementation of the Guiding Principles of Clinical Application of Antibacterials . Methods Data of anti-infective drugs from the Report of Drug Purchase A -nalysis In Hospital from 2007 to 2010 were collected and analyzed. Results Although the medication cost spent on anti infective was increasing from 2007 to 2010,the medication cost proportion of the anti infective was decreasing. Conclusion Anti-infectious agents cost proportion for the prescriptions is affected by macro -economic control, which is in compliance with the Guiding Principles of Clinical Ap -plication of Antibacterials and relevant documents .

  18. 77 FR 31025 - Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-05-24

    ...] [FR Doc No: 2012-12588] DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2012-N-0001] Oncologic Drugs Advisory Committee; Notice of Meeting AGENCY: Food and Drug... of the Food and Drug Administration (FDA). The meeting will be open to the public. Name of...

  19. 76 FR 39404 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-07-06

    ... HUMAN SERVICES Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; Notice of... to the public. Name of Committee: Cardiovascular and Renal Drugs Advisory Committee. General Function... application (NDA) 202439, rivaroxaban tablets, submitted by Johnson & Johnson Pharmaceutical Research...

  20. 75 FR 1395 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-01-11

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; Notice of... to the public. ] Name of Committee: Cardiovascular and Renal Drugs Advisory Committee....

  1. 78 FR 17413 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-03-21

    ... HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of..., Pulmonary-Allergy Drugs Advisory Committee meeting due to unanticipated weather conditions. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of the Committee: To provide...

  2. 75 FR 82031 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-12-29

    ... [Docket No. FDA-2010-N-0001] Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of the Committee:...

  3. 骨科抗菌药物不合理应用分析%Analysis on the irrational use of anti-infective drugs in the department of osteology

    Institute of Scientific and Technical Information of China (English)

    余巍; 张树荣; 左国营

    2011-01-01

    目的 促进临床合理应用抗菌药物.方法 通过我院骨科附属医院抗感染药物治疗的病例,从药物选用、用法用量、药物相互作用、配伍禁忌等方面对常见医嘱抗菌药物不合理用药进行探讨,指出用药不当的原因和可能的后果,以期帮助临床防范抗菌药物不合理用药的发生.结果 临床常见医嘱抗菌药物的使用存在很多不合理之处.结论 抗菌药物使用应全面考虑、综合分析,临床药师在抗菌药物的合理使用上可起到积极作用.%Objective To provide theory bases for further interference aiming at clinical using drugs rationally. Methods in order to find out and evaluate the main manifestations of clinical inconsequence use of anti - infective drugs , the records of typical irrational uae of anti - infective drugs from drug selection , usage and dosage , drug interactions, compatibility taboos were collected and analyzed in the department of osteology of our hospital. Results There are many shortcomings in the use of antimicrobial drugs in clinical. Conclusions The irrational utilization of antibiotics remains to be improved. Clinical pharmacists can play a positive role in the rational use of antimicrobial drugs.

  4. HT-SPOTi: A Rapid Drug Susceptibility Test (DST) to Evaluate Antibiotic Resistance Profiles and Novel Chemicals for Anti-Infective Drug Discovery.

    Science.gov (United States)

    Danquah, Cynthia A; Maitra, Arundhati; Gibbons, Simon; Faull, Jane; Bhakta, Sanjib

    2016-02-08

    Antibiotic resistance is one of the major threats to global health and well-being. The past decade has seen an alarming rise in the evolution and spread of drug-resistant strains of pathogenic microbes. The emergence of extensively drug resistant (XDR) strains of Mycobacterium tuberculosis and antimicrobial resistance among the ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species) as well as fungal pathogens (such as certain species of Candida, Aspergillus, Cryptococcus, and Trichophyton) poses a significant 21st century scientific challenge. With an extremely limited arsenal of efficacious antibiotics, techniques that can (a) identify novel antimicrobials and (b) detect antimicrobial resistance are becoming increasingly important. In this article, we illustrate the HT-SPOTi, an assay that is principally based on the growth of an organism on agar medium containing a range of different concentrations of drugs or inhibitors. The simple methodology makes this assay ideal for evaluating novel antimicrobial compounds as well as profiling an organism's antibiotic resistance profile.

  5. 临床药师在1例ICU重症患者抗感染药物治疗中的作用%Role of Clinical Pharmacists in Anti-infective Drug Therapy for a Severe Patient in ICU

    Institute of Scientific and Technical Information of China (English)

    陈燕; 王婧; 陆瑶华; 李颖川; 周明; 郭澄

    2012-01-01

    OBJECTIVE: To investigate the role of clinical pharmacists in the determining of drug therapy for ICU severe patients. METHODS: One case of intestinal obstruction patient with septic shock was analyzed descriptively in terms of disease course, drug therapy and outcome. The empirical anti-infective therapeutic strategies for the sepsis induced by the abdominal infection with unsatisfactory anti-infection and undetected pathogen were analyzed. Pharmaceutical care mainly concerned about the change of the routine blood test, biochemical function and other laboratory index, especially the specific inflammatory markers. RESULTS: In the course of therapy, clinical pharmacists identified the intraperitoneal drug-resistant E. coli infection was the main problem and selected a broad-spectrum carbapenem antibiotic for the treatment. De-escalation therapy was performed after controlling severe infection, and then the individual anti-infective program was formulated in the course of antibiotic therapy to promote disease condition. CONCLUSION: Clinical pharmacists should participate in the health care team, and help clinicians to adjust drug treatment programs. This attempt may enhance the effect of drug therapy.%目的:探讨临床药师在ICU重症患者药物治疗方案确定中的作用.方法:描述性分析1例肠梗阻术后休克患者的病程发展、药物治疗情况及转归,分析腹腔感染引起脓毒症、感染控制不佳、病原体不明确时的经验治疗策略.药学监护重点关注血常规、生化功能等实验室指标趋势,特别是特异性炎性指标.结果:临床药师针对多部位的耐药菌感染,明确腹腔大肠埃希菌感染为需解决的主要矛盾,选用耐酶广谱的碳青霉烯类及时控制感染后降阶梯治疗,制订个体化抗感染方案,使得病情好转.结论:临床药师参与医疗团队,协助医师调整药物治疗方案,有利于提升患者的药物治疗效果.

  6. 75 FR 8377 - Pulmonary-Allergy Drugs Advisory Committee; Amendment of Notice

    Science.gov (United States)

    2010-02-24

    ... HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Amendment of... Administration (FDA) is announcing an amendment to the notice of a meeting of the Pulmonary-Allergy Drugs... meeting of the Pulmonary-Allergy Drugs Advisory Committee would be held on March 10 and 11, 2010. On...

  7. 77 FR 14404 - Guidance for the Public, Food and Drug Administration (FDA) Advisory Committee Members, and FDA...

    Science.gov (United States)

    2012-03-09

    ... HUMAN SERVICES Food and Drug Administration Guidance for the Public, Food and Drug Administration (FDA) Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers; Availability AGENCY: Food and Drug Administration, HHS. ACTION:...

  8. 77 FR 43600 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-07-25

    ... HUMAN SERVICES Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; Notice of... to the public. Name of Committee: Cardiovascular and Renal Drugs Advisory Committee. General Function... West- Ward Pharmaceutical Corp., to increase blood pressure in acute hypotensive states, such as...

  9. 78 FR 36787 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-06-19

    ... HUMAN SERVICES Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; Notice of... to the public. Name of Committee: Cardiovascular and Renal Drugs Advisory Committee. General Function... Pharmaceutical Company, Ltd., for the proposed indication of slowing kidney disease in adults at risk of...

  10. 77 FR 21982 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-04-12

    ... HUMAN SERVICES Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; Notice of... to the public. Name of Committee: Cardiovascular and Renal Drugs Advisory Committee. General Function... patients with acute coronary syndrome (ACS) [ST elevation myocardial infarction (STEMI), non-ST...

  11. 78 FR 76307 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-12-17

    ... HUMAN SERVICES Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; Notice of... to the public. Name of Committee: Cardiovascular and Renal Drugs Advisory Committee. General Function... atherothrombotic events in patients with a history of myocardial infarction (MI). The applicant also proposes...

  12. 78 FR 76308 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-12-17

    ... HUMAN SERVICES Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; Notice of... to the public. Name of Committee: Cardiovascular and Renal Drugs Advisory Committee. General Function... coronary syndrome [ST elevation myocardial infarction, non-ST elevation myocardial infarction, or...

  13. 75 FR 5334 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-02-02

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of...

  14. 77 FR 4566 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-01-30

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of...

  15. 75 FR 5333 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-02-02

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of...

  16. 77 FR 74486 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-12-14

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of...

  17. 76 FR 29766 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-05-23

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of...

  18. 77 FR 69636 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-11-20

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of...

  19. 78 FR 46976 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-08-02

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of...

  20. 77 FR 69635 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-11-20

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of...

  1. 75 FR 9420 - Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-03-02

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee; Notice of... to the public. Name of Committee: Pulmonary-Allergy Drugs Advisory Committee. General Function of...

  2. 78 FR 50423 - Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-08-19

    ... HUMAN SERVICES Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee... be open to the public. Name of Committee: Endocrinologic and Metabolic Drugs Advisory Committee...) or a CHD risk equivalent. FDA intends to make background material available to the public no...

  3. Adverse Reaction Analysis of 572 Cases of Anti-infection Drugs%572例抗感染药物不良反应分析

    Institute of Scientific and Technical Information of China (English)

    张芸博; 张佳丽; 曹强

    2012-01-01

    0bjective T o analyze occurrence of adverse antHnfection drug reaction , and provide reference for safe drug use. M ethods A nalyzing 572 cases of adverse antHnfectbn drug reaction in our hospital from January 1, 2008 to D ecem ber 31, 2010 by retrospective m ethod . A nalyzing and evaluating 1he sex and age of 1he patients, adverse reaction in each year, drug types, dosage form and clinical manifestations of ADR . Results Annual average happened num ber present ascendant trend. Q uinobne have m ore adverse reactions, accounted for 28 .90% . The incidence of intravenous inaction pow dertnjection adverse reaction is higher than other dosage form , accounted for 56 .31% . Conclusfon The num ber of adverse antHnfectbn drug reaction is related to many factors such us drug types and route of adm inistration . M edicalw orker should pay high attention to 1he adverse anti-infectbn drug reaction, im prove 1he A D R m onitoring level, prom ote clinical rational safe drug use.%目的 分析近年来抗感染药物不良反应(Adverse drug reaction,ADR)发生情况,为安全使用药物提供参考.方法 采用回顾性方法,分析我院2008年1月1日-2010年12月31日收集到的572例抗感染药物不良反应,从患者的性别年龄、各年度不良反应发生情况、药品种类、剂型及ADR的临床表现等方面进行分析、评价.结果 年度发生例数呈现上升趋势,其中喹诺酮类发生不良反应较多,占28.90%;静脉注射粉针剂不良反应发生率高于其它剂型,占56.31%.结论 抗感染药物发生ADR的例数与药品种类、给药途径等多种因素相关.医务工作者应高度重视抗感染药物的不良反应,提高ADR监测水平,促进临床合理、安全用药.

  4. The Food and Drug Administration advisory committees and panels: how they are applied to the drug regulatory process.

    Science.gov (United States)

    Ciociola, Arthur A; Karlstadt, Robyn G; Pambianco, Daniel J; Woods, Karen L; Ehrenpreis, Eli D

    2014-10-01

    Food and Drug Administration (FDA) advisory panels and committees play a critical role in advising the FDA on the safety and efficacy of medical devices and drugs marketed in the US. Advisory panel recommendations are used by the FDA to make decisions regarding medical products. Currently, the FDA utilizes over 50 advisory panels that serve the three major FDA centers, including the Centers for Biologics, Drugs and Device Products. Members of an advisory panel typically include academicians, clinicians, consumers, patients, and industry representatives. The FDA establishes the schedules for advisory panel meetings on an annual basis and a panel usually meets several times a year for two consecutive days in Washington, DC. Typically, the advisory panel discusses issues highlighted by the FDA and is then asked to vote a response to the questions posed in advance by the FDA. Advisory panel recommendations have a strong influence on FDA's decision to approve a product, as evidenced by the 214 Advisory Panels FDA convened between January 2008 to November 2012, during which advisory panel members voted to approve the product (or use of the product) ∼74% of the time, with FDA ultimately approving the medical product (or use of the product) ∼79% of the time. The ACG membership are encouraged to consider serving the public's interest by participating in an FDA advisory panel utilizing their expertise for the evaluation of a new drug or medical device, and providing advice about whether the product should be sold in the US.

  5. 75 FR 2875 - Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-01-19

    ... another compound in structure) of growth hormone releasing hormone (GHRH). The proposed indication (use... HUMAN SERVICES Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee... in human immunodeficiency virus (HIV)-infected patients with lipodystrophy (a condition in...

  6. 75 FR 36427 - Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management...

    Science.gov (United States)

    2010-06-25

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Joint Meeting of the Arthritis Advisory Committee and the...: Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. ] General...

  7. 78 FR 13348 - Science Board to the Food and Drug Administration Advisory Committee; Amendment of Notice

    Science.gov (United States)

    2013-02-27

    ... HUMAN SERVICES Food and Drug Administration Science Board to the Food and Drug Administration Advisory... Administration (FDA) is announcing an amendment to the notice of meeting of the Science Board to the Food and... that a meeting of the Science Board to the Food and Drug Administration would be held on February...

  8. 75 FR 75681 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-12-06

    ... HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System Drugs... and circulation) of the central nervous system. The BBB is an area consisting of specialized...

  9. 75 FR 56548 - Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and the Drug...

    Science.gov (United States)

    2010-09-16

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Joint Meeting of the Peripheral and Central Nervous System... the public. Name of Committees: Peripheral and Central Nervous System Drugs Advisory Committee and...

  10. New Anti-Infective Coatings of Medical Implants▿

    Science.gov (United States)

    Matl, F. D.; Obermeier, A.; Repmann, S.; Friess, W.; Stemberger, A.; Kuehn, K.-D.

    2008-01-01

    Implantable devices are highly susceptible to infection and are therefore a major risk in surgery. The present work presents a novel strategy to prevent the formation of a biofilm on polytetrafluoroethylene (PTFE) grafts. PTFE grafts were coated with gentamicin and teicoplanin incorporated into different lipid-like carriers under aseptic conditions in a dipping process. Poly-d,l-lactic acid, tocopherol acetate, the diglyceride Softisan 649, and the triglyceride Dynasan 118 were used as drug carriers. The drug release kinetics, anti-infective characteristics, biocompatibility, and hemocompatibility of the coatings developed were studied. All coatings showed an initial drug burst, followed by a low continuous drug release over 96 h. The dimension of release kinetics depended on the carrier used. All coated prostheses reduced bacterial growth drastically over 24 h, even below pathologically relevant concentrations. Different cytotoxic levels could be observed, revealing tocopherol acetate as the most promising biocompatible carrier. A possible reason for the highly cytotoxic effect of Softisan 649 could be assessed by demonstrating incorporated lipids in the cell soma with Oil Red O staining. Tromboelastography studies, enzyme-linked immunosorbent assays, and an amidolytic substrate assay could confirm the hemocompatibility of individual coatings. The development of the biodegradable drug delivery systems described here and in vitro studies of those systems highlight the most important requirements for effective as well as compatible anti-infective coatings of PTFE grafts. Through continuous local release, high drug levels can be produced at only the targeted area and physiological bacterial proliferation can be completely inhibited, while biocompatibility as well as hemocompatibility can be ensured. PMID:18362194

  11. New anti-infective coatings of medical implants.

    Science.gov (United States)

    Matl, F D; Obermeier, A; Repmann, S; Friess, W; Stemberger, A; Kuehn, K-D

    2008-06-01

    Implantable devices are highly susceptible to infection and are therefore a major risk in surgery. The present work presents a novel strategy to prevent the formation of a biofilm on polytetrafluoroethylene (PTFE) grafts. PTFE grafts were coated with gentamicin and teicoplanin incorporated into different lipid-like carriers under aseptic conditions in a dipping process. Poly-d,l-lactic acid, tocopherol acetate, the diglyceride Softisan 649, and the triglyceride Dynasan 118 were used as drug carriers. The drug release kinetics, anti-infective characteristics, biocompatibility, and hemocompatibility of the coatings developed were studied. All coatings showed an initial drug burst, followed by a low continuous drug release over 96 h. The dimension of release kinetics depended on the carrier used. All coated prostheses reduced bacterial growth drastically over 24 h, even below pathologically relevant concentrations. Different cytotoxic levels could be observed, revealing tocopherol acetate as the most promising biocompatible carrier. A possible reason for the highly cytotoxic effect of Softisan 649 could be assessed by demonstrating incorporated lipids in the cell soma with Oil Red O staining. Tromboelastography studies, enzyme-linked immunosorbent assays, and an amidolytic substrate assay could confirm the hemocompatibility of individual coatings. The development of the biodegradable drug delivery systems described here and in vitro studies of those systems highlight the most important requirements for effective as well as compatible anti-infective coatings of PTFE grafts. Through continuous local release, high drug levels can be produced at only the targeted area and physiological bacterial proliferation can be completely inhibited, while biocompatibility as well as hemocompatibility can be ensured.

  12. 75 FR 13559 - Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-03-22

    ... analogue (a chemical compound that resembles another compound in structure) of growth hormone releasing hormone (GHRH). The proposed indication (use) for EGRIFTA in this application is to induce and maintain a... HUMAN SERVICES Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory...

  13. 76 FR 3912 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-01-21

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  14. 78 FR 63481 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-10-24

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  15. 75 FR 17417 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-04-06

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  16. 77 FR 20037 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-04-03

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  17. 75 FR 12768 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-03-17

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  18. 78 FR 20328 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-04-04

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  19. 75 FR 36428 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-06-25

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  20. 78 FR 63478 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-10-24

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  1. 76 FR 44595 - Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-07-26

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory...). The meeting will be open to the public. Name of Committee: Peripheral and Central Nervous System...

  2. Applications for Oncologic Drugs: A Descriptive Analysis of the Oncologic Drugs Advisory Committee Reviews

    Science.gov (United States)

    Kiet, Tuyen K.; Monk, Bradley J.; Young-Lin, Nichole; Blansit, Kevin; Kapp, Daniel S.; Amanam, Idoroenyi

    2014-01-01

    Background Despite advances in cancer research, the majority of drug applications submitted to the U.S. Food and Drug Administration (FDA) are not approved. It is important to identify the concerns of the Oncologic Drugs Advisory Committee (ODAC) from rejected applications. Methods All applications referred to the ODAC from 2001 to 2012 were reviewed. Results Of 46 applications, 31 (67%) were for full and 15 (33%) were for supplemental approval, 34 (74%) were for solid and 12 (26%) were for hematologic tumors. In all, 22 (48%) were not approved. ODAC comments addressed missing or inadequate data (65%), excessive toxicity (55%), inappropriate study endpoints (45%), poor study design (40%), and insufficient sample size (30%). To define efficacy, 19 applications used response rates (RR) (median = 38%), and 19 applications used hazard ratios (HR) (median = 0.67). For all organ systems combined, the median cumulative grade 3 or 4 toxicity was 64%. Drugs with higher RR, lower HR, and lower toxicity were more likely to be approved versus other drugs (89% vs. 45%; p = .02). Over time (2001–2004, 2005–2008, 2009–2012), there was an increase in the following: number of applications submitted for review (from 11 to 12 to 23, respectively), number of approvals (from 6 to 6 to 12, respectively), and proportion of trials using progression-free survival as a primary endpoint (from 0% to 50% to 70%, respectively; p = .01). Conclusion. Of all applications, common ODAC concerns included inadequate data, excessive toxicity, and inappropriate study endpoints. Over time, there was an approximate doubling of FDA application submissions and approved oncology drugs. PMID:24599479

  3. 76 FR 45578 - Request for Nominations for Members on a Public Advisory Committee; Medical Imaging Drugs...

    Science.gov (United States)

    2011-07-29

    ... requesting nominations for voting members on the Medical Imaging Drugs Advisory Committee (the Committee... more qualified persons for membership on the Committee. Self-nominations are also accepted. Nominations... committee for which the nominee is recommended. Nominations must also acknowledge that the nominee is...

  4. 75 FR 21000 - Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food...

    Science.gov (United States)

    2010-04-22

    ... HUMAN SERVICES Food and Drug Administration (formerly Docket No. 02D-0049) Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food and Drug Administration Staff: Public...) (added by the Food and Drug Administration Amendments Act of 2007, Public Law No. 110-85), and...

  5. Anti-infective potential of Citrus bergamia Risso et Poiteau (bergamot) derivatives: a systematic review.

    Science.gov (United States)

    Cirmi, Santa; Bisignano, Carlo; Mandalari, Giuseppina; Navarra, Michele

    2016-09-01

    Infectious diseases remain among the leading causes of morbidity and mortality worldwide, mainly because of the increase of resistance to chemotherapeutic drugs. Nature is the major source of anti-infective drugs and could represent a font of medicines that may help overcome antibiotic resistance. Recently, the potential antimicrobial effect of certain plant extracts has attracted attention within the scientific community as alternatives to synthetic drugs. Here, we present a systematic review on the anti-infective properties of bergamot derivatives that highlight the activity of bergamot essential oil against bacteria, mycetes and larvae, as well as the anti-Helicobacter pylori effect of bergamot juice and the antimicrobial properties of extracts from bergamot peel. Findings presented herein could be used to develop novel and alternative preventive and therapeutic strategies aimed to overcome antibiotic resistance. Copyright © 2016 John Wiley & Sons, Ltd.

  6. 抗感染新药非达霉素的药理作用与临床评价%Pharmacology and clinical evaluation of the new anti-infective drug fidaxomicin

    Institute of Scientific and Technical Information of China (English)

    姜春梅; 刘洋; 王京晶; 张清; 康博欣

    2011-01-01

    Fidaxomicin (edarbi) is the antibiotic with a novel structure of macrolides for the treatment of clostridium difficile-associated diarrhea ( CDAD). Literature was searched from FDA database with the key word edarbi. The pharmacology, pharmacokinetics, clinical evaluation, safety evaluation and drug interactions of fidaxomicin were reviewed.%非达霉素( fidaxomicin)是一种新型的大环内酯类抗生素,适用于艰难梭菌相关性腹泻(clostridium difficile-associated diarrhea,CDAD)的治疗.本文参考美国FDA的相关资料,对非达霉素的药理作用、药动学、临床评价、安全性评价及药物相互作用等进行综述.

  7. 75 FR 17417 - Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management...

    Science.gov (United States)

    2010-04-06

    ... Management Advisory Committee. This meeting was announced in the Federal Register of March 8, 2010 (75 FR... meeting. SUPPLEMENTARY INFORMATION: In the Federal Register of March 8, 2010, FDA announced that a joint... drug (NSAID) product indicated for the treatment of the signs and symptoms of osteoarthritis....

  8. 75 FR 9416 - Advisory Committee Information Hotline

    Science.gov (United States)

    2010-03-02

    ... HUMAN SERVICES Food and Drug Administration Advisory Committee Information Hotline AGENCY: Food and Drug... revised the Advisory Committee Information Hotline (the hotline). The hotline provides the public with... supersedes all previously published announcements of FDA's Advisory Committee Information Hotline....

  9. Marine peptides and their anti-infective activities.

    Science.gov (United States)

    Kang, Hee Kyoung; Seo, Chang Ho; Park, Yoonkyung

    2015-01-16

    Marine bioresources are a valuable source of bioactive compounds with industrial and nutraceutical potential. Numerous clinical trials evaluating novel chemotherapeutic agents derived from marine sources have revealed novel mechanisms of action. Recently, marine-derived bioactive peptides have attracted attention owing to their numerous beneficial effects. Moreover, several studies have reported that marine peptides exhibit various anti-infective activities, such as antimicrobial, antifungal, antimalarial, antiprotozoal, anti-tuberculosis, and antiviral activities. In the last several decades, studies of marine plants, animals, and microbes have revealed tremendous number of structurally diverse and bioactive secondary metabolites. However, the treatments available for many infectious diseases caused by bacteria, fungi, and viruses are limited. Thus, the identification of novel antimicrobial peptides should be continued, and all possible strategies should be explored. In this review, we will present the structures and anti-infective activity of peptides isolated from marine sources (sponges, algae, bacteria, fungi and fish) from 2006 to the present.

  10. Marine Peptides and Their Anti-Infective Activities

    Directory of Open Access Journals (Sweden)

    Hee Kyoung Kang

    2015-01-01

    Full Text Available Marine bioresources are a valuable source of bioactive compounds with industrial and nutraceutical potential. Numerous clinical trials evaluating novel chemotherapeutic agents derived from marine sources have revealed novel mechanisms of action. Recently, marine-derived bioactive peptides have attracted attention owing to their numerous beneficial effects. Moreover, several studies have reported that marine peptides exhibit various anti-infective activities, such as antimicrobial, antifungal, antimalarial, antiprotozoal, anti-tuberculosis, and antiviral activities. In the last several decades, studies of marine plants, animals, and microbes have revealed tremendous number of structurally diverse and bioactive secondary metabolites. However, the treatments available for many infectious diseases caused by bacteria, fungi, and viruses are limited. Thus, the identification of novel antimicrobial peptides should be continued, and all possible strategies should be explored. In this review, we will present the structures and anti-infective activity of peptides isolated from marine sources (sponges, algae, bacteria, fungi and fish from 2006 to the present.

  11. 洋葱伯克霍尔德菌感染家兔抗感染疗效与体外药物敏感性的比较%Comparison of the anti-infective drug sensitivity in rabbit model of Burkholderia cepacia infection and the effect of antimicrobial sensitivity monitoring in vitro

    Institute of Scientific and Technical Information of China (English)

    吕火祥; 胡庆丰; 沈蓓琼; 杨广宇; 俞赛

    2011-01-01

    rabbit in Group A was injected 1 mL of 2 g/mL Piperacillin-Tazobactam, each rabbit in Group B was injected 1 mL of 0.6 g/mL Ticarcillin-clavulanate, and each rabbits in Group C with 1 mL of 0. 1 g/mL Cefepime. The sensitivity test results by MIC method, disc agar diffusion method ( KB method) and VITEK method and their relationship with the efficacy of treatment were compared. Results The consistency of K-B assay results of Piperacillin/tazobactam treatment group ( group A) with the treatment of infection model was 72.2%, while that of MIC method was 66.7%, and that of VITEK method was 66.7% as well. In Ticarcillin/clavulanic acid treatment group (group B), the consistency of MIC method was 83.3%, that of VITEK method was 77.8%, and that of K-B method was 50.0%. In Cefepime treatment group (group C), the consistency of MIC method was 88.9%, that of VITEK method was 77.8%, and that of K-B method was 72.2%. Conclusion Among the 3 antimicrobial sensitivity test methods, the KB result of piperacillin/tazobactam was the closest to the results of anti-infective efficacy in infected rabbits,while the MIC results of ticarcillin/clavulanic acid and cefepime were the closest to the results of anti-infective efficacy; For the treatment of Burkholderia cepacia infection, it is suggested to determine the drug sensitivity in vitro using different methods.

  12. Screening for potential anti-infective agents towards Burkholderia pseudomallei infection

    Science.gov (United States)

    Eng, Su Anne; Nathan, Sheila

    2014-09-01

    The established treatment for melioidosis is antibiotic therapy. However, a constant threat to this form of treatment is resistance development of the causative agent, Burkholderia pseudomallei, towards antibiotics. One option to circumvent this threat of antibiotic resistance is to search for new alternative anti-infectives which target the host innate immune system and/or bacterial virulence. In this study, 29 synthetic compounds were evaluated for their potential to increase the lifespan of an infected host. The nematode Caenorhabditis elegans was adopted as the infection model as its innate immune pathways are homologous to humans. Screens were performed in a liquid-based survival assay containing infected worms exposed to individual compounds and survival of untreated and compound-treated worms were compared. A primary screen identified nine synthetic compounds that extended the lifespan of B. pseudomallei-infected worms. Subsequently, a disc diffusion test was performed on these selected compounds to delineate compounds into those that enhanced the survival of worms via antimicrobial activity i.e. reducing the number of infecting bacteria, or into those that did not target pathogen viability. Out of the nine hits selected, two demonstrated antimicrobial effects on B. pseudomallei. Therefore, the findings from this study suggest that the other seven identified compounds are potential anti-infectives which could protect a host against B. pseudomallei infection without developing the risk of drug resistance.

  13. Trends in Bone Morphogenetic Protein Usage since the U.S. Food and Drug Administration Advisory in 2008: What Happens to Physician Practices When the Food and Drug Administration Issues an Advisory?

    Science.gov (United States)

    Mckie, Janay; Qureshi, Sheeraz; Iatridis, James; Egorova, Natalia; Cho, Samuel; Hecht, Andrew

    2014-06-01

    Study Design Retrospective cross-sectional study of spinal procedures from 2002 to 2010 using the Nationwide Inpatient Sample database. Objective To determine the patterns of bone morphogenetic protein (BMP) usage in fusion surgery before and after the U.S. Food and Drug Administration (FDA) 2008 advisory for the anterior cervical spine to understand how advisories affect U.S. physician practices. Methods Procedures were identified through International Classification of Diseases, Ninth Revision procedure codes and were plotted over time based on fusion procedure type, site, and area of fusion. U.S. national trends were approximated by polynomial regression analysis. Results The majority of the data trends of BMP usage reflect a second-order polynomial model. BMP usage in anterior cervical spine fusion procedures plateaued during the fourth quarter of 2007. The most apparent change in trend was noted in BMP usage pre- and postadvisory in the analysis of anterior cervical spine fusions. BMP percentage of use decreased in this area by 5% from the time of the FDA advisory to the fourth quarter of 2010. Conclusions The decrease in BMP usage in anterior cervical spinal fusion procedures coincided with the timing of the FDA advisory. The fact that BMP continued to be used in cervical spine fusion procedures, even at lower rates, despite the advisory, may reflect the availability of new clinical information that could lessen complications (i.e., lower BMP dose, perioperative steroids, BMP containment). Furthermore, factors like the natural ceiling effect of use or demand for new technology, complications, prohibitive institutional costs, access to information, and insurance compensation may have all contributed to the BMP usage trends observed.

  14. 78 FR 69991 - Advisory Committee; Veterinary Medicine Advisory Committee; Termination

    Science.gov (United States)

    2013-11-22

    ... HUMAN SERVICES Food and Drug Administration 21 CFR Part 14 Advisory Committee; Veterinary Medicine... Food and Drug Administration (FDA) is announcing the termination of the Veterinary Medicine Advisory Committee. This document removes the Veterinary Advisory Committee from the Agency's list of...

  15. 75 FR 35496 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-06-22

    ... Inn and Conference Center, University of Maryland University College, 3501 University Blvd. East... attendance of the public at its advisory committee meetings and will make every effort to accommodate...

  16. 75 FR 57474 - Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-09-21

    ... Marriott Inn and Conference Center, University of Maryland University College, 3501 University Boulevard... attendance of the public at its advisory committee meetings and will make every effort to accommodate...

  17. 76 FR 30176 - Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-05-24

    ... Marriott Inn and Conference Center, University of Maryland University College (UMUC), 3501 University Blvd... attendance of the public at its advisory committee meetings and will make every effort to accommodate...

  18. Anti-infective properties of bacteriocins: an update.

    Science.gov (United States)

    Hammami, Riadh; Fernandez, Benoit; Lacroix, Christophe; Fliss, Ismail

    2013-08-01

    Bacteriocin production is a widespread phenomenon among bacteria. Bacteriocins hold great promise for the treatment of diseases caused by pathogenic bacteria and could be used in the future as alternatives to existing antibiotics. The anti-infective potential of bacteriocins for inhibiting pathogens has been shown in various food matrices including cheese, meat, and vegetables. However, their inhibition of pathogens in vivo remains unclear and needs more investigation, due mainly to difficulties associated with demonstrating their health benefits. Many bacteriocins produced by established or potential probiotic organisms have been evaluated as potential therapeutic agents and interesting findings have been documented in vitro as well as in a few in vivo studies. Some recent in vivo studies point to the efficacy of bacteriocin-based treatments of human and animal infections. While further investigation remains necessary before the possibilities for bacteriocins in clinical practice can be described more fully, this review provides an overview of their potential applications to human and veterinary health.

  19. 76 FR 59143 - Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and...

    Science.gov (United States)

    2011-09-23

    ..., from 8 a.m. to 5 p.m. Location: The Marriott Inn and Conference Center, University of Maryland University College, The Ballroom, 3501 University Blvd. East, Adelphi, MD. The conference center telephone... welcomes the attendance of the public at its advisory committee meetings and will make every effort...

  20. 76 FR 59142 - Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and...

    Science.gov (United States)

    2011-09-23

    ..., from 8 a.m. to 5 p.m. Location: The Marriott Inn and Conference Center, University of Maryland University College (UMUC), The Ballroom, 3501 University Blvd., ] East, Adelphi, MD. The conference center... welcomes the attendance of the public at its advisory committee meetings and will make every effort...

  1. 75 FR 32188 - Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and...

    Science.gov (United States)

    2010-06-07

    ... before July 8, 2010. Oral presentations from the public will be scheduled between approximately 8:15 a.m. and 9:15 a.m. on July 23, 2010. Those desiring to make formal oral presentations should notify the... will solicit feedback from the advisory committees and public on the components of that proposal....

  2. Avian cathelicidins: paradigms for the development of anti-infectives.

    Science.gov (United States)

    van Dijk, A; Molhoek, E M; Bikker, F J; Yu, P-L; Veldhuizen, E J A; Haagsman, H P

    2011-11-21

    The broad-spectrum defense system based on host defense peptides (HDPs) is evolutionary very old and many invertebrates rely on this system for protection from bacterial infections. However, in vertebrates the system remained important in spite of the superposition of a very sophisticated adaptive immune system. The cathelicidins comprise a major group of HDPs in mammals. About six years ago it was first described that cathelicidins are also present in birds. Here we review the properties and biological activities of the recently discovered avian cathelicidins and their potential to be used as a paradigm for the development of anti-infectives. Like the mammalian cathelicidins, avian cathelicidins exert direct antimicrobial activities but can also selectively boost host immune responses by regulation of cytokine production and recruitment of immune cells. In addition, it was found that chicken cathelicidins bind endotoxins and dampen the endotoxin-mediated inflammatory response. Molecular dissection has allowed identification of different structural elements involved in bacterial killing and immunomodulation. These studies have enabled the design of small HDP-based antibiotics with specific functions, i.e. having primarily immunomodulatory or antimicrobial activities. Since the immunomodulatory effects may, to a certain degree, be species-specific, we hypothesize that poultry-specific antibiotics can be developed based on avian cathelicidins.

  3. 77 FR 36548 - Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-06-19

    ... disability, visitor parking, and transportation may be accessed at: http://www.fda.gov/AdvisoryCommittees... neovascular (wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion... make every effort to accommodate persons with physical disabilities or special needs. If you...

  4. Anti-infective potential of hot-spring bacteria

    Directory of Open Access Journals (Sweden)

    Pallavi Pednekar

    2011-01-01

    Full Text Available Aim and Background: Antibiotic resistance currently spans most of the known classes of natural and synthetic antibiotics; limiting our options for treatment of infections and demanding discovery of new classes of antibiotics. Much effort is being directed towards developing new antibiotics to overcome this problem. Success in getting novel chemical entities from microbial sources depends essentially on novelty of its habitat. The diversity of geographical location decides the type of micro-flora. In the past various terrestrial and aqueous microorganisms have provided several novel bioactive secondary metabolites of pharmaceutical importance. Hot-springs have not been as extensively exploited as other terrestrial resources. However, perseverance with such microbes augment the probability of getting novel bioactive compounds. Materials and Methods: Hot-springs soil samples were collected from Hot-springs in Maharashtra. Actinomycetes and other eubacteria were isolated from these soil samples by selective methods and purified. They were classified based on gram′s nature and morphology. Six representative morphological strains were screened for their anti-infective potential by agar well diffusion method as reported by Nathan P. et al (1974. The bioactivity of the active microbes was confirmed. Results: Seventy three strains of bacteria encompassing eight actinomycetes, and 65 eubacteria were isolated and purified. Among the actives eubacteria PPVWK106001 showed broad spectrum antibacterial activity encompassing both gram positive and gram negative bacterial test models. The extract was active against resistant bacteria such as MRSA and VREs. Activity was very specific as there was no activity against fungi even at 100 fold concentration. The active principle was extractable in butanol. Conclusions: The study showed that Hot-springs exhibit diverse bacteria and it serves as potential reservoirs for bacteria of antimicrobial importance with

  5. 77 FR 20643 - Blood Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-04-05

    ... HUMAN SERVICES Food and Drug Administration Blood Products Advisory Committee; Notice of Meeting AGENCY... public. Name of Committee: Blood Products Advisory Committee. General Function of the Committee: To... following links. Blood Products Advisory Committee Web Cast Link May 15...

  6. 77 FR 67013 - Blood Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-11-08

    ... HUMAN SERVICES Food and Drug Administration Blood Products Advisory Committee; Notice of Meeting AGENCY... public. Name of Committee: Blood Products Advisory Committee. General Function of the Committee: To... links: December 4, 2012: Blood Products Advisory Committee Day 1:...

  7. Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy.

    Science.gov (United States)

    Lee, Sie Huey; Teo, Jeanette; Heng, Desmond; Zhao, Yanli; Ng, Wai Kiong; Chan, Hak-Kim; Tan, Reginald B H

    2014-04-01

    Despite advances in vaccination and antimicrobial therapy, community-acquired pneumonia (CAP) remains as a leading cause of morbidity and mortality worldwide. As the severity of CAP has been linked to the extent of inflammation in the body, adjunctive therapeutic measures aimed at modulating the immune response have therefore become increasingly attractive in recent years. In particular, for CAP patients with underlying medical conditions such as chronic obstructive pulmonary disease (COPD), a steroid-antibiotic combination will no doubt be a useful and timely therapeutic intervention. Unfortunately, no combined steroid-antibiotic dry powder formulation is available commercially or has been reported in the academic literature. The aim of this work was hence to develop a novel steroid-antibiotic dry powder inhaler formulation [ciprofloxacin hydrochloride (CIP) and beclomethasone dipropionate (BP)] for inhaled anti-infective therapy. The spray-dried powder was of respirable size (d50 of ∼2.3 μm), partially crystalline and had BP preferentially deposited on the particle surface. Favorably, when formulated as a binary mix, both CIP and BP showed much higher drug release and fine particle fractions (of the loaded dose) over their singly delivered counterparts, and had robust activity against the respiratory tract infection-causing bacteria Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus.

  8. 77 FR 57095 - Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-09-17

    ... HUMAN SERVICES Food and Drug Administration Pediatric Oncology Subcommittee of the Oncologic Drugs... (FDA). The meeting will be open to the public. Name of Committee: Pediatric Oncology Subcommittee of... plans for four products that are in development for an adult oncology indication. The subcommittee...

  9. 75 FR 66773 - Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-10-29

    ... HUMAN SERVICES Food and Drug Administration Pediatric Oncology Subcommittee of the Oncologic Drugs... (FDA). The meeting will be open to the public. Name of Committee: Pediatric Oncology Subcommittee of... were either recently approved by FDA or, are in late stage development for an adult oncology...

  10. 78 FR 63222 - Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-10-23

    ... HUMAN SERVICES Food and Drug Administration Pediatric Oncology Subcommittee of the Oncologic Drugs... ] (FDA). The meeting will be open to the public. Name of Committee: Pediatric Oncology Subcommittee of... relevance and potential use of such measures in the pediatric development plans of oncology products....

  11. 76 FR 58520 - Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-09-21

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Pediatric Oncology Subcommittee of the Oncologic Drugs... (FDA). The meeting will be open to the public. Name of Committee: Pediatric Oncology Subcommittee...

  12. 78 FR 63224 - Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-10-23

    ... HUMAN SERVICES Food and Drug Administration Pediatric Oncology Subcommittee of the Oncologic Drugs... (FDA). The meeting will be open to the public. Name of Committee: Pediatric Oncology Subcommittee of... late stage development for various adult oncology indications. The subcommittee will consider...

  13. 76 FR 61713 - Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-10-05

    ... HUMAN SERVICES Food and Drug Administration Pediatric Oncology Subcommittee of the Oncologic Drugs... (FDA). The meeting will be open to the public. Name of Committee: Pediatric Oncology Subcommittee of..., are in late stage development for an adult oncology indication, or in late stage development...

  14. New Anti-Infective Coatings of Medical Implants▿

    OpenAIRE

    Matl, F. D.; Obermeier, A.; Repmann, S.; Friess, W.; Stemberger, A; Kuehn, K.-D.

    2008-01-01

    Implantable devices are highly susceptible to infection and are therefore a major risk in surgery. The present work presents a novel strategy to prevent the formation of a biofilm on polytetrafluoroethylene (PTFE) grafts. PTFE grafts were coated with gentamicin and teicoplanin incorporated into different lipid-like carriers under aseptic conditions in a dipping process. Poly-d,l-lactic acid, tocopherol acetate, the diglyceride Softisan 649, and the triglyceride Dynasan 118 were used as drug c...

  15. 78 FR 734 - Medical Imaging Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-01-04

    ... Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver... (from neonates to 17 years of age) to detect and visualize areas with disruption of the blood...

  16. 78 FR 20327 - Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and...

    Science.gov (United States)

    2013-04-04

    ... indication of replacement ] therapy in adult males for conditions associated with a deficiency or absence of testosterone. The safety discussion will focus on postmarketing reports of oil microembolism in the lungs and... committee will discuss the efficacy and safety of new drug application (NDA) 22219, AVEED...

  17. Revealing indigenous Indonesian traditional medicine: anti-infective agents.

    Science.gov (United States)

    Nugraha, Ari S; Keller, Paul A

    2011-12-01

    Indonesia is rich in medicinal plants which the population has used traditionally from generation to generation for curing diseases. Our interest in the treatment of infectious diseases has lead to the investigation of traditional Indonesian treatments. In this review, we present a comprehensive review of ethnopharmacologically directed screening in Indonesian medicinal plants to search for new anti-viral, antimalarial, anti-bacterial and anti-fungal agents. Some potent drug leads have been isolated from Indonesian medicinal plants. Further research is still required for the lead development as well as the search for new bioactive compounds from the enormous medicinal plant resources.

  18. Analysis of use of anti-infectives in the hospital pharmacy%某住院药房抗感染药物使用情况分析

    Institute of Scientific and Technical Information of China (English)

    李秀敏; 范胜军

    2010-01-01

    Objective To analyze the use of anti-infectives in our hospital pharmacy and to provide basis for rational clinical use of anti-infectives. Methods The analysis was conducted using the methods of defined daily use and order of consumption sum based on the raw data retrieved from Hospital Drug Inventory Management System. Results Anti-infectives using proportion after November droped. The use of varieties followed by the biggest amount of injection cefminox sodium,piperacillin sodium and sulbactam sodium for injection,cefazolin sodium needles. Medication is the highest frequency of piperacillin sodium and sulbactam sodium needles,cefminox needle,needle penicillin sodium. Conclusion Use of anti-infectives'situation wholely became stable. β-lactams,Quinolones was our clinical anti-infection treatment leading medicine. The individual frequency of use high variety took the amount rise,and it explained that still waited for the standard in antibiotics use.%目的 分析住院药房抗感染药物的使用情况,为临床合理应用抗感染药提供参考.方法 根据"药局库存管理程序"的原始数据资料,按金额、限定日剂量进行排序、分析.结果 抗感染药物使用比例从11月份后有所下降,使用金额最大的品种依次是注射用头孢米诺钠、注射用哌拉西林钠舒巴坦钠、头孢唑啉钠针,用药频率最高的是哌拉西林钠舒巴坦钠针、头孢米诺钠针、青霉素钠针.结论 抗感染用药情况整体趋稳,β-内酰胺类、喹诺酮类是临床抗感染治疗的主导药物,个别使用频率较高的品种占用金额上升,说明在抗菌药物的使用上仍有待规范.

  19. Recent advances in design of potential quinoxaline anti-infectives.

    Science.gov (United States)

    Jampilek, Josef

    2014-01-01

    Antimicrobial diazanaphthalenes are indispensable in the treatment of various infections. The quinoxaline scaffold possesses unique physicochemical properties and provides a possibility of a great number of targeted modifications. Quinoxaline-based compounds have a wide range of promising biological properties; therefore a special attention is paid to them for research and designing of new drugs. In fact, quinoxaline can be considered as a privileged structure. The scaffold can be easily and rapidly constructed, which emphasizes the significance of this favourable structure. The review is focused on recently reported potential antibacterial, antimycobacterial, antifungal and antiprotozoal agents derived from the quinoxaline scaffold, their mechanism of action and structure-activity relationships. A brief classification of synthetic pathways of quinoxaline derivatives is provided too.

  20. 77 FR 6567 - Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-02-08

    ... the heading ``Resources for You,'' click on ``Public Meetings at the FDA White Oak Campus.'' Please... enough to provide timely notice. Therefore, you should always check the Agency's Web site and call the... preapproval and postapproval settings for drugs and biologics developed for the treatment of obesity....

  1. Are counterfeit or substandard anti-infective products the cause of treatment failure in Papua New Guinea?

    Science.gov (United States)

    Nair, Anita; Strauch, Stefanie; Lauwo, Jackson; Jähnke, Richard W O; Dressman, Jennifer

    2011-11-01

    Counterfeit and substandard products present a big challenge to any national plan or policy devised to improve public health. Poor quality drug products are especially a problem in lower income countries where product information and drug regulation enforcement are scant or absent. The primary aim of the present study was to evaluate the quality of amodiaquine and amoxicillin formulations sold in Papua New Guinea (PNG) and to detect the presence of counterfeit or substandard drugs in circulation, if any. Fourteen samples, collected from five registered pharmacies in Port Moresby, PNG, were subjected to visual inspection, quality control tests, and verification of product authenticity. The quality control tests included weight variation, content uniformity, thin layer chromatography, and dissolution. None of the products complied with all of the evaluation criteria. Two products, one of which was purportedly distributed by a company which proved to be nonexistent, contained no detectable amodiaquine. The present study confirms that counterfeit and substandard amodiaquine and amoxicillin products are finding their way into the distribution chain in Port Moresby, PNG. This quality problem with anti-infective products is of great concern, as it not only exposes patients to poor quality products but also fosters the development of resistant bacterial strains.

  2. Novel anti-infective potential of salvianolic acid B against human serious pathogen Neisseria meningitidis

    OpenAIRE

    Huttunen, Sanna; Toivanen, Marko; Liu, Chenghai; Tikkanen-Kaukanen, Carina

    2016-01-01

    Background Epidemics of meningococcal meningitis cause significant health problems especially in Sub-Saharan Africa. Novel anti-infective candidates are needed. In modern anti-adhesion therapy initial attachment of bacteria to host cells is prevented. Our unique studies have revealed anti-adhesive candidates from natural products, namely milk and berries, against Neisseria meningitidis adhesion. In the present study against N. meningitidis adhesion, a novel binding inhibitor was found; salvia...

  3. Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives.

    Science.gov (United States)

    Mahapatra, Debarshi Kar; Bharti, Sanjay Kumar; Asati, Vivek

    2015-08-28

    In recent years, widespread outbreak of numerous infectious diseases across the globe has created havoc among the population. Particularly, the inhabitants of tropical and sub-tropical regions are mainly affected by these pathogens. Several natural and (semi) synthetic chalcones deserve the credit of being potential anti-infective candidates that inhibit various parasitic, malarial, bacterial, viral, and fungal targets like cruzain-1/2, trypanopain-Tb, trans-sialidase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), fumarate reductase, falcipain-1/2, β-hematin, topoisomerase-II, plasmepsin-II, lactate dehydrogenase, protein kinases (Pfmrk and PfPK5), and sorbitol-induced hemolysis, DEN-1 NS3, H1N1, HIV (Integrase/Protease), protein tyrosine phosphatase A/B (Ptp-A/B), FtsZ, FAS-II, lactate/isocitrate dehydrogenase, NorA efflux pump, DNA gyrase, fatty acid synthase, chitin synthase, and β-(1,3)-glucan synthase. In this review, a comprehensive study (from Jan. 1982 to May 2015) of the structural features of anti-infective chalcones, their mechanism of actions (MOAs) and structure activity relationships (SARs) have been highlighted. With the knowledge of molecular targets, structural insights and SARs, this review may be helpful for (medicinal) chemists to design more potent, safe, selective and cost effective anti-infective agents.

  4. 75 FR 52605 - Veterinary Medicine Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-08-26

    ... HUMAN SERVICES Food and Drug Administration Veterinary Medicine Advisory Committee; Notice of Meeting... the public. Name of Committee: Veterinary Medicine Advisory Committee. General Function of the...-1100. Contact Person: Aleta Sindelar, Center for Veterinary Medicine (HFV-3), Food and...

  5. Chinese patent of anti-infective urinary catheter%抗感染尿管获中国专利现况

    Institute of Scientific and Technical Information of China (English)

    熊国兵; 王寓; 邱明星

    2015-01-01

    application. METHODS:Al related Chinese patent papers of anti-infective urinary catheters were retrieved by Google’s proprietary search platform (http://www.google.com/advanced_patent_search) until the deadline of March 26, 2014, with the search strategy of‘Return the patents with the fol owing proprietary name:urinary catheter’. RESULTS AND CONCLUSION:According to the predefined search strategy, 949 potential y relevant patent papers were screened out for further identification, and 23 papers referred to anti-infective catheters that were obviously eligible were included. The analyses showed that:(1) The antibacterial coating agents of the majority of papers were antibacterial agents of nano-inorganic metal cations, only four papers used antibiotic coated. (2) The drug-eluting catheters were mainly composite-coated. (3) The drug release modes from coating were mainly extended-release but release mechanism was not clarified. (4) The preparation process was chemical bond or ionic bond in one paper, blending methods in one paper, repeated electroplating in one paper, electrospinning technology in one paper, and physical impregnation methods in 12 papers (52.17%). (5) The antimicrobial mode was ultrasonic-antibacterial method in two patent papers, sterile sleeve in one paper, hydrophilic coating in one paper, catheter made by blending polymer material and anti-infective agents in one paper, drug coated films made by coating with antimicrobial drug liquid and drying process in 20 papers (82.61%). In conclusion, there have been no translational and applied clinical researches about the anti-infective urinary catheter, and the relevant researches were only at the laboratory level. The research methods of Chinese patent for anti-infective urinary catheter were limited, and need to be further improved.

  6. Chemogenomics driven discovery of endogenous polyketide anti-infective compounds from endosymbiotic Emericella variecolor CLB38 and their RNA secondary structure analysis

    Science.gov (United States)

    Yashavantha Rao, H. C.; Rakshith, Devaraju; Harini, Ballagere Puttaraju; Gurudatt, Doddahosuru Mahadevappa; Satish, Sreedharamurthy

    2017-01-01

    In the postgenomic era, a new strategy for chemical dereplication of polyketide anti-infective drugs requires novel genomics and chromatographic strategies. An endosymbiotic fungal strain CLB38 was isolated from the root tissue of Combretum latifolium Blume (Combretaceae) which was collected from the Western Ghats of India. The isolate CLB38 was then identified as Emericella variecolor by its characteristic stellate ascospores culture morphology and molecular analysis of ITS nuclear rDNA and intervening 5.8S rRNA gene sequence. ITS2 RNA secondary structure modeling clearly distinguished fungal endosymbiont E. variecolor CLB38 with other lifestyles in the same monophyletic clade. Ethyl acetate fraction of CLB38 explored a broad spectrum of antimicrobial activity against multidrug resistant pathogens. Biosynthetic PKS type-I gene and chromatographic approach afford two polyketide antimicrobial compounds which identified as evariquinone and isoindolones derivative emerimidine A. MIC of purified compounds against test microorganisms ranged between 3.12 μg/ml and 12.5 μg/ml. This research highlights the utility of E. variecolor CLB38 as an anticipate source for anti-infective polyketide metabolites evariquinone and emerimidine A to combat multidrug resistant microorganisms. Here we demonstrates a chemogenomics strategy via the feasibility of PKS type-I gene and chromatographic approach as a proficient method for the rapid prediction and discovery of new polyketides compounds from fungal endosymbionts. PMID:28245269

  7. The anti-infective activity of punicalagin against Salmonella enterica subsp. enterica serovar typhimurium in mice.

    Science.gov (United States)

    Li, Guanghui; Feng, Yuqing; Xu, Yunfeng; Wu, Qian; Han, Qi'an; Liang, Xiujun; Yang, Baowei; Wang, Xin; Xia, Xiaodong

    2015-07-01

    Punicalagin, a major bioactive component of pomegranate peel, has been proven to have antioxidant, antiviral, anti-apoptosis, and hepatoprotective properties. The aim of this study was to investigate the anti-infective activity of punicalagin in a mouse model. C57BL/6 mice were initially challenged with Salmonella enterica subsp. enterica serovar typhimurium (S. typhimurium) and then treated with punicalagin. Food and water consumption and body weight were recorded daily. On day 8 post infection, the mice were sacrificed to examine pathogen counts in tissues, hematological parameters, cytokine levels, and histological changes. Compared to mice only infected with S. typhimurium, punicalagin-treated mice had more food consumption and less weight loss. A higher survival rate and lower counts of viable S. typhimurium in feces, liver, spleen, and kidney were found in the punicalagin-treated mice. The enzyme linked immunosorbent assay showed that the levels of IL-6, IL-10, and IFN-γ in serum and the spleen and TNF-α in serum, the spleen and the liver were reduced by punicalagin. Moreover, more neutrophils and higher neutrophil-to-mononuclear cell ratios in the punicalagin-treated mice were observed. Histological examination showed that punicalagin protected cells in the liver and spleen from hemorrhagic necrosis. It is concluded that punicalagin has a beneficial effect against S. typhimurium infection in mice. The anti-infective properties, together with other nutritionally beneficial effects, make punicalagin a promising supplement in human food or animal feeds to prevent disease associated with S. typhimurium.

  8. Solvothermal synthesis of ZnO nanoparticles and anti-infection application in vivo.

    Science.gov (United States)

    Bai, Xiangyang; Li, Linlin; Liu, Huiyu; Tan, Longfei; Liu, Tianlong; Meng, Xianwei

    2015-01-21

    Zinc oxide nanoparticles (ZnONPs) have been widely studied as the bacteriostatic reagents. However, synthesis of small ZnO nanoparticles with good monodispersion and stability in aqueous solution is still a challenge. Anti-infection research of ZnONPs used as antibacterial agent in vivo is rare. In this paper, a novel, sustainable, and simple method to synthesize ZnO nanoparticles with good monodispersion in aqueous low-temperature conditions and with a small molecule agent is reported. Inhibition zone test and the minimum inhibitory concentration test were performed to examine the antibacterial activity of ZnONPs against bacteria Staphylococcus aureus and Escherichia coli in vitro. For further application in vivo, low cytotoxicity and low acute toxicity in mice of ZnO were demonstrated. Finally, 4 nm ZnONPs combined with poly(vinyl alcohol) gel was used as antibacterial agent in rodent elytritis model, and significant anti-infection effect was proven. In one word, the present research would shed new light on the designing of antibacterial materials like ZnO with promising application in disinfection.

  9. 75 FR 65641 - Risk Communication Advisory Committee; Amendment of Notice

    Science.gov (United States)

    2010-10-26

    ... HUMAN SERVICES Food and Drug Administration Risk Communication Advisory Committee; Amendment of Notice... announcing an amendment to the notice of meeting of the Risk Communication Advisory Committee. This meeting... announced that a meeting of the Risk Communication Advisory Committee would be held on November 8 and...

  10. 77 FR 4567 - Blood Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-01-30

    ... HUMAN SERVICES Food and Drug Administration Blood Products Advisory Committee; Notice of Meeting AGENCY... public. Name of Committee: Blood Products Advisory Committee. General Function of the Committee: To..., the meeting will also be Web cast. The Blood Products Advisory Committee Web cast will be available...

  11. Bioprospecting Micromonospora from Kaziranga National Park of India and their anti-infective potential.

    Science.gov (United States)

    Talukdar, Madhumita; Duarah, Aparajita; Talukdar, Shruti; Gohain, Manorama Bura; Debnath, Rajal; Yadav, Archana; Jha, Dhruva K; Bora, Tarun C

    2012-08-01

    Large number of strains was isolated from soils of Kaziranga National Park of North-East India using selective isolation procedure. They were assigned to the genus Micromonospora on the basis of their typical colonial and pigmentation features. The taxonomic identities of the isolates were confirmed on the basis of their molecular characters (16SrDNA). A total of one hundred Micromonospora strains were isolated during the present investigation. The diagnostic cell wall sugar and amino acids were determined from these Micromonospora strains. After preliminary screening most of the isolates exhibited excellent anti-infective activity against human bacterial pathogens Staphylococcus aureas, Bacillus subtilis, Proteus vulgaris, Echerichia coli, Pseudomonas aeroginosa and fungal pathogens Aspergillus niger, Fusarium oxysporum and Candida albicans. Among these isolates one strain designated as HK-10 showed promising activity against human pathogens S. aureas, B. subtilis, P. vulgaris and P. aeroginosa.

  12. Bacteriophages as anti-infective agents: recent developments and regulatory challenges.

    Science.gov (United States)

    Gilmore, Brendan F

    2012-05-01

    The biennial meeting on 'Exploiting Bacteriophages for Bioscience, Biotechnology and Medicine', held in London, UK, on 20 January 2012, and chaired by George Salmond (University of Cambridge, UK) hosted over 50 participants representing 13 countries. The highly multidisciplinary meeting covered a diverse range of topics, reflecting the current expansion of interest in this field, including the use of bacteriophages as the source of biochemical reagents for molecular biology, bacteriophages for the treatment of human and animal diseases, bacteriophage-based diagnostics and therapeutic delivery technologies and necessity for, and regulatory challenges associated with, robust clinical trials of phage-based therapeutics. This report focuses on a number of presentations from the meeting relating to cutting-edge research on bacteriophages as anti-infective agents.

  13. Identification of potential anti-infectives against Staphylococcus aureus using a Caenorhabditis elegans infection model

    Science.gov (United States)

    Kong, Cin; Rahman, Noorsaadah Abd; Nathan, Sheila

    2014-09-01

    The alarming increase of antibiotic-resistant Staphylococcus aureus and a delay in antibiotics development point to the need for novel therapeutic approaches to combat infection. To discover novel anti-infective agents, we screened a number of synthetic compounds comprising mainly of chalcone derivatives to explore their potential in promoting the survival of the nematode Caenorhabditis elegans upon infection by S. aureus. Screening of seven chalcone derivatives using both agar- and liquid-based assays revealed three positive hits that significantly prolonged the survival of S. aureus-infected nematodes. All the hits did not interfere with bacterial growth in vitro, proposing that the three compounds identified most probably act through mechanisms distinct from conventional antibiotics that target bacterial replication.

  14. PRENYLATED BENZOIC ACID DERIVATIVES FROM PIPER SPECIES AS SOURCE OF ANTI-INFECTIVE AGENTS

    Directory of Open Access Journals (Sweden)

    Ibrahim Malami

    2012-06-01

    Full Text Available A number of prenylated benzoic acids derivatives with interesting biological activities have been previously isolated and characterized from different species of piperaceae family. Several Piper species contained structurally similar compounds with diverse biological activities such as anti-bacterial, anti-fungal, insecticidal as well as anti-parasitic all of which produces compounds that can be classified as prenylated benzoic acid derivatives. Piper sp has proven to serve as a source of potential anti-infective agents by developing a biosynthetic route to the synthesis of prenylated benzoic acids derivative natural products as their chemical defense system. Despite the frequent isolation of these interesting compounds with strong biological activity, yet none have been taking into consideration for development into therapeutic agents.

  15. Using antimicrobial host defense peptides as anti-infective and immunomodulatory agents.

    Science.gov (United States)

    Kruse, Thomas; Kristensen, Hans-Henrik

    2008-12-01

    Virtually all life forms express short antimicrobial cationic peptides as an important component of their innate immune defenses. They serve as endogenous antibiotics that are able to rapidly kill an unusually broad range of bacteria, fungi and viruses. Consequently, considerable efforts have been expended to exploit the therapeutic potential of these antimicrobial peptides. Within the last couple of years, it has become increasingly clear that many of these peptides, in addition to their direct antimicrobial activity, also have a wide range of functions in modulating both innate and adaptive immunity. For one class of antimicrobial peptides, such as the human defensins, their primary role may even be as immunomodulators. These properties potentially provide entirely new therapeutic approaches to anti-infective therapy.

  16. 77 FR 10755 - Request for Nominations for Voting Members on a Public Advisory Committee; Risk Communication...

    Science.gov (United States)

    2012-02-23

    ... HUMAN SERVICES Food and Drug Administration Request for Nominations for Voting Members on a Public Advisory Committee; Risk Communication Advisory Committee AGENCY: Food and Drug Administration, HHS. ACTION... the Risk Communication Advisory Committee, Office of Planning, Office of Policy and Planning,...

  17. 76 FR 60848 - National Mammography Quality Assurance Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-09-30

    ... HUMAN SERVICES Food and Drug Administration National Mammography Quality Assurance Advisory Committee... be open to the public. Name of Committee: National Mammography Quality Assurance Advisory Committee...) Proposed changes to the Mammography Quality Standard Act (MQSA) policies and inspection procedures;...

  18. 78 FR 12068 - Device Good Manufacturing Practice Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-02-21

    ... HUMAN SERVICES Food and Drug Administration Device Good Manufacturing Practice Advisory Committee... meeting will be open to the public. Name of Committee: Device Good Manufacturing Practice Advisory... effects of extreme weather and natural disasters on medical device manufacturing chain processes...

  19. 75 FR 65640 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-10-26

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice and... Tumor Vaccines and Biotechnology Branch, Office of Cellular, Tissue and Gene Therapies, Center...

  20. 77 FR 73472 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-12-10

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice...

  1. 76 FR 52334 - Arthritis Advisory Committee; Notice of Postponement of Meeting

    Science.gov (United States)

    2011-08-22

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Postponement of... Administration (FDA) is postponing the Arthritis Advisory Committee meeting scheduled for September 13,...

  2. 75 FR 74735 - Food Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-12-01

    ...'s consumption of synthetic color additives in food and adverse effects on behavior. FDA intends to... HUMAN SERVICES Food and Drug Administration Food Advisory Committee; Notice of Meeting AGENCY: Food and... advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public....

  3. 77 FR 7588 - Blood Products Advisory Committee; Cancellation

    Science.gov (United States)

    2012-02-13

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Blood Products Advisory Committee; Cancellation AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The meeting of the Blood Products...

  4. Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis

    Directory of Open Access Journals (Sweden)

    Timothy L Comstock

    2010-03-01

    Full Text Available Timothy L Comstock1, Paul M Karpecki2, Timothy W Morris3, Jin-Zhong Zhang41Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc., Rochester, NY, USA; 2Koffler Vision Group, Lexington, KY, USA; 3Research and Development Microbiology and Sterilization Sciences, Bausch and Lomb, Inc., Rochester, NY, USA; 4Global Preclinical Development, Bausch and Lomb, Inc., Rochester, NY, USAAbstract: Bacterial conjunctivitis, commonly known as pink eye, is demographically unbiased in its prevalence and can be caused by a variety of aerobic and anaerobic bacteria. Timely empiric treatment with a broad-spectrum anti-infective, such as a topical fluoroquinolone, is critical in preventing potentially irreversible ocular damage. However, the rise in ocular methicillin-resistant Staphylococcus aureus isolates and the patterns of fluoroquinolone resistance for patients with other ocular bacterial infections mandate the need for new agents targeted for ocular use. Besifloxacin, a novel broad-spectrum fluoroquinolone, is approved for the treatment of bacterial conjunctivitis. It has a uniquely balanced dual-targeting activity that inhibits both DNA gyrase and topoisomerase IV and is associated with a lower incidence of resistance development. Besifloxacin is not marketed in other formulations, ensuring that its exposure is limited to bacterial populations in and around the eye. This specifically precludes any bacterial exposure to besifloxacin resulting from systemic use, which further reduces the likelihood of emergence of bacterial resistance. In vitro, besifloxacin has demonstrated equivalent or superior activity compared with other commonly used topical antibiotics. In clinical trials, besifloxacin has consistently demonstrated efficacy and safety in the treatment of patients with bacterial conjunctivitis. Besifloxacin is considered safe and is well tolerated with no observed contraindications.Keywords: conjunctivitis, fluoroquinolones, besifloxacin

  5. Drug: D00830 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available cal; Antiprotozoal [trichomonas, topical] Same as: C07999 ATC code: G01AX06 Anatomi...D00830 Drug Furazolidone (USP/INN); Furoxone (TN) C8H7N3O5 225.0386 225.1583 D00830.gif Anti-infective, topi

  6. Drugs + HIV, Learn the Link

    Medline Plus

    Full Text Available ... Adolescent Brain Comorbidity College-Age & Young Adults Criminal Justice Drugged Driving Drug Testing Drugs and the Brain ... Meetings & Events Media Guide About NIDA Director's Page Organization Legislative Activities Advisory Boards & Groups Working at NIDA ...

  7. Anti-infective properties of the melanin-glucan complex obtained from medicinal tinder bracket mushroom, Fomes fomentarius (L.: Fr.) Fr. (Aphyllophoromycetideae).

    Science.gov (United States)

    Seniuk, Olga F; Gorovoj, Leontiy F; Beketova, Galina V; Savichuk, Hatalia O; Rytik, Petr G; Kucherov, Igor I; Prilutskay, Alla B; Prilutsky, Alexandr I

    2011-01-01

    The goal of this investigation was to comparatively study the efficiency of traditionally used anti-infective drugs and biopolymer complexes originated from the medicinal mushroom Fomes fomentarius (L.:Fr.) Fr.: 1) water-soluble melanin-glucan complex (MGC; -80% melanins and -20% beta-glucans) and 2) insoluble chitin-glucan-melanin complex (ChGMC; -70% chitin, -20% beta-glucans, and -10% melanins). Infectious materials (Helicobacter pylori, Candida albicans, and Herpes vulgaris I and HIV-1(zmb) were used in pure cultures of in vitro and in vivo models on experimental animals. Comparison studies of fungal biopolymers and effective modern antifungal, antibacterial, and antiviral drugs were used in in vitro models. The comparative clinical efficiency of ChGMC and of etiotropic pharmaceuticals in models of H. pylori, C. albicans, and H. vulgaris I infection contamination were studied. Using in vitro models, it was established that MGC completely depresses growth of C. albicans. MGC had an antimicrobial effect on H. pylori identical to erythromycin in all concentrations, and had a stronger action on this bacterium than other tested antibiotics. Tested MGC possesses simultaneously weak toxicity and high anti-HIV-1 activity in comparison with zidovudine (Retrovir). The obtained results show that CLUDDT therapy in Wistar rats with the application of ChGMC is, on average, 1.35-1.43 times as effective as a traditional one. Considering the absence of MGC and ChGMC toxic properties on blood cells even in very high concentrations, these complexes may be used as a source of biopolymers for the creation of essentially new agents for wide application in infectious pathology.

  8. 77 FR 64524 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-10-22

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice...

  9. 76 FR 29767 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-05-23

    ... HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice and... arthritis attacks. ILARIS has also been shown to extend the time to the next attack and reduce the...

  10. 75 FR 55805 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-09-14

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice...

  11. 78 FR 32403 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-05-30

    ... HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice and... meeting. Agenda: On July 22, 2013, the committee will discuss the Assessment of...

  12. 77 FR 13611 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-03-07

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice...

  13. 77 FR 14529 - Arthritis Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-03-12

    ... HUMAN SERVICES Food and Drug Administration Arthritis Advisory Committee; Notice of Meeting AGENCY: Food... of Committee: Arthritis Advisory Committee. General Function of the Committee: To provide advice and... moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more...

  14. 75 FR 4576 - Veterinary Medicine Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-01-28

    ... HUMAN SERVICES Food and Drug Administration Veterinary Medicine Advisory Committee; Notice of Meeting... the public. Name of Committee: Veterinary Medicine Advisory Committee. General Function of the... Rockville Pike, Rockville MD 20852, 301-468-1100. Contact Person: Aleta Sindelar, Center for...

  15. 77 FR 29667 - Blood Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-05-18

    ... No. FDA-2012-N-0001] Blood Products Advisory Committee; Notice of Meeting AGENCY: Food and Drug... public. Name of Committee: Blood Products Advisory Committee. General Function of the Committee: To..., Office of Blood Research and Review, Center for Biologics Evaluation and Research, FDA. FDA intends...

  16. 78 FR 56899 - Blood Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-09-16

    ... HUMAN SERVICES Food and Drug Administration Blood Products Advisory Committee; Notice of Meeting AGENCY... will be closed to the public. Name of Committee: Blood Products Advisory Committee. General Function of... Blot 2.4, a Western Blot intended for use as a confirmatory test for blood donors. In the...

  17. 78 FR 38351 - Blood Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-06-26

    ... HUMAN SERVICES Food and Drug Administration Blood Products Advisory Committee; Notice of Meeting AGENCY... will be closed to the public. Name of Committee: Blood Products Advisory Committee. General Function of..., Office of Blood Research and Review, Center for Biologics Evaluation and Research, FDA. FDA intends...

  18. 78 FR 2677 - Blood Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-01-14

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Blood Products Advisory Committee; Notice of Meeting AGENCY... public. Name of Committee: Blood Products Advisory Committee. General Function of the Committee:...

  19. Effect of Winemaking on the Composition of Red Wine as a Source of Polyphenols for Anti-Infective Biomaterials

    Directory of Open Access Journals (Sweden)

    Arianna Di Lorenzo

    2016-04-01

    Full Text Available Biomaterials releasing bactericides have currently become tools for thwarting medical device-associated infections. The ideal anti-infective biomaterial must counteract infection while safeguarding eukaryotic cell integrity. Red wine is a widely consumed beverage to which many biological properties are ascribed, including protective effects against oral infections and related bone (osteoarthritis, osteomyelitis, periprosthetic joint infections and cardiovascular diseases. In this study, fifteen red wine samples derived from grapes native to the Oltrepò Pavese region (Italy, obtained from the winemaking processes of “Bonarda dell’Oltrepò Pavese” red wine, were analyzed alongside three samples obtained from marc pressing. Total polyphenol and monomeric anthocyanin contents were determined and metabolite profiling was conducted by means of a chromatographic analysis. Antibacterial activity of wine samples was evaluated against Streptococcus mutans, responsible for dental caries, Streptococcus salivarius, and Streptococcus pyogenes, two oral bacterial pathogens. Results highlighted the winemaking stages in which samples exhibit the highest content of polyphenols and the greatest antibacterial activity. Considering the global need for new weapons against bacterial infections and alternatives to conventional antibiotics, as well as the favorable bioactivities of polyphenols, results point to red wine as a source of antibacterial substances for developing new anti-infective biomaterials and coatings for biomedical devices.

  20. Anti-Infective Metabolites of a Newly Isolated Bacillus thuringiensis KL1 Associated with Kalmegh (Andrographis paniculata Nees.), a Traditional Medicinal Herb.

    Science.gov (United States)

    Roy, Sudipta; Yasmin, Sahana; Ghosh, Subhadeep; Bhattacharya, Somesankar; Banerjee, Debdulal

    2016-01-01

    This study was conducted to isolate endophytic bacteria possessing anti-infective property from Kalmegh (Andrographis paniculata Nees.), a well-known medicinal plant. A total of 23 strains were isolated from this plant among which the strain KL1, isolated from surface-sterilized leaf of this medicinal herb, showed broad-spectrum antagonism against an array of Gram-positive and -negative bacterial pathogens. Ethyl acetate extract of KL1-fermented media yielded a greenish amorphous substance retaining anti-infective property. Solvent-extracted crude material was separated by thin-layer chromatography, and the active ingredient was located by autobiogram analysis. The purified anti-infective compound was found as anthracene derivative as analyzed by ultraviolet and Fourier transform infrared spectroscopy. The strain was identified as Bacillus thuringiensis KL1 from cultural, physiochemical, and molecular aspects. The above results indicate the pharmaceutical potential of the candidate isolate.

  1. Population-based cohort study of anti-infective medication use before and after the onset of type 1 diabetes in children and adolescents

    NARCIS (Netherlands)

    Fazeli Farsani, Soulmaz; Souverein, Patrick C; van der Vorst, Marja M J; Knibbe, Catherijne A J; de Boer, Anthonius; Mantel-Teeuwisse, Aukje K

    2014-01-01

    A population-based cohort study was conducted in the Dutch PHARMO database to investigate prevalence and patterns of anti-infective medication use in children and adolescents with type 1 diabetes (T1D) before and after the onset of this disease. All patients <19 years with at least 2 insulin prescri

  2. 76 FR 17422 - Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of...

    Science.gov (United States)

    2011-03-29

    ... HUMAN SERVICES Food and Drug Administration Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and...

  3. Display technology on filamentous phage in the search for anti-infective biological agents

    Directory of Open Access Journals (Sweden)

    Nelson Santiago Vispo

    2016-01-01

    Full Text Available Introduction: The causes of antibiotic resistance are complex. The phage display technology has been used mainly to produce monoclonal antibodies (MAbs and peptides directed against cancer or inflammatory disease targets. Today, this technology is recognized as a powerful tool for selecting novel peptides and antibodies that can bind to a wide range of antigens, ranging from whole cells to proteins and lipid targets. In this review, we highlight research that exploits the phage display technology to discover new drugs against infectious diseases, with a focus on antimicrobial peptides and antibodies. Methods: Basic and recent literature review was made, mainly focused on general aspects of phage display technology and the application in the search of new peptides or antibodies of pharmaceutical use to combat the infectious diseases transmitted by bacteria and virus. Results: Updated information on the selected topics is shown, with a guiding and practical approach aimed at researchers in the field of molecular biology to continue deepening the technology with special emphasis in the applications that have been developed in Cuba. Conclusions: Advances in methods of screening, manufacturing, and humanization technologies show that phage display technology can significantly contribute in the fight against clinically important pathogens.

  4. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies.

    Science.gov (United States)

    Hancock, Robert E W; Sahl, Hans-Georg

    2006-12-01

    Short cationic amphiphilic peptides with antimicrobial and/or immunomodulatory activities are present in virtually every life form, as an important component of (innate) immune defenses. These host-defense peptides provide a template for two separate classes of antimicrobial drugs. Direct-acting antimicrobial host-defense peptides can be rapid-acting and potent, and possess an unusually broad spectrum of activity; consequently, they have prospects as new antibiotics, although clinical trials to date have shown efficacy only as topical agents. But for these compounds to fulfill their therapeutic promise and overcome clinical setbacks, further work is needed to understand their mechanisms of action and reduce the potential for unwanted toxicity, to make them more resistant to protease degradation and improve serum half-life, as well as to devise means of manufacturing them on a large scale in a consistent and cost-effective manner. In contrast, the role of cationic host-defense peptides in modulating the innate immune response and boosting infection-resolving immunity while dampening potentially harmful pro-inflammatory (septic) responses gives these peptides the potential to become an entirely new therapeutic approach against bacterial infections.

  5. Genetic and chemical knockdown: a complementary strategy for evaluating an anti-infective target

    Directory of Open Access Journals (Sweden)

    Ramachandran V

    2013-02-01

    Full Text Available Vasanthi Ramachandran,1,* Ragini Singh,2,* Xiaoyu Yang,1 Ragadeepthi Tunduguru,1 Subrat Mohapatra,2 Swati Khandelwal,2 Sanjana Patel,2 Santanu Datta21AstraZeneca India R&D, Bangalore, India; 2Cellworks India, Bangalore, India *These authors contributed equally to this workAbstract: The equity of a drug target is principally evaluated by its genetic vulnerability with tools ranging from antisense- and microRNA-driven knockdowns to induced expression of the target protein. In order to upgrade the process of antibacterial target identification and discern its most effective type of inhibition, an in silico toolbox that evaluates its genetic and chemical vulnerability leading either to stasis or cidal outcome was constructed and validated. By precise simulation and careful experimentation using enolpyruvyl shikimate-3-phosphate synthase and its specific inhibitor glyphosate, it was shown that genetic knockdown is distinct from chemical knockdown. It was also observed that depending on the particular mechanism of inhibition, viz competitive, uncompetitive, and noncompetitive, the antimicrobial potency of an inhibitor could be orders of magnitude different. Susceptibility of Escherichia coli to glyphosate and the lack of it in Mycobacterium tuberculosis could be predicted by the in silico platform. Finally, as predicted and simulated in the in silico platform, the translation of growth inhibition to a cidal effect was able to be demonstrated experimentally by altering the carbon source from sorbitol to glucose.Keywords: knockdown, inhibition, in silico, vulnerability

  6. The quest for anti-inflammatory and anti-infective biomaterials in clinical translation

    Directory of Open Access Journals (Sweden)

    May Griffith

    2016-09-01

    Full Text Available Biomaterials are now being used or evaluated clinically as implants to supplement the severe shortage of available human donor organs. To date however, such implants have mainly been developed as scaffolds to promote the regeneration of failing organs due to old age or congenital malformations. In the real world, however, infection or immunological issues often compromise patients. For example, bacterial and viral infections can result in uncontrolled immunopathological damage and lead to organ failure. Hence, there is a need for biomaterials and implants that not only promote regeneration but also address issues that are specific to compromised patients such as infection and inflammation. Different strategies are needed to address the regeneration of organs that have been damaged by infection or inflammation for successful clinical translation. Therefore, the real quest is for multi-functional biomaterials with combined properties that can combat infections, modulate inflammation and promote regeneration at the same time. These strategies will necessitate the inclusion of methodologies for management of the cellular and signaling components elicited within the local microenvironment. In the development of such biomaterials, strategies range from the inclusion of materials that have intrinsic anti-inflammatory properties, such as the synthetic lipid polymer, 2-methacryloyloxyethyl phosphorylcholine (MPC, to silver nanoparticles that have anti-bacterial properties, to inclusion of nano- and micro-particles in biomaterials composites that deliver active drugs. In this present review, we present examples of both kinds of materials in each group along with their pros and cons. Thus, as a promising next generation strategy to aid or replace tissue/organ transplantation, an integrated smart programmable platform is needed for regenerative medicine applications to create and/or restore normal function at the cell and tissue levels. Therefore, now it is

  7. The Quest for Anti-inflammatory and Anti-infective Biomaterials in Clinical Translation

    Science.gov (United States)

    Griffith, May; Islam, Mohammad M.; Edin, Joel; Papapavlou, Georgia; Buznyk, Oleksiy; Patra, Hirak K.

    2016-01-01

    Biomaterials are now being used or evaluated clinically as implants to supplement the severe shortage of available human donor organs. To date, however, such implants have mainly been developed as scaffolds to promote the regeneration of failing organs due to old age or congenital malformations. In the real world, however, infection or immunological issues often compromise patients. For example, bacterial and viral infections can result in uncontrolled immunopathological damage and lead to organ failure. Hence, there is a need for biomaterials and implants that not only promote regeneration but also address issues that are specific to compromised patients, such as infection and inflammation. Different strategies are needed to address the regeneration of organs that have been damaged by infection or inflammation for successful clinical translation. Therefore, the real quest is for multifunctional biomaterials with combined properties that can combat infections, modulate inflammation, and promote regeneration at the same time. These strategies will necessitate the inclusion of methodologies for management of the cellular and signaling components elicited within the local microenvironment. In the development of such biomaterials, strategies range from the inclusion of materials that have intrinsic anti-inflammatory properties, such as the synthetic lipid polymer, 2-methacryloyloxyethyl phosphorylcholine (MPC), to silver nanoparticles that have antibacterial properties, to inclusion of nano- and micro-particles in biomaterials composites that deliver active drugs. In this present review, we present examples of both kinds of materials in each group along with their pros and cons. Thus, as a promising next generation strategy to aid or replace tissue/organ transplantation, an integrated smart programmable platform is needed for regenerative medicine applications to create and/or restore normal function at the cell and tissue levels. Therefore, now it is of utmost

  8. Preparation of ZnO/Ag nanocomposite and coating on polymers for anti-infection biomaterial application

    Science.gov (United States)

    Sadeghi, Babak

    2014-01-01

    ZnO/Ag nanocomposites coated with polyvinyl chloride (PVC) were prepared by chemical reduction method, for anti-infection biomaterial application. There is a growing interest in attempts in using biomolecular as the templates to grow inorganic nanocomposites in controlled morphology and structure. By optimizing the experiment conditions, we successfully fabricated high yield of ZnO/Ag nanocomposite with full coverage of high-density polyvinyl chloride (PVC) coating. More importantly, ZnO/Ag nanocomposites were shown to significantly inhibit the growth of Staphylococcus aureus in solution. It was further shown that ZnO/Ag nanocomposites induced thiol depletion that caused death of S. aureus. The coatings were fully characterized using techniques such as scanning electron microscopy (SEM), transmission electron microscopy (TEM) and X-ray diffraction (XRD). Most importantly, compared to uncoated metals, the coatings on PVC promoted healthy antibacterial activity. Importantly, compared to ZnO-Ag -uncoated PVC, the ZnO/Ag nanocomposites coated was approximately triplet more effective in preventing bacteria attachment. The result of Thermal Gravimetric Analysis (TGA) indicates that, the ZnO/Ag nanocomposites are chemically stable in the temperature range from 50 to 900 °C. This result, for the first time, demonstrates the potential of using ZnO/Ag nanocomposites as a coating material for numerous anti-bacterial applications.

  9. 76 FR 18757 - Monthly Public Meetings of the Local Government Advisory Committee's Small Community Advisory...

    Science.gov (United States)

    2011-04-05

    ... AGENCY Monthly Public Meetings of the Local Government Advisory Committee's Small Community Advisory... Advisory Committee Act, the U.S. Environmental Protection Agency's Local Government Advisory Committee's... the Local Government Advisory Committee. BILLING CODE 6560-50-P...

  10. 77 FR 71591 - Meetings of the Local Government Advisory Committee and the Small Communities Advisory Subcommittee

    Science.gov (United States)

    2012-12-03

    ... AGENCY Meetings of the Local Government Advisory Committee and the Small Communities Advisory... environmental issues affecting small communities. The Local Government Advisory Committee (LGAC) will meet in... INFORMATION CONTACT: Local Government Advisory Committee (LGAC) and Small Communities Advisory...

  11. Extract of Pelargonium sidoides (EPs 7630) displays anti-infective properties by enhanced phagocytosis and differential modulation of host-bacteria interactions.

    Science.gov (United States)

    Conrad, Andreas; Frank, Uwe

    2008-05-01

    EPs 7630 is an aqueous-ethanolic extract of the roots of PELARGONIUM SIDOIDES that displays well-documented benefits in the treatment of upper respiratory tract infections (URTI). IN VITRO and animal investigations have revealed various anti-infective properties of EPs 7630. The present review sums up recently published IN VITRO investigations that have shown positive effects on the activity of human peripheral blood phagocytes (PBP) and differential modulation of the interactions between group A streptococci and the host's epithelial barrier.

  12. Anti-Infective Metabolites of a Newly Isolated Bacillus thuringiensis KL1 Associated with Kalmegh (Andrographis paniculata Nees.), a Traditional Medicinal Herb

    OpenAIRE

    Sudipta Roy; Sahana Yasmin; Subhadeep Ghosh; Somesankar Bhattacharya; Debdulal Banerjee

    2016-01-01

    This study was conducted to isolate endophytic bacteria possessing anti-infective property from Kalmegh (Andrographis paniculata Nees.), a well-known medicinal plant. A total of 23 strains were isolated from this plant among which the strain KL1, isolated from surface-sterilized leaf of this medicinal herb, showed broad-spectrum antagonism against an array of Gram-positive and -negative bacterial pathogens. Ethyl acetate extract of KL1-fermented media yielded a greenish amorphous substance re...

  13. Citizens Advisory Committees.

    Science.gov (United States)

    Stemnock, Suzanne K.

    1968-01-01

    This document contains the results of a national survey designed to determine the composition and location of permanent citizens advisory committees operating within the nation's school districts. The 52 district-wide, continuing citizens advisory bodies identified by 290 responding school systems are listed alphabetically by State. The following…

  14. Population-based cohort study of anti-infective medication use before and after the onset of type 1 diabetes in children and adolescents.

    Science.gov (United States)

    Fazeli Farsani, Soulmaz; Souverein, Patrick C; van der Vorst, Marja M J; Knibbe, Catherijne A J; de Boer, Anthonius; Mantel-Teeuwisse, Aukje K

    2014-08-01

    A population-based cohort study was conducted in the Dutch PHARMO database to investigate prevalence and patterns of anti-infective medication use in children and adolescents with type 1 diabetes (T1D) before and after the onset of this disease. All patients <19 years with at least 2 insulin prescriptions (1999 to 2009) were identified (T1D cohort) and compared with an age- and sex-matched (ratio: 1 up to 4) diabetes-free reference group. The prevalence and average number of anti-infective use was studied from (up to) 8 years before until a maximum of 4 years after the onset of T1D. A total of 925 patients with T1D and 3,591 children and adolescents in the reference cohort (51% boys, mean age of 10.1 [standard deviation, 4.5] years) were included. The overall prevalence of anti-infective use (62.6 compared to 52.6%, P < 0.001) and average number of prescriptions (2.71 compared to 1.42 per child, P < 0.001) in the T1D cohort were significantly higher than those in the reference cohort after the onset of diabetes. This pattern was consistent across sex and age categories and already observed in the year before the onset of type 1 diabetes. Patients in the T1D cohort received more antibacterials (49.8 compared to 40%, P < 0.001), antimycotics (4.0 compared to 1.3%, P < 0.001), antivirals (2.5 compared to 0.4%, P < 0.001), and second-line antibiotics, such as aminoglycosides, quinolones, and third-generation cephalosporins and carbapenems. Our findings that elevated anti-infective use in the T1D cohort exists in the period before the onset of type 1 diabetes and the consumption of more second-line anti-infective compounds in this time period warrant further research.

  15. 75 FR 17929 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-04-08

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... be open to the public. Name of Committee: Vaccines and Related Biological Products Advisory Committee... circovirus type 1 (PCV 1) in Rotarix, a U.S. licensed vaccine manufactured by GlaxoSmithKline and...

  16. 75 FR 2876 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-01-19

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... be open to the public. Name of Committee: Vaccines and Related Biological Products Advisory Committee... selection of strains to be included in the influenza virus vaccine for the 2010 - 2011 influenza season....

  17. 76 FR 52668 - Vaccines and Related Biological Products Advisory Committee; Amendment of Notice

    Science.gov (United States)

    2011-08-23

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... Administration (FDA) is announcing an amendment to the notice of meeting of the Vaccines and Related Biological... announced that a meeting of the Vaccines and Related Biological Products Advisory Committee would be held...

  18. 77 FR 42319 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-07-18

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... be open to the public. Name of Committee: Vaccines and Related Biological Products Advisory Committee... lines derived from human tumors for vaccine manufacture. FDA intends to make background...

  19. 76 FR 3639 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-01-20

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... be open to the public. Name of Committee: Vaccines and Related Biological Products Advisory Committee... selection of strains to be included in the influenza virus vaccine for the 2011-2012 influenza season....

  20. 77 FR 63839 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-10-17

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... be open to the public. Name of Committee: Vaccines and Related Biological Products Advisory Committee... immunogenicity of an Influenza A (H5N1) Virus Monovalent Vaccine manufactured by GlaxoSmithKline. On November...

  1. 78 FR 5465 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-01-25

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... be open to the public. Name of Committee: Vaccines and Related Biological Products Advisory Committee... strains to be included in the influenza virus vaccine for the 2013- 2014 influenza season. FDA intends...

  2. 78 FR 36309 - Research Advisory Committee on Gulf War Veterans' Illnesses, Notice of Meeting

    Science.gov (United States)

    2013-06-17

    ... diagnosing and treating Gulf War Veterans, and a drug treatment trial which is underway. On June 18, the... AFFAIRS Research Advisory Committee on Gulf War Veterans' Illnesses, Notice of Meeting The Department of... Research Advisory Committee on Gulf War Veterans' Illnesses will meet on June 17 and 18, 2013, in room...

  3. 78 FR 11655 - Neonatal Subcommittee of the Pediatric Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-02-19

    ... HUMAN SERVICES Food and Drug Administration Neonatal Subcommittee of the Pediatric Advisory Committee... be open to the public. Name of Committee: Neonatal Subcommittee of the Pediatric Advisory Committee... science to include the neonatal population. On March 15, 2013, FDA's Neonatal Subcommittee of...

  4. 78 FR 9060 - Request for Nominations for Voting Members on Public Advisory Panels or Committees

    Science.gov (United States)

    2013-02-07

    ... failure. Dental Products Panel of the 3 November 1, 2013. Medical Devices Advisory Committee--Dentists, engineers and scientists who have expertise in the areas of dental implants, dental materials... Radiological Health, Food and Drug Assurance Advisory Committee. Administration, 10903 New Hampshire...

  5. 75 FR 66381 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-10-28

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... be open to the public. Name of Committee: Cellular, Tissue and Gene Therapies Advisory Committee... Lentiviral Vector Based Gene Therapy Products. FDA intends to make background material available to...

  6. 78 FR 15726 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-03-12

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Cellular, Tissue and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice and recommendations...

  7. 77 FR 63840 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-10-17

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee..., Tissue and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice and..., Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, and...

  8. 76 FR 18768 - Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-04-05

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue, and Gene Therapies Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Cellular, Tissue, and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice and recommendations...

  9. 76 FR 22405 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-04-21

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... be open to the public. Name of Committee: Cellular, Tissue and Gene Therapies Advisory Committee... gene therapy products for the treatment of retinal disorders. Topics to be considered include...

  10. 78 FR 44133 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-07-23

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... be open to the public. Name of Committee: Cellular, Tissue and Gene Therapies Advisory Committee... on guidance documents issued from the Office of Cellular, Tissue and Gene Therapies, Center...

  11. 76 FR 81513 - Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-12-28

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue, and Gene Therapies Advisory Committee..., Tissue, and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice and... Gene Therapies, Center for Biologics Evaluation and Research, FDA. FDA intends to make...

  12. 76 FR 64951 - Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-10-19

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... be open to the public. Name of Committee: Cellular, Tissue and Gene Therapies Advisory...

  13. 78 FR 48438 - Pediatric Ethics Subcommittee of the Pediatric Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-08-08

    ... HUMAN SERVICES Food and Drug Administration Pediatric Ethics Subcommittee of the Pediatric Advisory... Administration (FDA). The meeting will be open to the public. Name of Subcommittee: Pediatric Ethics Subcommittee... recommendations to the Pediatric Advisory Committee on pediatric ethical issues. Date and Time: The meeting...

  14. VSWI Wetlands Advisory Layer

    Data.gov (United States)

    Vermont Center for Geographic Information — This dataset represents the DEC Wetlands Program's Advisory layer. This layer makes the most up-to-date, non-jurisdictional, wetlands mapping avaiable to the public...

  15. 76 FR 14980 - National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; Notice of...

    Science.gov (United States)

    2011-03-18

    ... HUMAN SERVICES National Institutes of Health National Institute on Alcohol Abuse and Alcoholism... Council on Alcohol Abuse and Alcoholism and the National Advisory Council on Drug Abuse. The meeting will...: National Advisory Council on Alcohol Abuse and Alcoholism and National Advisory Council on Drug Abuse....

  16. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.

    Science.gov (United States)

    Chakraborty, Sumit; Rhee, Kyu Y

    2015-04-15

    Modern tuberculosis (TB) chemotherapy is widely viewed as a crowning triumph of anti-infectives research. However, only one new TB drug has entered clinical practice in the past 40 years while drug resistance threatens to further destabilize the pandemic. Here, we review a brief history of TB drug development, focusing on the evolution of mechanism(s)-of-action studies and key conceptual barriers to rational, mechanism-based drugs.

  17. 78 FR 104 - Advisory Committees; Tentative Schedule of Meetings for 2013

    Science.gov (United States)

    2013-01-02

    ... dates to be determined. Cardiovascular and Renal Drugs Advisory April 17 and other date(s) to Committee... Pharmaceutical Date(s), if needed, to be Science and Clinical Pharmacology. determined. Psychopharmacologic...

  18. 16 CFR 1018.26 - Advisory functions.

    Science.gov (United States)

    2010-01-01

    ... 16 Commercial Practices 2 2010-01-01 2010-01-01 false Advisory functions. 1018.26 Section 1018.26... Advisory Committees § 1018.26 Advisory functions. (a) Unless otherwise specifically provided by statute, advisory committees shall be utilized solely for advisory functions. (b) The Commission shall ensure...

  19. 76 FR 42713 - General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Amendment of...

    Science.gov (United States)

    2011-07-19

    ... HUMAN SERVICES Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical... General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee. This meeting was... of the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee would...

  20. 78 FR 20328 - Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee: Notice of...

    Science.gov (United States)

    2013-04-04

    ... HUMAN SERVICES Food and Drug Administration Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee: Notice of Postponement of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is postponing the meeting of...

  1. 76 FR 64111 - NASA Advisory Council; Meeting

    Science.gov (United States)

    2011-10-17

    ... SPACE ADMINISTRATION NASA Advisory Council; Meeting AGENCY: National Aeronautics and Space Administration. ACTION: Notice of meeting. SUMMARY: In accordance with the Federal Advisory Committee Act, Public... Advisory Council Administrative Officer, National Aeronautics and Space Administration, Washington,...

  2. 75 FR 28542 - Superior Resource Advisory Committee

    Science.gov (United States)

    2010-05-21

    ... orient the new Superior Resource Advisory Committee members on their roles and responsibilities. DATES... of the roles and responsibilities of the Superior Resource Advisory Committee members; Election of... Forest Service Superior Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice...

  3. [Inhalation therapy: inhaled generics, inhaled antidotes, the future of anti-infectives and the indications of inhaled pentamidine. GAT aerosolstorming, Paris 2012].

    Science.gov (United States)

    Peron, N; Le Guen, P; Andrieu, V; Bardot, S; Ravilly, S; Oudyi, M; Dubus, J-C

    2013-12-01

    The working group on aerosol therapy (GAT) of the Société de pneumologie de langue française (SPLF) organized its third "Aerosolstorming" in 2012. During the course of one day, different aspects of inhaled therapy were discussed, and these will be treated separately in two articles, this one being the first. Inhaled products represent a large volume of prescriptions both in the community and in hospital settings and they involve various specialties particularly ENT and respiratory care. Technical aspects of the development of these products, their mode of administration and compliance with their indications are key elements for the effective therapeutic use of inhaled treatments. In this first article, we will review issues concerning generic inhaled products, the existence of inhaled antidotes, new anti-infective agents and indications for inhaled pentamidine.

  4. 75 FR 42100 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2010-07-20

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  5. 76 FR 2697 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2011-01-14

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... ] hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  6. 76 FR 81952 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2011-12-29

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  7. 77 FR 52752 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2012-08-30

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  8. 77 FR 22581 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2012-04-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  9. 76 FR 51381 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2011-08-18

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  10. 75 FR 14176 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2010-03-24

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  11. 78 FR 45252 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2013-07-26

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  12. 77 FR 72365 - National Institute on Drug Abuse; Notice of Meeting

    Science.gov (United States)

    2012-12-05

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting... hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be open to the... unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse....

  13. Antimicrobial Activity of Lippia Species from the Brazilian Semiarid Region Traditionally Used as Antiseptic and Anti-Infective Agents

    Directory of Open Access Journals (Sweden)

    Cristiana da Purificação Pinto

    2013-01-01

    Full Text Available Lippia origanoides Kunth, Lippia alnifolia Schauer, and Lippia thymoides Martius and Schauer are shrubs used in the traditional Brazilian medicine as antiseptics, as well as in the treatment of infectious diseases. This study was designed to investigate the antibacterial and antifungal activities of the methanolic extracts of these species, as new potential sources of antimicrobial drugs. The antimicrobial activity of methanolic extracts was investigated against resistant yeasts and bacteria by agar disk diffusion. Then, the MIC determination of the most active species and its fractions in hexane, dichloromethane, ethyl acetate, and water was performed. By the agar diffusion assay, all species were active against at least two microorganisms, giving evidence to support their use in the popular medicine. L. origanoides leaves exhibited the widest antimicrobial action, inhibiting the growth of two Gram-positive bacteria and two yeasts; this activity was also confirmed by the MIC evaluation. The fractionation of L. origanoides crude extracts improved the activity in spectrum and intensity. The results obtained in this study indicate that L. origanoides may be a promising alternative in the treatment of bacterial and fungal infections and in the seeking of new antimicrobial drugs.

  14. 76 FR 14009 - Federal Advisory Committee Act; Technological Advisory Council

    Science.gov (United States)

    2011-03-15

    ... Advisory Council will hold a meeting on Wednesday, March 30, 2011 in the Commission Meeting Room, from 1 p..., DC 20554. FOR FURTHER INFORMATION CONTACT: Walter Johnston, Chief, Electromagnetic Compatibility Division, 202-418-0807; Walter.Johnston@FCC.gov . SUPPLEMENTARY INFORMATION: Technical Advisory...

  15. 78 FR 55255 - Federal Advisory Committee Act; Technological Advisory Council

    Science.gov (United States)

    2013-09-10

    ... INFORMATION CONTACT: Walter Johnston, Chief, Electromagnetic Compatibility Division, 202-418-0807; Walter.Johnston@FCC.gov . SUPPLEMENTARY INFORMATION: The FCC Technological Advisory Council will discuss progress... Advisory Council (TAC) will hold a meeting in the Commission Meeting Room to discuss progress on...

  16. 78 FR 33092 - Federal Advisory Committee Act; Technological Advisory Council

    Science.gov (United States)

    2013-06-03

    ... Advisory Council will hold a meeting on Thursday, June 13, 2013 in the Commission Meeting Room, from 1 p.m.... FOR FURTHER INFORMATION CONTACT: Walter Johnston, Chief, Electromagnetic Compatibility Division, 202-418-0807; Walter.Johnston@FCC.gov . SUPPLEMENTARY INFORMATION: The FCC Technological Advisory...

  17. 76 FR 58513 - Federal Advisory Committee Act; Technological Advisory Council

    Science.gov (United States)

    2011-09-21

    ... Advisory Council will hold a meeting on Tuesday, September 27th, 2011, in the Commission Meeting Room, from...., Washington, DC 20554. FOR FURTHER INFORMATION CONTACT: Walter Johnston, Chief, Electromagnetic Compatibility Division, 202-418-0807; Walter.Johnston@FCC.gov . SUPPLEMENTARY INFORMATION: Technical Advisory...

  18. 77 FR 12839 - Federal Advisory Committee Act; Technological Advisory Council

    Science.gov (United States)

    2012-03-02

    ... Advisory Council will hold a meeting on Wednesday, March 28, 2012 in the Commission Meeting Room, from 1 p... 20554. FOR FURTHER INFORMATION CONTACT: Walter Johnston, Chief, Electromagnetic Compatibility Division, 202-418-0807; Walter.Johnston@FCC.gov . SUPPLEMENTARY INFORMATION: Technical Advisory Council...

  19. 78 FR 67362 - Federal Advisory Committee Act; Technological Advisory Council

    Science.gov (United States)

    2013-11-12

    ... Advisory Council will hold a meeting on Monday, December 9, 2013 in the Commission Meeting Room, from 1 p.m.... FOR FURTHER INFORMATION CONTACT: Walter Johnston, Chief, Electromagnetic Compatibility Division, 202-418-0807; Walter.Johnston@FCC.gov . SUPPLEMENTARY INFORMATION: The FCC Technological Advisory...

  20. 77 FR 30289 - Federal Advisory Committee Act; Technological Advisory Council

    Science.gov (United States)

    2012-05-22

    ... Advisory Council will hold a meeting on Wednesday, June 27, 2012 in the Commission Meeting Room, from 1 p.m.... FOR FURTHER INFORMATION CONTACT: Walter Johnston, Chief, Electromagnetic Compatibility Division, 202-418-0807; Walter.Johnston@FCC.gov . SUPPLEMENTARY INFORMATION: The FCC Technological Advisory...

  1. 78 FR 77443 - Electricity Advisory Committee

    Science.gov (United States)

    2013-12-23

    ... Electricity Advisory Committee AGENCY: Office of Electricity Delivery and Energy Reliability, Department of... Electricity Advisory Committee (EAC). The Federal Advisory Committee Act (Pub. L. 92-463, 86 Stat. 770.../oe/services/electricity-advisory-committee-eac . FOR FURTHER INFORMATION CONTACT: Matthew...

  2. Ash cloud aviation advisories

    Energy Technology Data Exchange (ETDEWEB)

    Sullivan, T.J.; Ellis, J.S. [Lawrence Livermore National Lab., CA (United States); Schalk, W.W.; Nasstrom, J.S. [EG and G, Inc., Pleasanton, CA (United States)

    1992-06-25

    During the recent (12--22 June 1991) Mount Pinatubo volcano eruptions, the US Air Force Global Weather Central (AFGWC) requested assistance of the US Department of Energy`s Atmospheric Release Advisory Capability (ARAC) in creating volcanic ash cloud aviation advisories for the region of the Philippine Islands. Through application of its three-dimensional material transport and diffusion models using AFGWC meteorological analysis and forecast wind fields ARAC developed extensive analysis and 12-hourly forecast ash cloud position advisories extending to 48 hours for a period of five days. The advisories consisted of ``relative`` ash cloud concentrations in ten layers (surface-5,000 feet, 5,000--10,000 feet and every 10,000 feet to 90,000 feet). The ash was represented as a log-normal size distribution of 10--200 {mu}m diameter solid particles. Size-dependent ``ashfall`` was simulated over time as the eruption clouds dispersed. Except for an internal experimental attempt to model one of the Mount Redoubt, Alaska, eruptions (12/89), ARAC had no prior experience in modeling volcanic eruption ash hazards. For the cataclysmic eruption of 15--16 June, the complex three-dimensional atmospheric structure of the region produced dramatically divergent ash cloud patterns. The large eruptions (> 7--10 km) produced ash plume clouds with strong westward transport over the South China Sea, Southeast Asia, India and beyond. The low-level eruptions (< 7 km) and quasi-steady-state venting produced a plume which generally dispersed to the north and east throughout the support period. Modeling the sequence of eruptions presented a unique challenge. Although the initial approach proved viable, further refinement is necessary and possible. A distinct need exists to quantify eruptions consistently such that ``relative`` ash concentrations relate to specific aviation hazard categories.

  3. Pharmaceutical Care for Elderly Patient with Chronic Obstructive Pulmonary Disease in Anti-infection and Immunoregulation Therapy by Clinical Pharmacists%临床药师参与慢性阻塞性肺疾病老年患者抗感染及免疫调节治疗的药学监护

    Institute of Scientific and Technical Information of China (English)

    张志清; 屠文莲; 曹玮

    2016-01-01

    OBJECTIVE:To provide reference for the anti-infection and immunoregulation therapy participated by the clinical pharmacists in respiration medicine .METHODS: By introducing the adjustments of anti-infection and immunoregulation therapy scheme for one elderly patient with chronic obstructive pulmonary disease with acute attack participated by the clinical pharmacists , the clinical characteristics of antibiotics were fully considered , the clinicians were suggested to select the related treatment drugs and increase the immunomodulator .RESULTS:Combined with the characteristics of the elderly patient , the clinical pharmacists cooperated with the clinicians from the aspect of anti-infection and immunoregulation therapy on chronic obstructive pulmonary disease with acute attack , so as to provide rational medication scheme for the patient .After treatment , the patient showed good infection control , and the acute attacking symptoms of chronic obstructive pulmonary disease were improved .CONCLUSIONS: The participation of clinical pharmacists in the clinical practice of anti-infection can took advantage in the perspective of pharmacy , optimize the treatment scheme , reduce the incidence of chronic obstructive pulmonary disease with acute attack and improve the life quality of patients .%目的:为临床药师在呼吸内科参与抗感染及免疫调节治疗提供参考。方法:介绍临床药师参与1例老年慢性阻塞性肺疾病急性发作患者抗感染及免疫调节治疗方案的调整,充分考虑抗菌药物的临床特点,建议医师选用相关治疗药物,增加免疫调节剂的过程。结果:临床药师结合老年患者的特点,从慢性阻塞性肺疾病急性发作抗感染及免疫调节方面积极配合医师,为患者提供了合理的用药方案。经治疗后,患者的感染控制良好,慢性阻塞性肺疾病急性发作症状得以缓解。结论:临床药师参与抗感染临床实践,可从药学的角

  4. 75 FR 20844 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2010-04-21

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  5. 77 FR 6113 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2012-02-07

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC's) Advisory Committee on Diversity for Communications in the Digital...

  6. 75 FR 70004 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2010-11-16

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  7. 77 FR 57085 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2012-09-17

    ... From the Federal Register Online via the Government Publishing Office ] FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  8. 78 FR 21354 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2013-04-10

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  9. 75 FR 6031 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2010-02-05

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  10. 76 FR 64348 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2011-10-18

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  11. 75 FR 60458 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2010-09-30

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  12. 78 FR 39289 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2013-07-01

    ... From the Federal Register Online via the Government Publishing Office ] FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital... Communications Commission's (FCC) Advisory Committee on Diversity for Communications in the Digital...

  13. 76 FR 52016 - NASA International Space Station Advisory Committee and the Aerospace Safety Advisory Panel; Meeting

    Science.gov (United States)

    2011-08-19

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee and the Aerospace Safety... International Space Station Advisory Committee and the Aerospace Safety Advisory Panel. The purpose of this... consideration by NASA for Commercial Resupply Services for the International Space Station (ISS),...

  14. OCLC and Its Advisory Committees.

    Science.gov (United States)

    Baker, Shirley K.

    1998-01-01

    Describes the Online Computer Library Center (OCLC) advisory committees in terms of research, public, college and university, and special libraries. All four of the type-of-library advisory groups work to shape OCLC policies and programs, according to the particular needs of each group. OCLC's financial and programmatic success depends upon…

  15. Quercetin-loaded PLGA nanoparticles: a highly effective antibacterial agent in vitro and anti-infection application in vivo

    Energy Technology Data Exchange (ETDEWEB)

    Sun, Dongdong; Li, Nuan; Zhang, Weiwei; Yang, Endong; Mou, Zhipeng; Zhao, Zhiwei; Liu, Haiping; Wang, Weiyun, E-mail: weiywswzy@163.com [Anhui Agricultural University, School of Life Sciences (China)

    2016-01-15

    Nanotechnology-based approaches have tremendous potential for enhancing efficacy against infectious diseases. PLGA-based nanoparticles as drug delivery carrier have shown promising potential, owing to their sizes and related unique properties. This article aims to develop nanosized poly (d, l-lactide-co-glycolide) PLGA nanoparticle formulation loaded with quercetin (QT). QT is an antioxidant and antibacterial compound isolated from Chinese traditional medicine with low skin permeability and extreme water insolubility. The quercetin-loaded PLGA nanoparticles (PQTs) were synthesized by emulsion–solvent evaporation method and stabilized by coating with poly (vinyl alcohol). The characteristics of PQTs were analyzed by Fourier transform infrared spectroscopy, Ultraviolet–Visible spectroscopy, scanning electron microscope, transmission electron microscopy, and atomic force microscopy, respectively. The PQTs showed a spherical shape with an average size of 100–150 nm. We compared the antibacterial effects of PQTs against Escherichia coli (E. coli) and Micrococcus tetragenus (M. tetragenus).The PQTs produced stronger antibacterial activity to E. coli than that to M. tetragenus through disrupting bacterial cell wall integrity. The antibacterial ratio was increased with the increasing dosages and incubation time. Next, we tested the in vivo antibacterial activity in mice. No noticeable organ damage was captured from H&E-staining organ slices, suggesting the promise of using PQTs for in vivo applications. The results of this study demonstrated the interaction between bacteria and PLGA-based nanoparticles, providing encouragement for conducting further investigations on properties and antimicrobial activity of the PQTs in clinical application.

  16. Quercetin-loaded PLGA nanoparticles: a highly effective antibacterial agent in vitro and anti-infection application in vivo

    Science.gov (United States)

    Sun, Dongdong; Li, Nuan; Zhang, Weiwei; Yang, Endong; Mou, Zhipeng; Zhao, Zhiwei; Liu, Haiping; Wang, Weiyun

    2016-01-01

    Nanotechnology-based approaches have tremendous potential for enhancing efficacy against infectious diseases. PLGA-based nanoparticles as drug delivery carrier have shown promising potential, owing to their sizes and related unique properties. This article aims to develop nanosized poly ( d, l-lactide-co-glycolide) PLGA nanoparticle formulation loaded with quercetin (QT). QT is an antioxidant and antibacterial compound isolated from Chinese traditional medicine with low skin permeability and extreme water insolubility. The quercetin-loaded PLGA nanoparticles (PQTs) were synthesized by emulsion-solvent evaporation method and stabilized by coating with poly (vinyl alcohol). The characteristics of PQTs were analyzed by Fourier transform infrared spectroscopy, Ultraviolet-Visible spectroscopy, scanning electron microscope, transmission electron microscopy, and atomic force microscopy, respectively. The PQTs showed a spherical shape with an average size of 100-150 nm. We compared the antibacterial effects of PQTs against Escherichia coli ( E. coli) and Micrococcus tetragenus ( M. tetragenus).The PQTs produced stronger antibacterial activity to E. coli than that to M. tetragenus through disrupting bacterial cell wall integrity. The antibacterial ratio was increased with the increasing dosages and incubation time. Next, we tested the in vivo antibacterial activity in mice. No noticeable organ damage was captured from H&E-staining organ slices, suggesting the promise of using PQTs for in vivo applications. The results of this study demonstrated the interaction between bacteria and PLGA-based nanoparticles, providing encouragement for conducting further investigations on properties and antimicrobial activity of the PQTs in clinical application.

  17. 78 FR 28237 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2013-05-14

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Advisory Committee Meeting. SUMMARY: The President's National Security Telecommunications Advisory... Telecommunications Advisory Committee, National Protection and Programs Directorate, Department of Homeland...

  18. 21 CFR 20.84 - Disclosure to consultants, advisory committees, State and local government officials commissioned...

    Science.gov (United States)

    2010-04-01

    ..., State and local government officials commissioned pursuant to 21 U.S.C. 372(a), and other special government employees. 20.84 Section 20.84 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH... consultants, advisory committees, State and local government officials commissioned pursuant to 21 U.S.C....

  19. 临床药师参与重症肺炎患者抗感染治疗的药学实践%Pharmaceutical Practice for the Severe Pneumonia Patient with Anti-infection Treatment by Clinical Pharmacists

    Institute of Scientific and Technical Information of China (English)

    梁秀群; 许明睿; 陆翠林; 唐云峡

    2016-01-01

    To probe into the role of clinical pharmacists in the treatment of patient with severe pneumonia. METHODS:The clinical pharmacists participated in to the ward round and consultation of one patient with severe pneumonia;combined with patient's clinical symptoms and drug susceptibility test result, the clinical pharmacists presented concrete suggestions about the formulation and adjustment of anti-infection treatment scheme:imipenem and cilastatin sodium combined with linezolid, and piperacillin sodium and tazobactam sodium combined with voriconazole. Meanwhile, the clinical pharmacists emphatically monitored the blood routine, liver and kidney function, and pulmonary lesions absorption of the patient.RESULTS: The therapeutic scheme provided by clinical pharmacists obtained a good therapeutic effect.The patient's pulmonary infected symptoms ( cough, expectoration, shortness of breath and hypoxemia, etc.) were controlled.The fungal infection was also gradually improved and discharged. CONCLUSIONS: The clinical pharmacists based on clinical, focus on the patient, assist clinicians to optimize therapeutic scheme and implement pharmaceutical care for patient, which can make the patient get the best therapeutic services.%目的:探讨临床药师在重症肺炎患者救治过程中的作用。方法:临床药师参与1例重症肺炎患者的查房、会诊,结合患者的临床症状和药物敏感性试验结果,对抗感染方案的制订和调整提出具体意见,先后使用亚安培南西司他丁钠联合利奈唑胺、哌拉西林钠他唑巴坦钠联合伏立康唑抗感染治疗,同时重点监测患者的血常规、肝肾功能、肺部病灶吸收情况。结果:临床药师提供的用药方案取得了良好的治疗效果,患者咳嗽、咳痰、气促、低氧血症等肺部感染症状得到了控制,相继出现的真菌感染也逐步好转。结论:临床药师立足临床,以患者为中心,协助医师优化治疗方案,

  20. NIOSOMES- A NOVEL DRUG CARRIER FOR DRUG TARGETING

    Directory of Open Access Journals (Sweden)

    A.KRISHNA SAILAJA

    2016-02-01

    Full Text Available Niosomes are vesicular drug delivery systems made of cholesterol and non ionic surfactants. Various novel drug delivery systems available for targeting of drugs include liposomes, nanoparticles, and resealed erythrocytes. Because of the instability and higher cost liposomes are less preferred over niosomes. The application of vesicular systems in cosmetics and for therapeutic purpose may offer several advantages for niosomes. They improve the therapeutic performance of the drug molecules by delayed clearance from the circulation, protecting the drug from biological environment and restricting effects to target cells. Niosomes have great drug delivery potential for targeted delivery of anti-cancer, anti-infective agents. Drug delivery potential of niosome can enhance by using novel concepts like proniosomes and aspasome. Niosomes also serve better aid in diagnostic imaging and as a vaccine adjuvant. Thus these areas need further exploration and research so as to bring out commercially available niosomal preparation. This article mainly focuses on the significance, advantages over other drug delivery systems, manufacturing methods, characterization methods, current research in niosomal drug delivery and their limitations.

  1. JOINT ADVISORY APPEALS BOARD

    CERN Multimedia

    Human Resources Division

    2002-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mr Serge Peraire with regard to exceptional advancement. As the appellant has not objected, the report of the Board and the final decision of the Director-General are brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (N° 60) from 17 to 31 May 2002. Human Resources Division Tel. 74128

  2. Joint Advisory Appeals Board

    CERN Multimedia

    2003-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mrs Judith Igo-Kemenes concerning the application of procedures foreseen by Administrative Circular N§ 26 (Rev. 3). As the appellant has not objected, the report of the Board and the final decision of the Director-General are brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (N° 60) from 6 to 20 June 2003. Human Resources Division Tel. 74128

  3. Joint Advisory Appeals Board

    CERN Multimedia

    2004-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mrs Maria DIMOU with regard to a periodic one-step increase. As the appellant has not objected, the report of the Board and the final decision of the Director-General are brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (N° 60) from 30 April to 14 May 2004. Human Resources Department Tel. 74128

  4. Joint Advisory Appeals Board

    CERN Multimedia

    2003-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mr Aloïs Girardoz with regard to classification and advancement. As the appellant has not objected, the Board's report and the Director-General's decision will be brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (N° 60) from 15 to 29 August 2003. Human Resources Division Tel. 74128

  5. JOINT ADVISORY APPEALS BOARD

    CERN Multimedia

    Human Resources Division

    2002-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mr Bertrand Nicquevert with regard to the non-resident allowance. As the appellant has not objected, the report of the Board and the final decision of the Director-General are brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (N° 60) from 29 November to 13 December 2002. Human Resources Division Tel. 74128

  6. JOINT ADVISORY APPEALS BOARD

    CERN Multimedia

    Human Resources Division

    2002-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mr Jack Blanchard with regard to 'non recognition of specific functions'. As the appellant has not objected, the report of the Board and the final decision of the Director-General are brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (N° 60) from 12th to 26th April 2002. Human Resources Division Tel. 74128

  7. JOINT ADVISORY APPEALS BOARD

    CERN Multimedia

    Human Resources Division

    2002-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mr Antonio Millich with regard to advancement. As the appellant has not objected, the report of the Board and the final decision of the Director-General are brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (N° 60) from 27 September to 11 October 2002. Human Resources Division Tel. 74128

  8. Joint Advisory Appeals Board

    CERN Multimedia

    2003-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mr Poul Frandsen concerning his assimilation into the new career structure. As the appellant has not objected, the report of the Board and the final decision of the Director-General are brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (N° 60) from 13 to 24 January 2003. Human Resources Division Tel. 74128

  9. JOINT ADVISORY APPEALS BOARD

    CERN Multimedia

    Human Resources Division

    2002-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mr Luc Vos with regard to advancement. As the appellant has not objected, the report of the Board and the final decision of the Director-General are brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (N° 60) from 14 to 28 June 2002. Human Resources Division Tel. 74128

  10. JOINT ADVISORY APPEALS BOARD

    CERN Multimedia

    Personnel Division

    1999-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mr Joào Bento with regard to residential category. As the appellant has not objected, the recommendations of the Board and the final decision of the Director-General are brought to the notice of the personnel in accordance with Article RÊVIÊ1.20 of the Staff Regulations.The relevant documents will therefore be posted on the notice boards of the Administration Building (N¡ 60) from 29 October to 12 November 1999.Personnel DivisionTel. 74128

  11. Joint Advisory Appeals Board

    CERN Multimedia

    HR Department

    2006-01-01

    The Joint Advisory Appeals Board was convened to examine an appeal lodged by a member of the personnel with regard to advancement. The person concerned has requested that the report of the Board and the final decision of the Director-General be brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (No. 60) from 24 March to 10 April 2006. Human Resources Department Tel. 74128

  12. Joint Advisory Appeals Board

    CERN Multimedia

    HR Department

    2008-01-01

    The Joint Advisory Appeals Board has examined the internal appeal lodged by a member of the personnel with regard to the decision not to award him a periodic one-step advancement for the 2006 reference year. The person concerned has not objected to the report of the Board and the final decision of the Director-General being brought to the notice of the members of the personnel. In application of Article R VI 1.18 of the Staff Regulations, these documents will therefore be posted on the notice board of the Main building (Bldg. 500) from 17 March to 30 March 2008. Human Resources Department Tel. 73911

  13. Joint Advisory Appeals Board

    CERN Document Server

    2013-01-01

    The Joint Advisory Appeals Board has examined the internal appeal lodged by a former member of the personnel, a beneficiary of the CERN Pension Fund, against the calculation of his pension in the framework of the Progressive Retirement Programme.   The person concerned has not objected to the report of the Board and the final decision of the Director-General being brought to the attention of the members of the personnel. In application of Article R VI 1.18 of the Staff Regulations, these documents will therefore be available from 26 July to 11 August 2013 at the following link. HR Department Head Office

  14. Joint Advisory Appeals Board

    CERN Multimedia

    HR Department

    2008-01-01

    The Joint Advisory Appeals Board has examined the internal appeal lodged by a member of the personnel against the decision to grant him only a periodic one-step advancement for the 2006 reference year. The person concerned has not objected to the report of the Board and the final decision of the Director-General being brought to the attention of the members of the personnel. In application of Article R VI 1.18 of the Staff Regulations, these documents will therefore be posted on the notice board of the Main Building (Bldg. 500) from 1 September to 14 September 2008. Human Resources Department (73911)

  15. Joint Advisory Appeals Board

    CERN Multimedia

    HR Department

    2008-01-01

    The Joint Advisory Appeals Board has examined the internal appeal lodged by a member of the personnel with regard to the decision not to grant him an indefinite contract. The person concerned has not objected to the report of the Board and the final decision of the Director-General being brought to the notice of the members of the personnel. In application of Article R VI 1.18 of the Staff Regulations, these documents will therefore be posted on the notice board of the Main Building (Bldg. 500) from 26 May to 6 June 2008. Human Resources Department (73911)

  16. Joint Advisory Appeals Board

    CERN Multimedia

    HR Department

    2007-01-01

    The Joint Advisory Appeals Board was convened to examine an internal appeal lodged by a member of the personnel with regard to the decision not to grant him an indefinite contract. The person concerned has requested that the report of the Board and the final decision of the Director-General be brought to the notice of the members of the personnel, in accordance with Article R VI 1.18 of the Staff Regulations. The relevant documents will therefore be posted on the notice board of the Main building (Bldg. 60) from 24 September to 7 October 2007. Human Resources Department

  17. Joint Advisory Appeals Board

    CERN Document Server

    HR Department

    2008-01-01

    The Joint Advisory Appeals Board was convened to examine an internal appeal lodged by a member of the personnel with regard to the decision not to grant him an indefinite contract. The person concerned has not objected to the report of the Board and the final decision of the Director-General being brought to the notice of the members of the personnel, in accordance with Article R VI 1.18 of the Staff Regulations. These documents will therefore be posted on the notice board of the Main Building (Bldg. 60) from 21 January to 3 February 2008. Human Resources Department (73911)

  18. Joint Advisory Appeals Board

    CERN Document Server

    HR Department

    2008-01-01

    The Joint Advisory Appeals Board has examined the internal appeal lodged by a member of the personnel against the decision to grant him only a periodic one-step advancement for the 2006 reference year. The person concerned has not objected to the report of the Board and the final decision of the Director-General being brought to the attention of the members of the personnel. In application of Article R VI 1.18 of the Staff Regulations, these documents will therefore be posted on the notice board of the Main building (bldg. 500) from 1 September to 14 September 2008. Human Resources Department (73911)

  19. 75 FR 22754 - Federal Advisory Committee; Chief of Engineers Environmental Advisory Board; Charter Renewal

    Science.gov (United States)

    2010-04-30

    ... of the Secretary Federal Advisory Committee; Chief of Engineers Environmental Advisory Board; Charter... that it is renewing the charter for the Chief of Engineers Environmental Advisory Board (hereafter referred to as the Board). FOR FURTHER INFORMATION CONTACT: Jim Freeman, Deputy Advisory...

  20. 75 FR 22560 - Federal Advisory Committee; U.S. Air Force Scientific Advisory Board; Charter Renewal

    Science.gov (United States)

    2010-04-29

    ... of the Secretary Federal Advisory Committee; U.S. Air Force Scientific Advisory Board; Charter... that it is renewing the charter for the U.S. Air Force Scientific Advisory Board (hereafter referred to as the Board). FOR FURTHER INFORMATION CONTACT: Jim Freeman, Deputy Advisory Committee...

  1. 78 FR 77663 - Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting

    Science.gov (United States)

    2013-12-24

    ... of the Secretary Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting... Federal advisory committee meeting of the Threat Reduction Advisory Committee (``the Committee''). This... Wednesday, January 29, 2014, from, 8:30 a.m. to 4:30 p.m. ADDRESSES: National Geospatial-Intelligence...

  2. 77 FR 15751 - Meetings of the Local Government Advisory Committee and the Small Communities Advisory Subcommittee

    Science.gov (United States)

    2012-03-16

    ... AGENCY Meetings of the Local Government Advisory Committee and the Small Communities Advisory... requests for appearances requires it. The Local Government Advisory Committee (LGAC) will meet at EPA's...: Local Government Advisory Committee (LGAC) contact Frances Eargle at (202) 564-3115 or email at...

  3. 77 FR 2539 - Meetings of the Small Communities Advisory Subcommittee and the Local Government Advisory Committee

    Science.gov (United States)

    2012-01-18

    ... AGENCY Meetings of the Small Communities Advisory Subcommittee and the Local Government Advisory... if the number of requests for appearances requires it. The Local Government Advisory Committee (LGAC... at davis.catherinem@epa.gov . For the Local Government Advisory Committee (LGAC) contact...

  4. 76 FR 64122 - NASA Advisory Committee; Renewal of NASA's International Space Station Advisory Committee Charter

    Science.gov (United States)

    2011-10-17

    ... SPACE ADMINISTRATION NASA Advisory Committee; Renewal of NASA's International Space Station Advisory... and amendment of the Charter of the International Space Station Advisory Committee. SUMMARY: Pursuant... Space Station Advisory Committee is in the public interest in connection with the performance of...

  5. Crash course in readers' advisory

    CERN Document Server

    Orr, Cynthia

    2014-01-01

    One of the key services librarians provide is helping readers find books they'll enjoy. This ""crash course"" will furnish you with the basic, practical information you need to excel at readers' advisory (RA) for adults and teens.

  6. KZMA Center Weather Advisory (CWA)

    Data.gov (United States)

    National Oceanic and Atmospheric Administration, Department of Commerce — The CWA is an aviation weather warning for conditions meeting or approaching national in-flight advisory (AIRMET, SIGMET or SIGMET for convection) criteria. CWAs are...

  7. KZLC Center Weather Advisory (CWA)

    Data.gov (United States)

    National Oceanic and Atmospheric Administration, Department of Commerce — The CWA is an aviation weather warning for conditions meeting or approaching national in-flight advisory (AIRMET, SIGMET or SIGMET for convection) criteria. CWAs are...

  8. KZBW Center Weather Advisory (CWA)

    Data.gov (United States)

    National Oceanic and Atmospheric Administration, Department of Commerce — The CWA is an aviation weather warning for conditions meeting or approaching national in-flight advisory (AIRMET, SIGMET or SIGMET for convection) criteria. CWAs are...

  9. KZOA Center Weather Advisory (CWA)

    Data.gov (United States)

    National Oceanic and Atmospheric Administration, Department of Commerce — The CWA is an aviation weather warning for conditions meeting or approaching national in-flight advisory (AIRMET, SIGMET or SIGMET for convection) criteria. CWAs are...

  10. KZSE Center Weather Advisory (CWA)

    Data.gov (United States)

    National Oceanic and Atmospheric Administration, Department of Commerce — The CWA is an aviation weather warning for conditions meeting or approaching national in-flight advisory (AIRMET, SIGMET or SIGMET for convection) criteria. CWAs are...

  11. Anti-infective treatment for the HIV-infected patient during perioperative period%围手术期HIV感染者的抗感染治疗

    Institute of Scientific and Technical Information of China (English)

    刘保池; 张磊; 李垒; 司炎辉; 宋言峥; 赵中辛

    2012-01-01

      Objective:To investigate anti-infective treatments in HIV-infected surgical patients during the perioperative period. Methods 〓 A retrospective study of sepsis and surgical site infections (SSIs) was conducted in 266 HIV-infected patients from January 2009 to December 2011 in Shanghai Public Health Clinical Center. The patients were divided into 3 groups based on CD4 cells counts in the preoperative period: group A (<200 cell/μl), group B (200-349 cell/μl) and group C (≥350 cell/μl). Highly active anti-retrovirus therapy (HAART) was started in group B. Preoperative antibiotic medication SMZ and fluconazole against Pneumocystis carinii pneumonia (PCP) and other fungal infection was started in group A. No special treatment in group C. Results〓There were only 6 patients dead at 30 days after surgery, with the death rate of 2.3%. Sepsis appeared in 110 patients (41.3%). Patients in group A were more likely to get sepsis than patients in the other two groups (P <0.01). Conclusion〓Complete evalua- tion of surgical risk and suitable perioperative anti-infective treatment may lead to better outcome for HIV-infected surgical patients.%  〓〓[]〓目的〓探讨 HIV 感染者围手术期合理的抗感染治疗.方法〓回顾性分析上海市公共卫生临床中心外科2009年1月至2011年12月救治的266例 HIV 感染患者围手术期临床资料,根据患者术前 CD4 T 淋巴细胞水平分 A 组<200 cell/μl,B 组200~349 cell/μl 和 C 组≥350 cell/μl 三组,对 B 组给予抗 HIV 病毒治疗,对 A 组给予抗 HIV 病毒、磺胺甲唑(SMZ)和氟康唑预防肺孢子虫和真菌感染,对已经合并结核、真菌等机会性感染者给予相应的抗感染治疗.对 C组无特殊处理.结果〓经适当的抗感染治疗,266例患者手术后30 d 内死亡6例,病死率2.3%.110例发生脓毒症,脓毒症发生率41.3%.A 组脓毒症发病率明显高于 B 组和 C 组(P <0.01).结论〓精细的手术与合理的围手术

  12. 抗感染中心静脉导管临床应用的研究%Effect of clinical application of anti-infective central venous catheter

    Institute of Scientific and Technical Information of China (English)

    谢明英; 申建维; 刘显畅

    2014-01-01

    目的:探讨抗感染中心静脉导管在减少导管相关性感染和细菌定植中的作用,以降低导管相关感染率。方法选取2011年5月-2013年5月于IC U行深静脉置管患者64例,随机分为观察组和对照组,各32例,对照组采用普通中心静脉导管,观察组采用黄嘧啶银和氯己定抗感染中心静脉导管,观察比较两组患者导管留置、导管拔除、导管相关性感染和细菌定植。结果留置导管时间观察组为(14.5±2.6)d,对照组为(8.3±3.7)d,观察组留置导管时间长于对照组,两组比较差异有统计学意义(χ2=6.563,P<0.05),观察组无局部感染,对照组局部感染6例感染率18.75%,观察组局部感染、导管细菌定植例数明显少于对照组,两组比较差异有统计学意义(P<0.05);观察组细菌定植和感染延时显著优于对照组,差异有统计学意义(P<0.001)。结论抗感染中心静脉导管在减少导管相关性感染和细菌定植中具有重要的积极作用,但导管留置时间>两周,抗感染中心静脉导管的细菌定植和导管相关性感染明显增加,通过缩短导管留置时间是减少导管相关性感染的重要手段。%OBJECTIVE To explore the effect of use of anti-infective central venous catheter on reduction of incidence of catheter-related infections or bacterial colonization so as to reduce the incidence of catheter-related infections .METHODS Totally 64 patients who underwent the deep venous catheterization in the ICU from May 2011 to May 2013 were enrolled in the study and randomly divided into the observation group and the control group ,with 32 cases in each group ,the control group was treated with conventional central venous catheter ,while the observation group was given yellow-Ag and chlorhexidine anti-infective central venous catheter ; the intubation ,extubation , catheter-associated infections , and bacterial

  13. 77 FR 57086 - Open Internet Advisory Committee

    Science.gov (United States)

    2012-09-17

    ... COMMISSION Open Internet Advisory Committee AGENCY: Federal Communications Commission. ACTION: Notice. SUMMARY: The Commission announces the next meeting date, time, and agenda of the Open Internet Advisory... Open Internet rules, and to provide any recommendations it deems appropriate to the...

  14. 77 FR 74661 - Open Internet Advisory Committee

    Science.gov (United States)

    2012-12-17

    ... COMMISSION Open Internet Advisory Committee AGENCY: Federal Communications Commission. ACTION: Notice. SUMMARY: The Commission announces the next meeting date, time, and agenda of the Open Internet Advisory... Open Internet rules, and to provide any recommendations it deems appropriate to the...

  15. 78 FR 16852 - Open Internet Advisory Committee

    Science.gov (United States)

    2013-03-19

    ... COMMISSION Open Internet Advisory Committee AGENCY: Federal Communications Commission. ACTION: Notice. SUMMARY: The Commission announces the next meeting date, time, and agenda of the Open Internet Advisory... Open Internet rules, and to provide any recommendations it deems appropriate to the...

  16. 76 FR 3633 - Consumer Advisory Committee

    Science.gov (United States)

    2011-01-20

    ... COMMISSION Consumer Advisory Committee AGENCY: Federal Communications Commission. ACTION: Notice. SUMMARY: This document announces the rechartering of the Consumer Advisory Committee (hereinafter ``the... ``Commission'') regarding consumer issues within the jurisdiction of the Commission and to facilitate...

  17. 78 FR 54629 - Consumer Advisory Board meeting

    Science.gov (United States)

    2013-09-05

    ... From the Federal Register Online via the Government Publishing Office CONSUMER FINANCIAL PROTECTION BUREAU Consumer Advisory Board meeting AGENCY: Bureau of Consumer Financial Protection. ACTION... Consumer Advisory Board (``CAB'' or ``Board'') of the Consumer Financial Protection Bureau (Bureau)....

  18. 76 FR 56454 - Consumer Advisory Committee Meeting

    Science.gov (United States)

    2011-09-13

    ... COMMISSION Consumer Advisory Committee Meeting AGENCY: Federal Communications Commission. ACTION: Notice. SUMMARY: The Commission announces the next meeting date and agenda of its Consumer Advisory Committee (Committee). The purpose of the Committee is to make recommendations to the Commission regarding...

  19. 75 FR 9898 - Consumer Advisory Committee

    Science.gov (United States)

    2010-03-04

    ... COMMISSION Consumer Advisory Committee AGENCY: Federal Communications Commission. ACTION: Notice. SUMMARY: The Commission announces the next meeting date and agenda of its Consumer Advisory Committee (``Committee''). The purpose of the ] Committee is to make recommendations to the Commission regarding...

  20. 75 FR 4819 - Consumer Advisory Committee

    Science.gov (United States)

    2010-01-29

    ... COMMISSION Consumer Advisory Committee AGENCY: Federal Communications Commission. ACTION: Notice. SUMMARY: The Commission announces the next meeting date and agenda of its Consumer Advisory Committee (``Committee''). The purpose of the Committee is to make recommendations to the Commission regarding...

  1. 76 FR 34230 - Technological Advisory Council

    Science.gov (United States)

    2011-06-13

    ... persons that the Federal Communications Commission's (FCC) Technological Advisory Council will hold a... Johnston, Chief, Electromagnetic Compatibility Division, Office of Engineering and Technology 202-418-0807; Walter.Johnston@FCC.gov . SUPPLEMENTARY INFORMATION: Technical Advisory Council members have...

  2. JOINT ADVISORY APPEALS BOARD

    CERN Multimedia

    Human Resources Division

    2001-01-01

    The Joint Advisory Appeals Board was convened to examine the appeal lodged by Mr Neil Calder, Mrs Sudeshna Datta Cockerill, Mrs Andrée Fontbonne, Mrs Moniek Laurent and Mr Ulrich Liptow with regard to membership in the Pension Fund under the period with a Paid Associate contract, appeals dealt with on a collective basis. As the appellants have not objected, the report of the Board and the final decision of the Director-General are brought to the notice of the personnel in accordance with Article R VI 1.20 of the Staff Regulations. The relevant documents will therefore be posted on the notice boards of the Administration Building (N° 60) from 10 to 31 August 2001.

  3. 39 CFR 447.31 - Advisory service.

    Science.gov (United States)

    2010-07-01

    ... Advisory Services and Post-Employment Activities § 447.31 Advisory service. (a) The Ethical Conduct Officer is responsible for the administration of the ethics program of the Postal Service. In the exercise of that responsibility, the Ethical Conduct Officer shall coordinate the advisory service provided by...

  4. 77 FR 476 - Science Advisory Board

    Science.gov (United States)

    2012-01-05

    ... National Oceanic and Atmospheric Administration (NOAA) Science Advisory Board AGENCY: Office of Oceanic and... agenda of a forthcoming meeting of the NOAA Science Advisory Board. The members will discuss and provide... be reviewed prior to the meeting date. SUPPLEMENTARY INFORMATION: The Science Advisory Board...

  5. 76 FR 63664 - Arts Advisory Panel

    Science.gov (United States)

    2011-10-13

    ... Doc No: 2011-26421] NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES National Endowment for the Arts Arts Advisory Panel Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), as amended, notice is hereby given that thirteen meetings of the Arts Advisory Panel to the...

  6. 5 CFR 724.403 - Advisory guidelines.

    Science.gov (United States)

    2010-01-01

    ... 5 Administrative Personnel 2 2010-01-01 2010-01-01 false Advisory guidelines. 724.403 Section 724.403 Administrative Personnel OFFICE OF PERSONNEL MANAGEMENT (CONTINUED) CIVIL SERVICE REGULATIONS... RETALIATION ACT OF 2002 Best Practices § 724.403 Advisory guidelines. OPM will issue advisory guidelines...

  7. 48 CFR 401.371 - AGAR Advisories.

    Science.gov (United States)

    2010-10-01

    ... 48 Federal Acquisition Regulations System 4 2010-10-01 2010-10-01 false AGAR Advisories. 401.371... ACQUISITION REGULATION SYSTEM Agency Acquisition Regulations 401.371 AGAR Advisories. The SPE may issue AGAR Advisories, consistent with the policies of the FAR and the AGAR, for the following purposes: (a)...

  8. 77 FR 4238 - Advisory Committee Management

    Science.gov (United States)

    2012-01-27

    ... Part 8 RIN 1400-AC64 Advisory Committee Management AGENCY: Department of State. ACTION: Final rule... establish uniform administrative guidelines and management controls for advisory committees established by... of Subjects in 22 CFR Part 8 Advisory Committee Management. Accordingly, under the authority of 22...

  9. 77 FR 10486 - Electricity Advisory Committee Meeting

    Science.gov (United States)

    2012-02-22

    ... Electricity Advisory Committee Meeting AGENCY: Office of Electricity Delivery and Energy Reliability... Electricity Advisory Committee (EAC). The Federal Advisory Committee Act (Pub. L. 92- 463, 86 Stat. 770... INFORMATION CONTACT: Matthew Rosenbaum, Office of Electricity Delivery and Energy Reliability, U.S....

  10. 76 FR 10577 - Electricity Advisory Committee Meeting

    Science.gov (United States)

    2011-02-25

    ... Electricity Advisory Committee Meeting AGENCY: Office of Electricity Delivery and Energy Reliability... reestablished Electricity Advisory Committee (EAC). The Federal Advisory Committee Act (Pub. L. 92-463, 86 Stat... of Electricity Delivery and Energy Reliability, U.S. Department of Energy, Forrestal Building,...

  11. 75 FR 61454 - Electricity Advisory Committee

    Science.gov (United States)

    2010-10-05

    ... Electricity Advisory Committee AGENCY: Department of Energy, Office of Electricity Delivery and Energy...-established DOE Electricity Advisory Committee. The Federal Advisory Committee Act (Pub. L. 92-463, 86 Stat...: David Meyer, Designated Federal Officer, Office of Electricity Delivery and Energy Reliability,...

  12. 78 FR 9038 - Electricity Advisory Committee Meeting

    Science.gov (United States)

    2013-02-07

    ... Electricity Advisory Committee Meeting AGENCY: Office of Electricity Delivery and Energy Reliability... Electricity Advisory Committee (EAC). The Federal Advisory Committee Act (Pub. L. 92-463, 86 Stat. 770... FURTHER INFORMATION CONTACT: Matthew Rosenbaum, Office of Electricity Delivery and Energy Reliability,...

  13. 75 FR 59729 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-09-28

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Vaccines and Related Biological... for protective antigen-based anthrax vaccines for a post-exposure prophylaxis indication using...

  14. 76 FR 44016 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-07-22

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Vaccines and Related Biological..., Division of Bacterial, Parasitic and Allergenic Products, Office of Vaccines Research and Review,...

  15. 76 FR 55397 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-09-07

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Vaccines and Related Biological... the Laboratory of Method Development, Division of Viral Products, Office of Vaccines Research...

  16. 76 FR 13646 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-03-14

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Vaccines and Related Biological... Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA. In...

  17. 78 FR 60884 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-10-02

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Vaccines and Related Biological... of Retroviruses and Laboratory of Immunoregulation, Division of Viral Products, Office of...

  18. 77 FR 3780 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2012-01-25

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Vaccines and Related Biological..., Parasitic and Allergenic Products, Office of Vaccines Research and Review, Center for Biologics...

  19. 78 FR 20663 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-04-05

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Vaccines and Related Biological... DNA Viruses, Division of Viral Products, Office of Vaccines Research and Review, Center for...

  20. 75 FR 47605 - Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2010-08-06

    ... HUMAN SERVICES Food and Drug Administration Vaccines and Related Biological Products Advisory Committee... portion of the meeting will be closed to the public. Name of Committee: Vaccines and Related Biological..., Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA. FDA intends...

  1. 78 FR 19717 - Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory...

    Science.gov (United States)

    2013-04-02

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory Committee: Notice of Change of Meeting Schedule AGENCY: Food and...

  2. 78 FR 13347 - Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory...

    Science.gov (United States)

    2013-02-27

    ... From the Federal Register Online via the Government Publishing Office ] DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Clinical Chemistry and Clinical Toxicology Devices Panel of... Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory Committee. General...

  3. 76 FR 38667 - Transmissible Spongiform Encephalopathies Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2011-07-01

    ... deferral for time spent in Saudi Arabia to reduce the risk of variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products and human cells, tissues and cellular and tissue-based products. FDA intends to... HUMAN SERVICES Food and Drug Administration Transmissible Spongiform Encephalopathies Advisory...

  4. 78 FR 26786 - Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

    Science.gov (United States)

    2013-05-08

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Microbiology Devices Panel of the Medical Devices Advisory...). The meeting will be open to the public. Name of Committee: Microbiology Devices Panel of the...

  5. 76 FR 50485 - Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee; Amendment of...

    Science.gov (United States)

    2011-08-15

    ... HUMAN SERVICES Food and Drug Administration Obstetrics and Gynecology Devices Panel of the Medical... Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee. This meeting was announced... July 14, 2011, FDA announced that a meeting of the Obstetrics and Gynecology Devices Panel of...

  6. 75 FR 33814 - Tobacco Product Constituents Subcommittee of the Tobacco Products Scientific Advisory Committee...

    Science.gov (United States)

    2010-06-15

    ... HUMAN SERVICES Food and Drug Administration Tobacco Product Constituents Subcommittee of the Tobacco... Administration (FDA). The meeting will be open to the public. Name of Committee: Tobacco Product Constituents Subcommittee of the Tobacco Products Scientific Advisory Committee. General Function of the Committee:...

  7. 77 FR 65693 - Cellular, Tissue and Gene Therapies Advisory Committee; Amendment of Notice

    Science.gov (United States)

    2012-10-30

    ... HUMAN SERVICES Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee... Register of October 17, 2012, FDA announced that a meeting of the Cellular, Tissue and Gene Therapies..., Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, FDA. On...

  8. 77 FR 4370 - NASA Advisory Council; Commercial Space Committee; Meeting

    Science.gov (United States)

    2012-01-27

    ... SPACE ADMINISTRATION NASA Advisory Council; Commercial Space Committee; Meeting AGENCY: National... announces a meeting of the Commercial Space Committee (CSC) of the NASA Advisory Council (NAC). DATES... Admission to the NASA Advisory Council (NAC) Commercial Space Committee (CSC).'' For security...

  9. 75 FR 22553 - Technology Innovation Program Advisory Board

    Science.gov (United States)

    2010-04-29

    ... National Institute of Standards and Technology Technology Innovation Program Advisory Board AGENCY.... SUMMARY: The Technology Innovation Program Advisory Board, National Institute of Standards and Technology... Technology Innovation Program (TIP) Advisory Board is composed of ten members appointed by the Director...

  10. 75 FR 2923 - Motor Carrier Safety Advisory Committee Public Meeting

    Science.gov (United States)

    2010-01-19

    ... Federal Motor Carrier Safety Administration Motor Carrier Safety Advisory Committee Public Meeting AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT. ACTION: Notice of Motor Carrier Safety Advisory Committee Meeting. SUMMARY: FMCSA announces that its Motor Carrier Safety Advisory Committee (MCSAC)...

  11. 75 FR 72863 - Motor Carrier Safety Advisory Committee Public Meeting

    Science.gov (United States)

    2010-11-26

    ... Federal Motor Carrier Safety Administration Motor Carrier Safety Advisory Committee Public Meeting AGENCY: Federal Motor Carrier Safety Administration, DOT. ACTION: Notice of Motor Carrier Safety Advisory Committee Meeting. SUMMARY: FMCSA announces that the Agency's Motor Carrier Safety Advisory Committee...

  12. 75 FR 50797 - Motor Carrier Safety Advisory Committee Public Meeting

    Science.gov (United States)

    2010-08-17

    ... Federal Motor Carrier Safety Administration Motor Carrier Safety Advisory Committee Public Meeting AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT. ACTION: Notice of Motor Carrier Safety Advisory Committee Meeting. SUMMARY: FMCSA announces that its Motor Carrier Safety Advisory Committee (MCSAC)...

  13. 75 FR 29384 - Motor Carrier Safety Advisory Committee Public Meeting

    Science.gov (United States)

    2010-05-25

    ... Federal Motor Carrier Safety Administration Motor Carrier Safety Advisory Committee Public Meeting AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT. ACTION: Notice of Motor Carrier Safety Advisory Committee meeting. SUMMARY: FMCSA announces that its Motor Carrier Safety Advisory Committee (MCSAC)...

  14. 78 FR 20685 - Aviation Security Advisory Committee (ASAC) Meeting

    Science.gov (United States)

    2013-04-05

    ... SECURITY Transportation Security Administration Aviation Security Advisory Committee (ASAC) Meeting AGENCY... Committee Meeting. SUMMARY: The Aviation Security Advisory Committee (ASAC) will meet in Arlington, VA. This.... L. 92-463). The Aviation Security Advisory Committee (ASAC) provides advice and...

  15. 75 FR 60493 - Aviation Rulemaking Advisory Committee; Renewal

    Science.gov (United States)

    2010-09-30

    ... Federal Aviation Administration Aviation Rulemaking Advisory Committee; Renewal AGENCY: Federal Aviation... Regulations, the FAA gives notice it has renewed the Aviation Rulemaking Advisory Committee (ARAC) for a 2..., Executive Director, Aviation Rulemaking Advisory Committee. BILLING CODE 4910-13-P...

  16. 77 FR 56909 - Aviation Rulemaking Advisory Committee (ARAC); Renewal

    Science.gov (United States)

    2012-09-14

    ... Federal Aviation Administration Aviation Rulemaking Advisory Committee (ARAC); Renewal AGENCY: Federal Aviation Administration (FAA), DOT. ACTION: Notice of Renewal. SUMMARY: The FAA announces the charter renewal of the Aviation Rulemaking Advisory Committee (ARAC), a Federal Advisory Committee that works...

  17. 76 FR 14647 - Sabine National Forest Resource Advisory Committee Meeting

    Science.gov (United States)

    2011-03-17

    ...; ] DEPARTMENT OF AGRICULTURE Sabine National Forest Resource Advisory Committee Meeting AGENCY: Forest Service, USDA. ACTION: Notice of Public Meeting, Sabine National Forest Resource Advisory Committee. SUMMARY: In.... Department of Agriculture, Forest Service, Sabine National Forest Resource Advisory Committee (RAC)...

  18. 75 FR 51169 - OTS Minority Depository Institutions Advisory Committee

    Science.gov (United States)

    2010-08-18

    ... Office of Thrift Supervision OTS Minority Depository Institutions Advisory Committee AGENCY: Department... Minority Depository Institutions Advisory Committee will renew for a two-year period beginning August 2... Depository Institutions Advisory Committee (MDIAC). The purpose of the OTS Minority Depository...

  19. 78 FR 53497 - Commercial Space Transportation Advisory Committee; Closed Session

    Science.gov (United States)

    2013-08-29

    ... Federal Aviation Administration Commercial Space Transportation Advisory Committee; Closed Session AGENCY: Federal Aviation Administration (FAA), DOT. ACTION: Notice of Commercial Space Transportation Advisory... closed session of the Commercial Space Transportation Advisory Committee (COMSTAC). The special...

  20. 75 FR 3913 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2010-01-25

    ... SECURITY National Communications System President's National Security Telecommunications Advisory Committee...: The President's National Security Telecommunications Advisory Committee (NSTAC) will be meeting by... telecommunications policy. Notice of this meeting is given under the Federal Advisory Committee Act (FACA),...

  1. 77 FR 24728 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2012-04-25

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Advisory Committee Meeting. SUMMARY: The President's National Security Telecommunications Advisory... telecommunications policy. Agenda: The committee will meet in open session to receive a briefing on the...

  2. 75 FR 29781 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2010-05-27

    ... SECURITY National Communications System President's National Security Telecommunications Advisory Committee... meeting. SUMMARY: The President's National Security Telecommunications Advisory Committee (NSTAC) will be... preparedness telecommunications policy. Notice of this meeting is given under the Federal Advisory...

  3. 76 FR 43988 - National Technical Information Service Advisory Board

    Science.gov (United States)

    2011-07-22

    ... National Technical Information Service National Technical Information Service Advisory Board AGENCY: National Technical Information Service, Commerce. ACTION: Notice of open meeting. SUMMARY: This notice announces the next meeting of the National Technical Information Service Advisory Board (the Advisory...

  4. 78 FR 61337 - National Technical Information Service Advisory Board

    Science.gov (United States)

    2013-10-03

    ... National Technical Information Service National Technical Information Service Advisory Board AGENCY: National Technical Information Service, Commerce. ACTION: Notice of open meeting SUMMARY: This notice announces the next meeting of the National Technical Information Service Advisory Board (the Advisory...

  5. 78 FR 16255 - National Technical Information Service Advisory Board

    Science.gov (United States)

    2013-03-14

    ... National Technical Information Service National Technical Information Service Advisory Board AGENCY: National Technical Information Service, Commerce. ACTION: Notice of Open Meeting. SUMMARY: This notice announces the next meeting of the National Technical Information Service Advisory Board (the Advisory...

  6. 77 FR 57559 - National Technical Information Service Advisory Board

    Science.gov (United States)

    2012-09-18

    ... National Technical Information Service National Technical Information Service Advisory Board AGENCY: National Technical Information Service, Commerce. ACTION: Notice of open meeting. SUMMARY: This notice announces the next meeting of the National Technical Information Service Advisory Board (the Advisory...

  7. 77 FR 70434 - Federal Advisory Committee Act; Technological Advisory Council

    Science.gov (United States)

    2012-11-26

    ... Advisory Council will hold a meeting on Monday, December 10, 2012 in the Commission Meeting Room, from 1 p..., DC 20554. FOR FURTHER INFORMATION CONTACT: Walter Johnston, Chief, Electromagnetic Compatibility Division, 202-418-0807; Walter.Johnston@FCC.gov . SUPPLEMENTARY INFORMATION: The FCC Technological...

  8. 77 FR 52332 - Federal Advisory Committee Act; Technological Advisory Council

    Science.gov (United States)

    2012-08-29

    ... Advisory Council will hold a meeting on Monday, September 24, 2012 in the Commission Meeting Room, from 1 p..., DC 20554. FOR FURTHER INFORMATION CONTACT: Walter Johnston, Chief, Electromagnetic Compatibility Division, 202-418-0807; Walter.Johnston@FCC.gov . SUPPLEMENTARY INFORMATION: The FCC Technological...

  9. 75 FR 53694 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2010-09-01

    ... Doc No: 2010-21890] FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital Age AGENCY: Federal Communications Commission... on Diversity for Communications in the Digital Age (``Diversity Committee'') will hold a meeting...

  10. 76 FR 5160 - Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital...

    Science.gov (United States)

    2011-01-28

    ... From the Federal Register Online via the Government Publishing Office FEDERAL COMMUNICATIONS COMMISSION Federal Advisory Committee Act; Advisory Committee on Diversity for Communications in the Digital Age AGENCY: Federal Communications Commission. ACTION: Notice of intent to renew charter. SUMMARY:...

  11. 78 FR 11142 - The National Advisory Council on Innovation and Entrepreneurship Meeting of the National Advisory...

    Science.gov (United States)

    2013-02-15

    ... Economic Development Administration The National Advisory Council on Innovation and Entrepreneurship Meeting of the National Advisory Council on Innovation and Entrepreneurship AGENCY: U.S. Department of... Innovation and Entrepreneurship (NACIE) has cancelled its open meeting, originally planned for...

  12. 76 FR 51122 - National Emergency Medical Services Advisory Council (NEMSAC); Notice of Federal Advisory...

    Science.gov (United States)

    2011-08-17

    ... National Highway Traffic Safety Administration National Emergency Medical Services Advisory Council (NEMSAC... (NHTSA), Department of Transportation (DOT). Title: National Emergency Medical Services Advisory Council... services representatives and consumers to provide advice and recommendations regarding Emergency...

  13. 78 FR 5772 - The National Advisory Council on Innovation and Entrepreneurship Meeting of the National Advisory...

    Science.gov (United States)

    2013-01-28

    ... Commerce. ACTION: Notice of an open meeting. SUMMARY: The National Advisory Council on Innovation and... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF COMMERCE Economic Development Administration The National Advisory Council on Innovation and...

  14. 77 FR 41403 - Meetings of the Local Government Advisory Committee and the Small Communities Advisory...

    Science.gov (United States)

    2012-07-13

    ... AGENCY Meetings of the Local Government Advisory Committee and the Small Communities Advisory.../or Title VI, and other environmental issues of importance to local governments. ADDRESSES: EPA's Local Government Advisory Committee meetings will be held via teleconference. Meeting summaries will...

  15. 78 FR 17993 - Request for Nominations for the General Advisory Committee and the Scientific Advisory...

    Science.gov (United States)

    2013-03-25

    ...-American Tropical Tuna Commission (IATTC) as well as to a Scientific Advisory Subcommittee of the General... for Nominations for the General Advisory Committee and the Scientific Advisory Subcommittee to the United States Section to the Inter-American Tropical Tuna Commission SUMMARY: The Department of State...

  16. 75 FR 18824 - Federal Advisory Committee; U.S. Strategic Command Strategic Advisory Group; Closed Meeting

    Science.gov (United States)

    2010-04-13

    ..., intelligence, and policy-related issues to the Commander, U.S. Strategic Command, during the development of the... of the Secretary Federal Advisory Committee; U.S. Strategic Command Strategic Advisory Group; Closed... announces that the U.S. Strategic Command Strategic Advisory Group will meet on May 6 and 7, 2010....

  17. 77 FR 47397 - Request for Nominations of Specific Drug/Biologic Product(s) That Could Be Brought Before the...

    Science.gov (United States)

    2012-08-08

    ... HUMAN SERVICES Food and Drug Administration Request for Nominations of Specific Drug/Biologic Product(s... invites the public to suggest one or more specific drug or biologic products that could be brought before... Drugs Advisory Committee AGENCY: Food and Drug Administration, HHS. ACTION: Notice; request for...

  18. 78 FR 33049 - Advisory Committee Meeting

    Science.gov (United States)

    2013-06-03

    ... Federal Grain Inspection Service operations-market overview, international programs, moisture meter... orally address the Advisory Committee. The meeting will be open to the public. Persons with...

  19. Working with Advisory Committees . . . Promising Practices. Operations Notebook 16.

    Science.gov (United States)

    Olivero, James L.

    This publication is intended to aid school-level educational administrators in working with citizen advisory committees. After a brief discussion of the rationale for advisory committees, it focuses in turn on 1) functions of advisory committees, 2) ways to determine philosophical positions of agreement and disagreement among advisory committee…

  20. 76 FR 65750 - Aerospace Safety Advisory Panel; Charter Renewal

    Science.gov (United States)

    2011-10-24

    ... SPACE ADMINISTRATION Aerospace Safety Advisory Panel; Charter Renewal AGENCY: National Aeronautics and... Aerospace Safety Advisory Panel. SUMMARY: Pursuant to sections 14(b)(1) and 9(c) of the Federal Advisory... of the NASA Aerospace Safety Advisory Panel is in the public interest in connection with...

  1. Practice of Participation of Clinical Pharmacists in Adjustment of Anti-infection Therapeutic Scheme in One Case of Flavobacterium Breve Infection%临床药师参与短黄杆菌感染患者抗感染治疗的实践

    Institute of Scientific and Technical Information of China (English)

    鲁晓燕; 孟静

    2016-01-01

    OBJECTIVE:To probe into the pharmaceutical practice of participation of clinical pharmacists in adjustment of anti-infection therapeutic scheme in one case of flavobacterium breve infection.METHODS:The clinical pharmacists participated into the drug treatment process of one case of flavobacterium breve infection by consultation and continuous monitoring, analyzed the medication status, put forward suggestions for the clinicians to formulate rational therapeutic regimen and monitored the patient’s medication process.RESULTS: The clinical pharmacists assisted the clinicians to adjust therapeutic regimen and promoted the improvement of the disease condition.CONCLUSIONS: The clinical pharmacists participate into the individualized treatment process, bring their pharmaceutical speciality into full play and assist the clinicians with safety and effective medication, which fully reflect their own value.%目的:探讨临床药师参与短黄杆菌感染患者抗感染治疗的药学实践。方法:临床药师参加会诊并持续性监护1例短黄杆菌感染患者的药物治疗过程,分析用药情况,为医师制订合理的用药方案提出建议,并对药品不良反应进行监护。结果:临床药师协助医师调整用药方案,促进患者病情好转。结论:临床药师参与个体化治疗过程,发挥药学专长,协助医师安全、有效地用药,体现了自身的价值。

  2. 75 FR 6358 - Federal Advisory Committee; Defense Advisory Board for Employer Support of the Guard and Reserve...

    Science.gov (United States)

    2010-02-09

    ... of the Secretary Federal Advisory Committee; Defense Advisory Board for Employer Support of the Guard and Reserve; Defense Advisory Board for Employer Partnership; Charter Revision AGENCY: Department of... intends to revise the charter for the Defense Advisory Board for Employer Support of the Guard and...

  3. 75 FR 60145 - PNT Advisory Board; Meeting

    Science.gov (United States)

    2010-09-29

    ... SPACE ADMINISTRATION PNT Advisory Board; Meeting AGENCY: National Aeronautics and Space Administration. ACTION: Notice of Meeting. SUMMARY: In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration announces a meeting of the...

  4. 76 FR 2672 - Science Advisory Board Meeting

    Science.gov (United States)

    2011-01-14

    ... National Oceanic and Atmospheric Administration Science Advisory Board Meeting AGENCY: Office of Oceanic... Commerce (DOC). ACTION: Notice of public meeting. SUMMARY: This notice sets forth the schedule and proposed agenda of a forthcoming meeting of the NOAA Science Advisory Board. The members will discuss and...

  5. 76 FR 35410 - Science Advisory Board; Meeting

    Science.gov (United States)

    2011-06-17

    ... National Oceanic and Atmospheric Administration Science Advisory Board; Meeting AGENCY: Office of Oceanic... Commerce (DOC). ACTION: Notice of open meeting. SUMMARY: The Science Advisory Board (SAB) was established... meeting will be held Wednesday, July 20, 2011, from 9:30 a.m. to 5:30 p.m. and Thursday, July 21,...

  6. 75 FR 61774 - Advisory Board Meeting

    Science.gov (United States)

    2010-10-06

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF JUSTICE National Institute of Corrections Advisory Board Meeting Time and Date: 8 a.m. to 4:30 p.m. on Monday... Considered: Welcome New Advisory Board Members; NIC Orientation; Briefing on NIC Reports; Agency...

  7. 77 FR 13634 - Advisory Board Meeting

    Science.gov (United States)

    2012-03-07

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF JUSTICE National Institute of Corrections Advisory Board Meeting Time and Date: 8 a.m.-4:30 p.m. on Monday, April... outcomes of November 2-3, 2011 Advisory Board Hearing (Shifting the Focus to Reshape Our Thinking...

  8. 78 FR 60851 - Science Advisory Board Meeting

    Science.gov (United States)

    2013-10-02

    ... National Oceanic and Atmospheric Administration Science Advisory Board Meeting AGENCY: Office of Oceanic... Commerce (DOC). ACTION: Notice of open meeting. SUMMARY: The NOAA Science Advisory Board (SAB) was... meeting will be held Tuesday, November 19, 2013 from 10:00 a.m. to 5:30 p.m. and Wednesday, November...

  9. 77 FR 14425 - Advisory Board Meeting

    Science.gov (United States)

    2012-03-09

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF JUSTICE National Institute of Corrections Advisory Board Meeting Time and Date: 8 AM-4:30 PM on Monday, April 02... November 2-3, 2011 Advisory Board Hearing (Shifting the Focus to Reshape Our Thinking Toward...

  10. 77 FR 69503 - Advisory Board Meeting

    Science.gov (United States)

    2012-11-19

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF JUSTICE National Institute of Corrections Advisory Board Meeting TIME AND DATE: 8:00 a.m.-4:30 p.m. on Monday...; review of outcomes of August 22-23, 2012 Advisory Board Hearing (Balancing Fiscal Challenges,...

  11. 77 FR 38273 - Science Advisory Board; Meeting

    Science.gov (United States)

    2012-06-27

    ... National Oceanic and Atmospheric Administration Science Advisory Board; Meeting AGENCY: Office of Oceanic... Commerce (DOC). ACTION: Notice of open meeting. SUMMARY: The Science Advisory Board (SAB) was established... meeting will be held Monday, July 16, 2012 from 9 a.m. to 5:30 p.m. and Tuesday, July 17, 2012 from 8:30...

  12. 76 FR 23845 - Arts Advisory Panel

    Science.gov (United States)

    2011-04-28

    ... ARTS AND THE HUMANITIES National Endowment for the Arts Arts Advisory Panel Pursuant to Section 10(a)(2... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks..., evaluation, and recommendations on financial assistance under the National Foundation on the Arts and...

  13. 77 FR 27803 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-05-11

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  14. 78 FR 17942 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-03-25

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meetings. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  15. 78 FR 5213 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-01-24

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  16. 76 FR 3677 - Arts Advisory Panel

    Science.gov (United States)

    2011-01-20

    ... ARTS AND THE HUMANITIES National Endowment for the Arts Arts Advisory Panel Pursuant to Section 10(a)(2... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks..., discussion, evaluation, and recommendations on financial assistance under the National Foundation on the...

  17. 78 FR 59978 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-09-30

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  18. 78 FR 42982 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-07-18

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meetings SUMMARY: Pursuant to Section 10(a)(2) of... the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks...

  19. 78 FR 28244 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-05-14

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meetings SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  20. 77 FR 41808 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-07-16

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  1. 76 FR 50499 - Arts Advisory Panel

    Science.gov (United States)

    2011-08-15

    ... ARTS AND THE HUMANITIES National Endowment for the Arts Arts Advisory Panel Pursuant to Section 10(a)(2... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks... financial assistance under the National Foundation on the Arts and the Humanities Act of 1965, as...

  2. 78 FR 50451 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-08-19

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meetings. SUMMARY: Pursuant to Section 10(a)(2) of... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  3. 78 FR 26399 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-05-06

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meeting of the Arts Advisory Panel to the National Council on the Arts will be held by teleconference...

  4. 78 FR 21978 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-04-12

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  5. 77 FR 49026 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-08-15

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meeting of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  6. 78 FR 68099 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-11-13

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meeting. SUMMARY: Pursuant to Section 10(a)(2) of...- one meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the...

  7. 78 FR 76660 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-12-18

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  8. 77 FR 75672 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-12-21

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  9. 77 FR 13367 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-03-06

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... of the Arts Advisory Panel to the National Council on the Arts will be held by teleconference at...

  10. 77 FR 61643 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-10-10

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  11. 78 FR 38410 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-06-26

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meetings. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  12. 77 FR 13154 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-03-05

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice--meeting. Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), as amended, notice is hereby given that a meeting of the...

  13. 77 FR 67836 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-11-14

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  14. 77 FR 56875 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-09-14

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held by teleconference...

  15. 77 FR 35067 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-06-12

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2) of... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  16. 75 FR 56146 - Arts Advisory Panel; Meetings

    Science.gov (United States)

    2010-09-15

    ... ARTS AND THE HUMANITIES National Endowment for the Arts Arts Advisory Panel; Meetings Pursuant to... given that four meetings of the Arts Advisory Panel to the National Council on the Arts will be held at... are approximate): Arts Education (application review): October 4-5, 2010 in Room 716. A portion...

  17. 77 FR 22613 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2012-04-16

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and the Humanities. ACTION: Notice of meeting. SUMMARY: Pursuant to Section 10(a)(2... meetings of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy...

  18. 78 FR 64026 - Arts Advisory Panel Meeting

    Science.gov (United States)

    2013-10-25

    ... ARTS AND THE HUMANITIES Arts Advisory Panel Meeting AGENCY: National Endowment for the Arts, National Foundation on the Arts and Humanities. ACTION: Notice of Meeting SUMMARY: Pursuant to Section 10(a)(2) of the... of the Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks...

  19. 77 FR 9997 - NASA Advisory Council; Meeting

    Science.gov (United States)

    2012-02-21

    ... SPACE ADMINISTRATION NASA Advisory Council; Meeting AGENCY: National Aeronautics and Space Administration. ACTION: Notice of meeting. SUMMARY: In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration announces a meeting of...

  20. 77 FR 38336 - NASA Advisory Council; Meeting

    Science.gov (United States)

    2012-06-27

    ... SPACE ADMINISTRATION NASA Advisory Council; Meeting AGENCY: National Aeronautics and Space Administration. ACTION: Notice of meeting. SUMMARY: In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration (NASA) announces a...

  1. 75 FR 18240 - NASA Advisory Council; Meeting

    Science.gov (United States)

    2010-04-09

    ... SPACE ADMINISTRATION NASA Advisory Council; Meeting AGENCY: National Aeronautics and Space Administration. ACTION: Notice of meeting. SUMMARY: In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration announces a meeting of...

  2. 77 FR 67029 - NASA Advisory Council Meeting

    Science.gov (United States)

    2012-11-08

    ... SPACE ADMINISTRATION NASA Advisory Council Meeting AGENCY: National Aeronautics and Space Administration... amended, the National Aeronautics and Space Administration announces a meeting of the NASA Advisory Council. DATES: Wednesday, November 28, 2012, from 1:00 to 5:00 p.m. Thursday, November 29, 2012, from...

  3. 76 FR 4133 - NASA Advisory Council; Meeting

    Science.gov (United States)

    2011-01-24

    ... SPACE ADMINISTRATION NASA Advisory Council; Meeting AGENCY: National Aeronautics and Space Administration. ACTION: Notice of Meeting. SUMMARY: In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration announces a meeting of...

  4. 75 FR 59747 - NASA Advisory Council; Meeting.

    Science.gov (United States)

    2010-09-28

    ... SPACE ADMINISTRATION NASA Advisory Council; Meeting. AGENCY: National Aeronautics and Space Administration. ACTION: Notice of meeting. SUMMARY: In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration announces a meeting of...

  5. 75 FR 5629 - NASA Advisory Council; Meeting

    Science.gov (United States)

    2010-02-03

    ... SPACE ADMINISTRATION NASA Advisory Council; Meeting AGENCY: National Aeronautics and Space Administration. ACTION: Notice of Meeting. SUMMARY: In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration announces a meeting of...

  6. 78 FR 41804 - NASA Advisory Council; Meeting.

    Science.gov (United States)

    2013-07-11

    ... SPACE ADMINISTRATION NASA Advisory Council; Meeting. AGENCY: National Aeronautics and Space Administration. ACTION: Notice of Meeting. SUMMARY: In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration announces a meeting of...

  7. 76 FR 34750 - Advisory Committee Meeting

    Science.gov (United States)

    2011-06-14

    ... ENROLLMENT OF ACTUARIES Advisory Committee Meeting AGENCY: Joint Board for the Enrollment of Actuaries... for the Enrollment of Actuaries gives notice of a meeting of the Advisory Committee on Actuarial... W. McDonough, Executive Director of the Joint Board for the Enrollment of Actuaries, 202-622-...

  8. 78 FR 57174 - Advisory Committee Meeting

    Science.gov (United States)

    2013-09-17

    ... ENROLLMENT OF ACTUARIES Advisory Committee Meeting AGENCY: Joint Board for the Enrollment of Actuaries... for the Enrollment of Actuaries gives notice of a closed meeting of the Advisory Committee on... Joint Board for the Enrollment of Actuaries, 703-414- 2173. SUPPLEMENTARY INFORMATION: Notice is...

  9. 77 FR 67809 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2012-11-14

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Department of Energy, Office of Nuclear Energy. ACTION: Notice of Open Meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  10. 75 FR 13269 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2010-03-19

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Department of Energy, Office of Nuclear Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  11. 78 FR 70932 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2013-11-27

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Office of Nuclear Energy, Department of Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  12. 78 FR 76599 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2013-12-18

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Office of Nuclear Energy, Department of Energy. ACTION: Notice of... that the Nuclear Energy Advisory Committee (NEAC) will be renewed for a two-year period beginning...

  13. 76 FR 67717 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2011-11-02

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Department of Energy, Office of Nuclear Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  14. 75 FR 67351 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2010-11-02

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Office of Nuclear Energy, Department of Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  15. 77 FR 26274 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2012-05-03

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Department of Energy, Office of Nuclear Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  16. 78 FR 29125 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2013-05-17

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Office of Nuclear Energy, Department of Energy. ACTION: Notice of open meeting. SUMMARY: This notice announces a meeting of the Nuclear Energy Advisory Committee (NEAC)....

  17. 77 FR 49441 - Electricity Advisory Committee

    Science.gov (United States)

    2012-08-16

    ... Electricity Advisory Committee AGENCY: Office of Electricity Delivery and Energy Reliability, Department of... that the Electricity Advisory ] Committee's (EAC) charter has been renewed for a two-year period... Secretary for Electricity Delivery and Energy Reliability on programs to modernize the Nation's...

  18. 76 FR 23537 - Resource Advisory Committee Meeting

    Science.gov (United States)

    2011-04-27

    ... Resource Advisory Committee Meeting AGENCY: Forest Service, USDA. ACTION: Notice of Public Meeting, Sabine..., Sabine National Forest Resource Advisory Committee (RAC) meeting will meet as indicated below. DATES: The Sabine National Forest RAC meeting will be held on Thursday, May 5, 2011. ADDRESSES: The Sabine...

  19. 76 FR 28950 - Sabine Resource Advisory Committee

    Science.gov (United States)

    2011-05-19

    ... Sabine Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Sabine Resource Advisory Committee will meet in Hemphill, Texas. The committee is authorized under the.... ADDRESSES: The meeting will be held at the Sabine NF Office, 5050 State Hwy. 21 East, Hemphill, TX...

  20. 77 FR 53842 - Sabine Resource Advisory Committee

    Science.gov (United States)

    2012-09-04

    ... Forest Service Sabine Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Sabine Resource Advisory Committee will meet in Hemphill, Texas. The committee is authorized... held on Thursday, September 13, 2012, 3:30 p.m. ADDRESSES: The meeting will be held at the Sabine...

  1. 76 FR 44574 - Sabine Resource Advisory Committee

    Science.gov (United States)

    2011-07-26

    ... Forest Service Sabine Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Sabine Resource Advisory Committee will meet in Hemphill, Texas. The committee is authorized..., September 7, 2011, 3:30 p.m. ADDRESSES: The meeting will be held at the Sabine NF Office, 5050 State Hwy...

  2. 76 FR 34962 - Sabine Resource Advisory Committee

    Science.gov (United States)

    2011-06-15

    ... Forest Service Sabine Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Sabine Resource Advisory Committee will meet in Hemphill, Texas. The committee is authorized..., July 7, 2011, 3:30 p.m. ADDRESSES: The meeting will be held at the Sabine NF Office, 5050 State Hwy...

  3. 76 FR 66033 - Sabine Resource Advisory Committee

    Science.gov (United States)

    2011-10-25

    ... Forest Service Sabine Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting cancellation. SUMMARY: The Sabine-Angelina Resource Advisory Committee was scheduled to meet October 20, 2011... Thursday, October 20, 2011, 3:30 p.m. ADDRESSES: The canceled meeting would have been held at the...

  4. 77 FR 45329 - Sabine Resource Advisory Committee

    Science.gov (United States)

    2012-07-31

    ... Forest Service Sabine Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Sabine Resource Advisory Committee will meet in ] Hemphill, Texas. The committee is... held on Thursday, August 23, 2012, 3:30 p.m. ADDRESSES: The meeting will be held at the Sabine...

  5. 76 FR 62342 - Sabine Resource Advisory Committee

    Science.gov (United States)

    2011-10-07

    ... Forest Service Sabine Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Sabine Resource Advisory Committee will meet in Hemphill, Texas. The committee is authorized... teleconference call on Thursday, October 20, 2011, 3:30 p.m. ADDRESSES: The meeting will be held at the Sabine...

  6. 77 FR 19300 - National Infrastructure Advisory Council

    Science.gov (United States)

    2012-03-30

    ... SECURITY National Infrastructure Advisory Council AGENCY: National Protection and Programs Directorate, DHS... Infrastructure Advisory Council (NIAC) will meet on Tuesday, April 17, 2012, 1310 N. Courthouse Road, Suite 300, Virginia Room, Arlington, VA 22201. The meeting will be open to the public. DATES: The NIAC will...

  7. 77 FR 39247 - National Infrastructure Advisory Council

    Science.gov (United States)

    2012-07-02

    ... SECURITY National Infrastructure Advisory Council AGENCY: National Protection and Programs Directorate, DHS... Infrastructure Advisory Council (NIAC) will meet on Tuesday, July 17, 2012, at the Department of Transportation's... meeting will be open to the public. DATES: The NIAC will meet Tuesday, July 17, 2012, from 1:30 p.m. to...

  8. 78 FR 65675 - National Infrastructure Advisory Council

    Science.gov (United States)

    2013-11-01

    ... SECURITY National Infrastructure Advisory Council AGENCY: National Protection and Programs Directorate, DHS... Infrastructure Advisory Council (NIAC) will meet Thursday, November 21, 2013, at the United States Patent and... the public. DATES: The NIAC will meet Thursday, November 21, 2013, from 1:30 p.m. to 4:30 p.m....

  9. 78 FR 40487 - National Infrastructure Advisory Council

    Science.gov (United States)

    2013-07-05

    ... SECURITY National Infrastructure Advisory Council AGENCY: National Protection and Programs Directorate, DHS... Infrastructure Advisory Council (NIAC) will meet Monday, July 29, 2013, at the United States Access Board, 1331 F Street NW., Suite 800, Washington, DC 20004. The meeting will be open to the public. DATES: The NIAC...

  10. 77 FR 62521 - National Infrastructure Advisory Council

    Science.gov (United States)

    2012-10-15

    ... SECURITY National Infrastructure Advisory Council AGENCY: National Protection and Programs Directorate, DHS... Infrastructure Advisory Council (NIAC) will meet Tuesday, October 16, 2012, at the United States Access Board, 1331 F Street NW., Suite 800, Washington, DC 20004. The meeting will be open to the public. DATES:...

  11. 78 FR 57128 - Census Advisory Committees; Meetings

    Science.gov (United States)

    2013-09-17

    ... Census Bureau Census Advisory Committees; Meetings AGENCY: Bureau of the Census, Department of Commerce. ACTION: Notice of public meeting. SUMMARY: The Bureau of the Census (Census Bureau) is giving notice of a meeting, the National Advisory Committee on Racial, Ethnic, and Other Populations (NAC). The...

  12. 75 FR 7255 - Army Educational Advisory Committee

    Science.gov (United States)

    2010-02-18

    ... Department of the Army Army Educational Advisory Committee AGENCY: Department of the Army, DoD. ACTION... CFR 102-3.150, the following meeting notice is announced: Name of Committee: U.S. Army War College Subcommittee of the Army Education Advisory Committee. Date of Meeting: March 11, 2010. Place of Meeting:...

  13. Advisory and autonomous cooperative driving systems

    NARCIS (Netherlands)

    Broek, T.H.A. van den; Ploeg, J.; Netten, B.D.

    2011-01-01

    In this paper, the traffic efficiency of an advisory cooperative driving system, Advisory Acceleration Control is examined and compared to the efficiency of an autonomous cooperative driving system, Cooperative Adaptive Cruise Control. The algorithms and implementation thereof are explained. The res

  14. Drug-Induced Nephrotoxicity and Dose Adjustment Recommendations: Agreement Among Four Drug Information Sources.

    Science.gov (United States)

    Bicalho, Millena Drumond; Soares, Danielly Botelho; Botoni, Fernando Antonio; Reis, Adriano Max Moreira; Martins, Maria Auxiliadora Parreiras

    2015-09-09

    : Hospitalized patients require the use of a variety of drugs, many of which individually or in combination have the potential to cause kidney damage. The use of potentially nephrotoxic drugs is often unavoidable, and the need for dose adjustment should be evaluated. This study is aimed at assessing concordance in information on drug-induced nephrotoxicity and dose adjustment recommendations by comparing four drug information sources (DRUGDEX(®), UpToDate(®), Medscape(®) and the Brazilian Therapeutic Formulary) using the formulary of a Brazilian public hospital. A total of 218 drugs were investigated. The global Fleiss' kappa coefficient was 0.265 for nephrotoxicity (p < 0.001; CI 95%, 0.211-0.319) and 0.346 for recommendations (p < 0.001; CI 95%, 0.292-0.401), indicating fair concordance among the sources. Anti-infectives and anti-hypertensives were the main drugs cited as nephrotoxic by the different sources. There were no clear definitions for qualitative data or quantitative values for dose adjustments among the four information sources. There was no advice for dosing for a large number of the drugs in the international databases. The National Therapeutic Formulary offered imprecise dose adjustment recommendations for many nephrotoxic drugs. Discrepancies among information sources may have a clinical impact on patient care and contribute to drug-related morbidity and mortality.

  15. Drug-Induced Nephrotoxicity and Dose Adjustment Recommendations: Agreement Among Four Drug Information Sources

    Directory of Open Access Journals (Sweden)

    Millena Drumond Bicalho

    2015-09-01

    Full Text Available : Hospitalized patients require the use of a variety of drugs, many of which individually or in combination have the potential to cause kidney damage. The use of potentially nephrotoxic drugs is often unavoidable, and the need for dose adjustment should be evaluated. This study is aimed at assessing concordance in information on drug-induced nephrotoxicity and dose adjustment recommendations by comparing four drug information sources (DRUGDEX®, UpToDate®, Medscape® and the Brazilian Therapeutic Formulary using the formulary of a Brazilian public hospital. A total of 218 drugs were investigated. The global Fleiss’ kappa coefficient was 0.265 for nephrotoxicity (p < 0.001; CI 95%, 0.211–0.319 and 0.346 for recommendations (p < 0.001; CI 95%, 0.292–0.401, indicating fair concordance among the sources. Anti-infectives and anti-hypertensives were the main drugs cited as nephrotoxic by the different sources. There were no clear definitions for qualitative data or quantitative values for dose adjustments among the four information sources. There was no advice for dosing for a large number of the drugs in the international databases. The National Therapeutic Formulary offered imprecise dose adjustment recommendations for many nephrotoxic drugs. Discrepancies among information sources may have a clinical impact on patient care and contribute to drug-related morbidity and mortality.

  16. 78 FR 71631 - Committee Name: Homeland Security Information Network Advisory Committee (HSINAC)

    Science.gov (United States)

    2013-11-29

    ... SECURITY Committee Name: Homeland Security Information Network Advisory Committee (HSINAC) AGENCY... Management; Notice of Federal Advisory Committee Meeting. SUMMARY: The Homeland Security Information Network... Homeland Security Information Network Advisory Committee (HSINAC) is an advisory body to the...

  17. 76 FR 65200 - General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee: Notice of...

    Science.gov (United States)

    2011-10-20

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical... and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee scheduled for December...

  18. 75 FR 1395 - General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Amendment of...

    Science.gov (United States)

    2010-01-11

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical... the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee. This...

  19. 75 FR 61507 - General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Amendment of...

    Science.gov (United States)

    2010-10-05

    ... HUMAN SERVICES Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical... General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee. This meeting was...: In the Federal Register of August 16, 2010, FDA announced that a meeting of the General and...

  20. 神经外科手术患者应用氟喹诺酮类药抗感染疗效的影响因素%Analysis of influencing factors for anti-infection efficacy of fluoroquinolones in neurosurgical patients

    Institute of Scientific and Technical Information of China (English)

    唐宗椿; 王晓峰; 杨兴奎; 张荣军

    2012-01-01

    Objective To analyze the influencing factors of therapeutic efficacy of antibacterial fluoroquinolones in neurosurgical patients, and to provide reference for rational use of fluoroquinolones in clinic. Methods The scale of influencing factors for 133 neurosurgical patients who treated with fluoroquinolones , including age, gender, liver and renal function index, and other factors, were designed and filled according to the data of clinical case. The data were analyzed through Logistic regression analysis to determine the main factors that influenced therapeutic effects. Results In 133 cases,pathogens were cultured by microbial test in 16 cases (12. 03% ). Among influencing factors of therapeutic efficacy of fluoroquinolones, the age, gender, creatinine, alanine aminotransferase and aspartate aminotransferase were major factors. Logistic regression analysis showed that the OR values were from 0. 029 to 5. 317 and P values from 0. 003 to 0.026. Conclusion The results suggest that elderly and poor liver and kidney function patients using fluoroquinolones as anti-infective therapy are ineffective. Fluoroquinolone drugs for the elderly and liver and kidney dysfunction patients with anti-infective therapy, individual therapy should be based on susceptibility testing and changes in condition.%目的 对影响神经外科手术中氟喹诺酮类药抗感染疗效的影响因素进行分析,为该类药临床合理应用提供参考.方法 对133例使用氟喹诺酮类药治疗的神经外科手术患者制定抗感染疗效影响因素调查量表,并根据患者临床病例提供的数据填写,对包括年龄、性别、肝肾功能等在内的11个因素进行多因素Logistic回归分析,确定影响抗感染疗效的主要因素.结果 在133例患者中,有16例(12.03%)微生物试验培养出致病菌.影响氟喹诺酮类药物疗效的主要因素包括年龄、性别、血清肌酐、丙氨酸氨基转移酶、天门冬氨酸氨基转移酶

  1. Carbonic anhydrase inhibitors drug design.

    Science.gov (United States)

    McKenna, Robert; Supuran, Claudiu T

    2014-01-01

    Inhibition of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) has pharmacologic applications in the field of antiglaucoma, anticonvulsant, antiobesity, and anticancer agents but is also emerging for designing anti-infectives (antifungal and antibacterial agents) with a novel mechanism of action. As a consequence, the drug design of CA inhibitors (CAIs) is a very dynamic field. Sulfonamides and their isosteres (sulfamates/sulfamides) constitute the main class of CAIs which bind to the metal ion in the enzyme active site. Recently the dithiocarbamates, possessing a similar mechanism of action, were reported as a new class of inhibitors. Other families of CAIs possess a distinct mechanism of action: phenols, polyamines, some carboxylates, and sulfocoumarins anchor to the zinc-coordinated water molecule. Coumarins and five/six-membered lactones are prodrug inhibitors, binding in hydrolyzed form at the entrance of the active site cavity. Novel drug design strategies have been reported principally based on the tail approach for obtaining all these types of CAIs, which exploit more external binding regions within the enzyme active site (in addition to coordination to the metal ion), leading thus to isoform-selective compounds. Sugar-based tails as well as click chemistry were the most fruitful developments of the tail approach. Promising compounds that inhibit CAs from bacterial and fungal pathogens, of the dithiocarbamate, phenol and carboxylate types have also been reported.

  2. 76 FR 20960 - Public Advisory Committees

    Science.gov (United States)

    2011-04-14

    ..., science, technology, and office automation.'' 35 U.S.C. 5(b)(3). In the case of the Patent Public Advisory.... While away from home or regular place of business, each member will be allowed travel...

  3. Right Whale Sightings Advisory System (RWSAS)

    Data.gov (United States)

    National Oceanic and Atmospheric Administration, Department of Commerce — The Right Whale Sighting Advisory System (RWSAS) is a NOAA Fisheries program which was designed to reduce collisions between ships and the critically endangered...

  4. 76 FR 36137 - National Infrastructure Advisory Council

    Science.gov (United States)

    2011-06-21

    ... Infrastructure Advisory Council (NIAC) will meet on Tuesday, July 12, 2011, at the Washington Marriott at Metro... NIAC@dhs.gov . ADDRESSES: The meeting will be held at the Washington Marriott at Metro Center, Salon...

  5. 77 FR 16894 - Financial Research Advisory Committee

    Science.gov (United States)

    2012-03-22

    ... recognized experts in the fields of economics, financial institutions and markets, statistical analysis, financial markets analysis, econometrics, applied sciences, risk management, data, information standards... Financial Research Advisory Committee AGENCY: Office of Financial Research, Treasury. ACTION: Notice...

  6. 76 FR 54748 - State Energy Advisory Board

    Science.gov (United States)

    2011-09-02

    ... From the Federal Register Online via the Government Publishing Office ] DEPARTMENT OF ENERGY Energy Efficiency and Renewable Energy State Energy Advisory Board AGENCY: Energy Efficiency and Renewable Energy, Department of Energy. ACTION: Notice of open teleconference. SUMMARY: This...

  7. 76 FR 78252 - Nuclear Energy Advisory Committee

    Science.gov (United States)

    2011-12-16

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF ENERGY Nuclear Energy Advisory Committee AGENCY: Department of Energy, Office of Nuclear Energy. ACTION: Notice of... Management Secretariat, General Services Administration, notice is hereby given that the Nuclear...

  8. 75 FR 61693 - Coconino Resource Advisory Committee

    Science.gov (United States)

    2010-10-06

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF AGRICULTURE Forest Service Coconino Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of... Act, Travel Reimbursement procedures, establish proposal meeting dates, and proposal outreach....

  9. Advisory Tools for Use in Organic Farming

    OpenAIRE

    Peers, David; van Diepen, Pauline

    2008-01-01

    Advisory tools are an invaluable aid for advisers in providing farmers with the necessary information for analysis and planning of all aspects of the farm. The review of Advisory Tools provides access to and a comprehensive list of all the templates, calculators and analytical tools available to organic advisers, covering the nutrient managment, business, soils and animal husbandry. The review identifies relevant research and development, the tools developed and draws on farm and adviso...

  10. Mercury advisories: Information, education, and fish consumption

    OpenAIRE

    Shimshack, Jay P; Ward, Michael B.; Beatty, Timothy K.M.

    2007-01-01

    This paper examines responses to a national FDA advisory that urged at-risk individuals to limit store-bought fish consumption due to the dangers of methyl-mercury. We investigate consumer response using both parametric and nonparametric methods. Some targeted consumers significantly reduced canned fish purchases as a result of the advisory, suggesting that information-based policies can achieve the issuing agency’s goals. Education and newspaper readership were important determinants of resp...

  11. 77 FR 72322 - The National Advisory Council on Innovation and Entrepreneurship Meeting of the National Advisory...

    Science.gov (United States)

    2012-12-05

    ... Economic Development Administration The National Advisory Council on Innovation and Entrepreneurship Meeting of the National Advisory Council on Innovation and Entrepreneurship AGENCY: U.S. Department of... Entrepreneurship will hold a meeting on Tuesday, December 11, 2012. The open meeting will be held from 10:00...

  12. 76 FR 35891 - Meeting of the Local Government Advisory Committee and Small Community Advisory Subcommittee

    Science.gov (United States)

    2011-06-20

    ... AGENCY Meeting of the Local Government Advisory Committee and Small Community Advisory Subcommittee AGENCY: Environmental Protection Agency (EPA). ACTION: Notice. SUMMARY: The U.S. EPA's Local Government...., Chicago, Illinois. FOR FURTHER INFORMATION CONTACT: Paula Zampieri, DFO for the Local Government...

  13. 78 FR 66929 - Meetings of the Local Government Advisory Committee and the Small Communities Advisory...

    Science.gov (United States)

    2013-11-07

    ... AGENCY Meetings of the Local Government Advisory Committee and the Small Communities Advisory... comments may be extended if the number of requests for appearances requires it. The Local Government... local governments. This is an open meeting and all interested persons are invited to participate....

  14. 75 FR 22561 - Federal Advisory Committee; United States Strategic Command Strategic Advisory Group; Charter...

    Science.gov (United States)

    2010-04-29

    ..., intelligence, and policy-related matters of interest to the Joint Chiefs of Staff and the U.S. Strategic..., communications, intelligence and information operations, or other important aspects of the Nation's strategic... of the Secretary Federal Advisory Committee; United States Strategic Command Strategic Advisory...

  15. 76 FR 7815 - Renewable Energy and Energy Efficiency Advisory Committee

    Science.gov (United States)

    2011-02-11

    ... International Trade Administration Renewable Energy and Energy Efficiency Advisory Committee AGENCY... Renewable Energy and Energy Efficiency Advisory Committee (RE&EEAC) will hold a meeting to hear....S. renewable energy and energy efficiency companies, to review subcommittee reports on...

  16. 76 FR 38608 - Sensors and Instrumentation Technical Advisory Committee;

    Science.gov (United States)

    2011-07-01

    ... Bureau of Industry and Security Sensors and Instrumentation Technical Advisory Committee; Notice of Partially Closed Meeting The Sensors and Instrumentation Technical Advisory Committee (SITAC) will meet on... applicable to sensors and instrumentation equipment and technology. Agenda Public Session 1. Welcome...

  17. 76 FR 22674 - Manufacturing Extension Partnership Advisory Board

    Science.gov (United States)

    2011-04-22

    ... National Institute of Standards and Technology Manufacturing Extension Partnership Advisory Board AGENCY... announces that the Manufacturing Extension Partnership (MEP) Advisory Board, National Institute of Standards... than May 2, 2011. FOR FURTHER INFORMATION CONTACT: Karen Lellock, Manufacturing Extension...

  18. 75 FR 50749 - Manufacturing Extension Partnership Advisory Board

    Science.gov (United States)

    2010-08-17

    ... National Institute of Standards and Technology Manufacturing Extension Partnership Advisory Board AGENCY... announces that the Manufacturing Extension Partnership (MEP) Advisory Board, National Institute of Standards... INFORMATION CONTACT: Karen Lellock, Manufacturing Extension Partnership, National Institute of Standards...

  19. 75 FR 19941 - Manufacturing Extension Partnership Advisory Board

    Science.gov (United States)

    2010-04-16

    ... National Institute of Standards and Technology Manufacturing Extension Partnership Advisory Board AGENCY... announces that the Manufacturing Extension Partnership (MEP) Advisory Board, National Institute of Standards..., 2010. FOR FURTHER INFORMATION CONTACT: Karen Lellock, Manufacturing Extension Partnership,...

  20. 77 FR 20790 - Manufacturing Extension Partnership Advisory Board

    Science.gov (United States)

    2012-04-06

    ... National Institute of Standards and Technology Manufacturing Extension Partnership Advisory Board AGENCY... announces that the Manufacturing Extension Partnership (MEP) Advisory Board, National Institute of Standards... INFORMATION section below. FOR FURTHER INFORMATION CONTACT: Karen Lellock, Manufacturing Extension...

  1. 75 FR 1839 - Departmental Offices; Debt Management Advisory Committee Meeting

    Science.gov (United States)

    2010-01-13

    .... App. 2, Sec. 10(a)(2), that a meeting will be held at the Hay-Adams Hotel, 16th Street and... advisory committee: Treasury Borrowing Advisory Committee of The Securities Industry and Financial...

  2. 75 FR 63541 - Departmental Offices; Debt Management Advisory Committee Meeting

    Science.gov (United States)

    2010-10-15

    .... App. 2, Sec. 10(a)(2), that a meeting will be held at the Hay-Adams Hotel, 16th Street and... advisory committee: Treasury Borrowing Advisory Committee of The Securities Industry and Financial...

  3. 77 FR 41476 - Departmental Offices; Debt Management Advisory Committee Meeting

    Science.gov (United States)

    2012-07-13

    .... App. 2, Sec. 10(a)(2), that a meeting will be held at the Hay-Adams Hotel, 16th Street and... advisory committee: Treasury Borrowing Advisory Committee of The Securities Industry and Financial...

  4. 75 FR 18482 - Environmental Technologies Trade Advisory Committee (ETTAC)

    Science.gov (United States)

    2010-04-12

    ... Environmental Technologies Trade Advisory Committee (ETTAC) AGENCY: International Trade Administration, U.S. Department of Commerce. ACTION: Notice of open meeting. SUMMARY: The Environmental Technologies Trade Advisory Committee (ETTAC) will hold its quarterly meeting to discuss environmental technologies...

  5. 75 FR 52716 - Environmental Technologies Trade Advisory Committee (ETTAC)

    Science.gov (United States)

    2010-08-27

    ... Environmental Technologies Trade Advisory Committee (ETTAC) AGENCY: International Trade Administration, U.S. Department of Commerce. ACTION: Notice of open meeting. SUMMARY: The Environmental Technologies Trade Advisory Committee (ETTAC) will hold its quarterly meeting to discuss environmental technologies...

  6. 76 FR 20717 - NASA Advisory Council; Space Operations Committee; Meeting.

    Science.gov (United States)

    2011-04-13

    ... SPACE ADMINISTRATION NASA Advisory Council; Space Operations Committee; Meeting. AGENCY: National Aeronautics and Space Administration. ACTION: Notice of meeting. SUMMARY: In accordance with the Federal... announces a meeting of the NASA Advisory Council (NAC) Space Operations Committee. DATES: Tuesday, May...

  7. 75 FR 39974 - NASA Advisory Council; Space Operations Committee; Meeting

    Science.gov (United States)

    2010-07-13

    ... SPACE ADMINISTRATION NASA Advisory Council; Space Operations Committee; Meeting AGENCY: National... announces a meeting of the Space Operations Committee of the NASA Advisory Council. DATES: Wednesday, July... Aeronautics and Space Administration Headquarters, Washington, DC 20546, 202/358-1507,...

  8. 78 FR 10213 - NASA Advisory Council; Commercial Space Committee; Meeting

    Science.gov (United States)

    2013-02-13

    ... SPACE ADMINISTRATION NASA Advisory Council; Commercial Space Committee; Meeting AGENCY: National Aeronautics and Space Administration. ACTION: Notice of meeting. SUMMARY: In accordance with the Federal... (NASA) announces a meeting of the Commercial Space Committee of the NASA Advisory Council (NAC)....

  9. 78 FR 42111 - NASA Advisory Council; Commercial Space Committee; Meeting

    Science.gov (United States)

    2013-07-15

    ... SPACE ADMINISTRATION NASA Advisory Council; Commercial Space Committee; Meeting AGENCY: National... (NASA) announces a meeting of the Commercial Space Committee of the NASA Advisory Council (NAC). This... --International Space Station Utilization Status and Plans --Description of NASA's Agency Level...

  10. 76 FR 78329 - Commercial Space Transportation Advisory Committee; Public Teleconference

    Science.gov (United States)

    2011-12-16

    ... TRANSPORTATION Federal Aviation Administration Commercial Space Transportation Advisory Committee; Public Teleconference AGENCY: Federal Aviation Administration (FAA), DOT. ACTION: Notice of Commercial Space... Commercial Space Transportation Advisory Committee (COMSTAC). The teleconference will take place on...

  11. 77 FR 35102 - Commercial Space Transportation Advisory Committee; Public Teleconference

    Science.gov (United States)

    2012-06-12

    ... Federal Aviation Administration Commercial Space Transportation Advisory Committee; Public Teleconference AGENCY: Federal Aviation Administration (FAA), DOT. ACTION: Notice of Commercial Space Transportation... Working Group (OWG) of the Commercial Space Transportation Advisory Committee (COMSTAC)....

  12. 78 FR 53496 - Commercial Space Transportation Advisory Committee; Public Teleconference

    Science.gov (United States)

    2013-08-29

    ... Federal Aviation Administration Commercial Space Transportation Advisory Committee; Public Teleconference AGENCY: Federal Aviation Administration (FAA), DOT. ACTION: Notice of Commercial Space Transportation... Space Transportation Advisory Committee (COMSTAC). DATES: The teleconference will take place on...

  13. 76 FR 82031 - Commercial Space Transportation Advisory Committee; Public Teleconference

    Science.gov (United States)

    2011-12-29

    ... Federal Aviation Administration Commercial Space Transportation Advisory Committee; Public Teleconference AGENCY: Federal Aviation Administration (FAA), DOT. ACTION: Notice of Commercial Space Transportation... teleconference of the Commercial Space Transportation Advisory Committee (COMSTAC) Risk Management Working...

  14. Beach Advisory and Closing Online Notification (BEACON) system

    Data.gov (United States)

    U.S. Environmental Protection Agency — Beach Advisory and Closing Online Notification system (BEACON) is a colletion of state and local data reported to EPA about beach closings and advisories. BEACON is...

  15. 75 FR 57102 - Occupational Information Development Advisory Panel Meeting; Correction

    Science.gov (United States)

    2010-09-17

    ... ADMINISTRATION Occupational Information Development Advisory Panel Meeting; Correction AGENCY: Social Security Administration. ACTION: Notice; correction. SUMMARY: The Social Security Administration published a document in...: Occupational Information Development Advisory Panel, Social Security Administration, 6401 Security...

  16. 76 FR 70804 - Occupational Information Development Advisory Panel Meeting

    Science.gov (United States)

    2011-11-15

    ... From the Federal Register Online via the Government Publishing Office SOCIAL SECURITY ADMINISTRATION Occupational Information Development Advisory Panel Meeting AGENCY: Social Security Administration... Advisory Panel, Social Security Administration, 6401 Security Boulevard, Robert M. Ball Federal Building,...

  17. Federal Advisory Committee Act (FACA) Database-Complete-Raw

    Data.gov (United States)

    General Services Administration — The Federal Advisory Committee Act (FACA) database is used by Federal agencies to continuously manage an average of 1,000 advisory committees government-wide. This...

  18. 78 FR 57454 - Marine Transportation System National Advisory Council

    Science.gov (United States)

    2013-09-18

    ... Maritime Administration Marine Transportation System National Advisory Council AGENCY: Maritime Administration, DOT. ACTION: Notice of request for applications. SUMMARY: The Maritime Administration (MarAd) is seeking applications for membership on the Marine Transportation System National Advisory Council...

  19. 75 FR 2892 - NASA Advisory Council; Science Committee; Meeting

    Science.gov (United States)

    2010-01-19

    ... SPACE ADMINISTRATION NASA Advisory Council; Science Committee; Meeting AGENCY: National Aeronautics and Space Administration. ACTION: Notice of meeting. SUMMARY: The National Aeronautics and Space Administration (NASA) announces a meeting of the Science Committee of the NASA Advisory Council (NAC)....

  20. 75 FR 78777 - Advisory Committee On Reactor Safeguards; Renewal

    Science.gov (United States)

    2010-12-16

    ... with the Federal Advisory Committee Act. FOR FURTHER INFORMATION CONTACT: Andrew L. Bates, Office of...: December 10, 2010. Andrew L. Bates, Advisory Committee Management Officer. BILLING CODE 7590-01-P...

  1. 76 FR 70970 - Technology Innovation Program Advisory Board

    Science.gov (United States)

    2011-11-16

    ... National Institute of Standards and Technology Technology Innovation Program Advisory Board AGENCY.... SUMMARY: The Technology Innovation Program (TIP) Advisory Board will hold a meeting via teleconference on... Innovation Program Acting Deputy Director, National Institute of Standards and Technology, 100 Bureau...

  2. 75 FR 62369 - Technology Innovation Program Advisory Board

    Science.gov (United States)

    2010-10-08

    ... Innovation Program Advisory Board AGENCY: National Institute of Standards and Technology, Department of Commerce. ACTION: Notice of public meeting. SUMMARY: The Technology Innovation Program Advisory Board... address is rene.cesaro@nist.gov . SUPPLEMENTARY INFORMATION: The Technology Innovation Program...

  3. 76 FR 18166 - Technology Innovation Program Advisory Board

    Science.gov (United States)

    2011-04-01

    ... National Institute of Standards and Technology Technology Innovation Program Advisory Board AGENCY.... SUMMARY: The Technology Innovation Program Advisory Board, National Institute of Standards and Technology.... Cesaro's e-mail address is rene.cesaro@nist.gov . SUPPLEMENTARY INFORMATION: The Technology...

  4. 76 FR 22673 - Technology Innovation Program Advisory Board

    Science.gov (United States)

    2011-04-22

    ... National Institute of Standards and Technology Technology Innovation Program Advisory Board AGENCY... notice in the Federal Register announcing an open meeting for the Technology Innovation Program Advisory... rene.cesaro@nist.gov . SUPPLEMENTARY INFORMATION: The Technology Innovation Program (TIP)...

  5. 77 FR 51753 - Daniel Boone National Forest Resource Advisory Committee

    Science.gov (United States)

    2012-08-27

    ... Forest Service Daniel Boone National Forest Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting. SUMMARY: The Daniel Boone National Forest Resource Advisory Committee (RAC... public may inspect comments received at Daniel Boone National Forest, 1700 Bypass Road,...

  6. 78 FR 66801 - Motor Carrier Safety Advisory Committee; Charter Renewal

    Science.gov (United States)

    2013-11-06

    ... Federal Motor Carrier Safety Administration Motor Carrier Safety Advisory Committee; Charter Renewal AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT. ACTION: Announcement of advisory... Committee that provides the Agency with advice and recommendations on motor carrier safety programs...

  7. 76 FR 12214 - Motor Carrier Safety Advisory Committee Public Meeting

    Science.gov (United States)

    2011-03-04

    ... Federal Motor Carrier Safety Administration Motor Carrier Safety Advisory Committee Public Meeting AGENCY: Federal Motor Carrier Safety Administration, DOT. ACTION: Notice: Announcement of Motor Carrier Safety Advisory Committee meeting; request for comment. SUMMARY: The Federal Motor Carrier Safety...

  8. 78 FR 72141 - Aviation Rulemaking Advisory Committee; Meeting

    Science.gov (United States)

    2013-12-02

    ... Federal Aviation Administration Aviation Rulemaking Advisory Committee; Meeting AGENCY: Federal Aviation Administration (FAA), DOT. ACTION: Notice of Aviation Rulemaking Advisory Committee (ARAC) meeting. SUMMARY: The... December 12, 2013. ADDRESSES: The meeting will take place at the Federal Aviation Administration,...

  9. 78 FR 34139 - Aviation Rulemaking Advisory Committee; Meeting

    Science.gov (United States)

    2013-06-06

    ... Federal Aviation Administration Aviation Rulemaking Advisory Committee; Meeting AGENCY: Federal Aviation Administration (FAA), DOT. ACTION: Notice of Aviation Rulemaking Advisory Committee (ARAC) meeting. SUMMARY: The... 13, 2013. ADDRESSES: The meeting will take place at the Federal Aviation Administration,...

  10. 78 FR 50138 - Aviation Rulemaking Advisory Committee; Meeting

    Science.gov (United States)

    2013-08-16

    ... Federal Aviation Administration Aviation Rulemaking Advisory Committee; Meeting AGENCY: Federal Aviation Administration (FAA), DOT. ACTION: Notice of Aviation Rulemaking Advisory Committee (ARAC) meeting. SUMMARY: The... September 12, 2013. ADDRESSES: The meeting will take place at the Federal Aviation Administration,...

  11. 77 FR 26641 - Aviation Security Advisory Committee (ASAC) Meeting

    Science.gov (United States)

    2012-05-04

    ... 4, 2012 Part III Department of Homeland Security Transportation Security Administration Aviation... Aviation Security Advisory Committee (ASAC) Meeting AGENCY: Transportation Security Administration, DHS... Security Administration (TSA) will hold a meeting of the Aviation Security Advisory Committee (ASAC) on...

  12. 77 FR 10742 - Local Government Advisory Committee; Request for Nominations

    Science.gov (United States)

    2012-02-23

    ... AGENCY Local Government Advisory Committee; Request for Nominations AGENCY: Environmental Protection... demonstrated ability to work constructively and effectively on committees. How to Submit Nominations: Any... ] advisory committee. Individuals may self-nominate. Nominations can be submitted in electronic...

  13. 76 FR 71438 - Minority Depository Institutions Advisory Committee

    Science.gov (United States)

    2011-11-17

    ... Office of the Comptroller of the Currency Minority Depository Institutions Advisory Committee AGENCY... Minority Depository Institutions Advisory Committee (MDIAC or Committee) formerly administered by the... preserve the present number of minority depository institutions and encourage the creation of new...

  14. 76 FR 67403 - Madera County Resource Advisory Committee

    Science.gov (United States)

    2011-11-01

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF AGRICULTURE Forest Service Madera County Resource Advisory Committee AGENCY: Forest Service, USDA. ACTION: Notice of meeting cancellation. SUMMARY: The Madera County Resource Advisory Committee was scheduled to...

  15. 78 FR 49296 - NASA International Space Station Advisory Committee; Meeting

    Science.gov (United States)

    2013-08-13

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee; Meeting AGENCY: National Aeronautics and Space Administration (NASA). ACTION: Notice of meeting. SUMMARY: In accordance with the... Administration announces a meeting of the NASA International Space Station (ISS) Advisory Committee. The...

  16. 77 FR 41203 - NASA International Space Station Advisory Committee; Meeting

    Science.gov (United States)

    2012-07-12

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee; Meeting AGENCY: National... Administration announces an open meeting of the NASA International Space Station (ISS) Advisory Committee. The... aboard the International Space Station, including transportation, and crew rotation; and, to assess...

  17. 77 FR 66082 - NASA International Space Station Advisory Committee; Meeting

    Science.gov (United States)

    2012-11-01

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee; Meeting AGENCY: National... Administration announces an open meeting of the NASA International Space Station (ISS) Advisory Committee. The... aboard the International Space Station, including transportation, and crew rotation; and, to assess...

  18. 78 FR 77502 - NASA International Space Station Advisory Committee; Meeting

    Science.gov (United States)

    2013-12-23

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee; Meeting AGENCY: National Aeronautics and Space Administration (NASA). ACTION: Notice of Meeting. SUMMARY: In accordance with the... Administration announces a meeting of the NASA International Space Station (ISS) Advisory Committee. The...

  19. 77 FR 2765 - NASA International Space Station Advisory Committee; Meeting

    Science.gov (United States)

    2012-01-19

    ... SPACE ADMINISTRATION NASA International Space Station Advisory Committee; Meeting AGENCY: National... Administration announces an open meeting of the NASA International Space Station (ISS) Advisory Committee. The... aboard the International Space Station, including transportation, and crew rotation; and, to assess...

  20. 77 FR 75182 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2012-12-19

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Committee Teleconference. SUMMARY: The President's National Security Telecommunications Advisory Committee... telecommunications policy. Agenda: The NSTAC members will receive an update on progress made to date by the...

  1. 76 FR 17424 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2011-03-29

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Committee Meeting. SUMMARY: The President's National Security Telecommunications Advisory Committee (NSTAC... preparedness telecommunications policy. The NSTAC Chair, Mr. James Crowe, will call the meeting to order...

  2. 75 FR 16159 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2010-03-31

    ... SECURITY National Communications System President's National Security Telecommunications Advisory Committee...: The President's National Security Telecommunications Advisory Committee (NSTAC) will hold its annual... and emergency preparedness telecommunications policy. Notice of this meeting is given under...

  3. 76 FR 52672 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2011-08-23

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Committee Teleconference. SUMMARY: The President's National Security Telecommunications Advisory Committee... telecommunications policy. During the conference call, the NSTAC members will receive an update regarding...

  4. 77 FR 44641 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2012-07-30

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Committee Teleconference. SUMMARY: The President's National Security Telecommunications Advisory Committee... security and emergency preparedness telecommunications policy. Agenda: The NSTAC members will receive...

  5. 76 FR 72427 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2011-11-23

    ... Security Telecommunications Advisory Committee AGENCY: National Protection and Programs Directorate, DHS... President's National Security Telecommunications Advisory Committee (NSTAC) will meet on Thursday, December...) telecommunications policy. During the meeting, NSTAC members will receive feedback from the Department of...

  6. 78 FR 8160 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2013-02-05

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Committee Teleconference. SUMMARY: The President's National Security Telecommunications Advisory Committee... telecommunications policy. Agenda: The NSTAC members will review and discuss the draft NSTAC Report to the...

  7. 78 FR 63232 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2013-10-23

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Committee Meeting. SUMMARY: The President's National Security Telecommunications Advisory Committee (NSTAC... related to national security and emergency preparedness (NS/EP) telecommunications policy. During...

  8. 77 FR 65393 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2012-10-26

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Committee Teleconference. SUMMARY: The President's National Security Telecommunications Advisory Committee... national security and emergency preparedness (NS/EP) telecommunications policy. Agenda: The NSTAC...

  9. 77 FR 6813 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2012-02-09

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Committee Teleconference. SUMMARY: The President's National Security Telecommunications Advisory Committee... and emergency preparedness telecommunications policy. During the conference call, the NSTAC...

  10. 78 FR 45255 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2013-07-26

    ... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Committee Teleconference. SUMMARY: The President's National Security Telecommunications Advisory Committee... preparedness (NS/EP) telecommunications policy. Agenda: The NSTAC members will deliberate and vote on the...

  11. 78 FR 29145 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2013-05-17

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HOMELAND SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection...'s National Security Telecommunications Advisory Committee (NSTAC). The document contained...

  12. 78 FR 49752 - National Environmental Education Advisory Council

    Science.gov (United States)

    2013-08-15

    ... AGENCY National Environmental Education Advisory Council AGENCY: Environmental Protection Agency (EPA... series of teleconference meetings of the National Environmental Education Advisory Council (NEEAC). The... EPA under the National Environmental Education Act (the Act). The purpose of these...

  13. 78 FR 12056 - National Environmental Education Advisory Council

    Science.gov (United States)

    2013-02-21

    ... AGENCY National Environmental Education Advisory Council AGENCY: Environmental Protection Agency (EPA... series of teleconference meetings of the National Environmental Education Advisory Council (NEEAC). The... EPA under the National Environmental Education Act (the Act). The purpose of these...

  14. 76 FR 67750 - Homeland Security Information Network Advisory Committee

    Science.gov (United States)

    2011-11-02

    ... SECURITY Homeland Security Information Network Advisory Committee AGENCY: Department of Homeland Security... Applicants for Appointment to Homeland Security Information Network Advisory Committee. SUMMARY: The Secretary of Homeland Security has determined that the renewal of the Homeland Security Information...

  15. 76 FR 28443 - President's National Security Telecommunications Advisory Committee

    Science.gov (United States)

    2011-05-17

    ... users from legacy Land Mobile Radio to 4G technologies for their mobile telecommunications needs. The... SECURITY President's National Security Telecommunications Advisory Committee AGENCY: National Protection... Advisory Committee Meeting. SUMMARY: The President's National Security Telecommunications...

  16. THE PERFORMANCE OF AGRICULTURAL MARKET ADVISORY SERVICES IN MARKETING WHEAT

    OpenAIRE

    Jirik, Mark A.; Irwin, Scott H.; Good, Darrel L.; Jackson, Thomas E.; Martines-Filho, Joao Gomes

    2000-01-01

    The purpose of this paper is to investigate the performance of agricultural market advisory services in marketing wheat. Two key performance questions are addressed: 1) Do market advisory services, on average, outperform an appropriate wheat market benchmark? and 2) Do market advisory services exhibit persistence in their wheat performance from year-to-year? Market advisory service recommendations for wheat are available from the AgMAS Project for the 1995, 1996, 1997 and 1998 marketing years...

  17. 77 FR 70543 - Pipeline Safety: Meeting of the Gas Pipeline Advisory Committee and the Liquid Pipeline Advisory...

    Science.gov (United States)

    2012-11-26

    ... for natural gas pipelines and for hazardous liquid pipelines. Both committees were established under... TRANSPORTATION Pipeline and Hazardous Materials Safety Administration Pipeline Safety: Meeting of the Gas Pipeline Advisory Committee and the Liquid Pipeline Advisory Committee AGENCY: Pipeline and...

  18. 76 FR 80952 - Request for Nominations for Voting Members on a Public Advisory Committee; Food Advisory Committee

    Science.gov (United States)

    2011-12-27

    ... are adequately represented on advisory committees and, therefore, encourages nominations of qualified... consideration for membership on the Food Advisory Committee. Nominations received after February 27, 2012 will be considered for nomination to the committee if nominees are still needed. ADDRESSES:...

  19. SVI technical advisory group meets.

    Science.gov (United States)

    1997-10-01

    The 12th Technical Advisory Group Meeting on Vaccine-Preventable Diseases (TAG) was held in Guatemala during September 8-12, 1997. Created in 1985 during the polio eradication campaign, TAG meets every 2 years and is the leading forum to promote regional initiatives to control and eliminate vaccine-preventable diseases. One of the group's main objectives has been to strengthen the policy dialogue upon immunization among governments in the region and participating agencies. Some of TAG's major conclusions and recommendations are presented with regard to immunization in a changing policy environment, measles eradication, poliomyelitis, neonatal tetanus, rubella and congenital rubella, hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), vaccines of quality, and research and development in the regional vaccine initiative.

  20. Anti-infective activities of Pelargonium sidoides (EPS® 7630): effects of induced NO production on Leishmania major in infected macrophages and antiviral effects as assessed in a fibroblast-virus protection assay.

    Science.gov (United States)

    Thäle, Carsten; Kiderlen, Albrecht Ferdinand; Kolodziej, Herbert

    2011-05-01

    EPs® 7630 is an aqueous-ethanolic extract of the roots of Pelargonium sidoides, employed in the treatment of upper respiratory tract infections. Its anti-infective activity is supposed to be associated with the activation of the nonspecific immune system. Using Leishmania major GFP-infected murine BMMΦ, the NO production of EPs® 7630-activated macrophages was correlated with the reduction of the GFP signal measured at single cell levels using flow cytometry. The anti-infectious effect of EPs® 7630 (3-10 µg/mL) on its own (NO production: 4-13 µM; signal reduction: 25-73 %) was less prominent than that in combination with IFN- γ (100 U/mL) (NO production: 20-27 µM; signal reduction: 35-78 %). Furthermore, supernatants of EPs® 7630-stimulated BMMΦ (10 µg/mL) significantly reduced the cytopathic effect of EMCV on L929 fibroblasts (antiviral activity 80 U/mL) when compared with an IFN- γ standard (100 U/mL). Direct addition of EPs® 7630 to L929 did not mediate cytoprotective effects. The antiviral components induced in BMMΦ by EPs® 7630 remain to be identified. Detection of any IFNs by ELISA was unsuccessful, which may be due to their very low concentrations in cell supernatants. The current data provide convincing support for the induction of anti-infectious responses by EPs® 7630.